

in vivo

**International Journal of Experimental and
Clinical Pathophysiology and Drug Research**

PRINT ISSN: 0258-851X – ONLINE ISSN: 1791-7549

**Volume 32
2018**

INDEX

Editorial Board

- I. ABRAHAM**, *The HOPE Center, University of Arizona, Tucson, AZ, USA*
- N.J. AGNANTIS**, *Department of Pathology, University of Ioannina, Ioannina, Greece*
- D. ANDERSON**, *Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK*
- V. BARAK**, *Department of Oncology, Hadassah University Hospital, Jerusalem, Israel*
- M.H. BARCELLOS-HOFF**, *Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA*
- K. BEIER**, *Department of Histology, University of Basel, Basel, Switzerland*
- M. BERGQVIST**, *Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden*
- R. BJERKVIG**, *Norlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway*
- W. BOWNE**, *Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USA*
- M. CARAGLIA**, *Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy*
- P. CHANDRA**, *Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany*
- J.-G. CHUNG**, *Department of Medicine, China Medical College, Taichung, Taiwan, ROC*
- L.A. COHEN**, *Northhampton, MA, USA*
- A.I. CONSTANTINOU**, *Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus*
- T. DALIANIS**, *Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden*
- G. DELICONSTANTINOS**, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*
- D.T. DENHARDT**, *Division of Life Sciences, Rutgers University, Bridgewater, NJ, USA*
- W. DEN OTTER**, *VUMC - Department of Urology, Amsterdam, The Netherlands*
- K. DE MEIRLEIR**, *Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium*
- L. DE RIDDER**, *Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium*
- E.P. DIAMANDIS**, *Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada*
- J.M. DRAKE**, *Division of Medical Oncology, RBHS-Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA*
- T. EFFERTH**, *Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany*
- W. ENGSTRÖM**, *Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden*
- M. ESKELINEN**, *Department of Surgery, University Hospital of Kuopio, Kuopio, Finland*
- J.A. FERNANDEZ-POL**, *Metalloproteomics, LLC, Chesterfield, MO, USA*
- G. FIORENTINI**, *UOC Oncologia, Azienda Ospedaliera Marche Nord, Pesaro, Italy*
- P.B. FISHER**, *Virginia Commonwealth University, School of Medicine, Richmond, VA, USA*
- I. FREITAS**, *Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy*
- M. FRIEDRICH**, *Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany*
- R.E. FRIEDRICH**, *Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany*
- R. GANAPATHI**, *Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA*
- G. GITSCHE**, *Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany*
- V. GORGOULIS**, *Department of Histology-Embryology, Medical School, University of Athens, Greece*
- J.S. GREENBERGER**, *Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA*
- J.W. GREINER**, *National Cancer Institute, NIH, Bethesda, MD, USA*
- D.S. GRIDLEY**, *Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA*
- C.J. GRUBBS**, *Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA*
- F. GUADAGNI**, *IRCCS San Raffaele, Rome, Italy*

- J. HAU**, Department of Comparative Medicine, University of Copenhagen, Denmark
- M. HAUER-JENSEN**, Arkansas Cancer Research Center, University of Arkansas Medical Sciences, Little Rock, AR, USA
- K. HIBI**, Tokai Central Hospital, Kakamigahara, Gifu, Japan
- S.A. IMAM**, Huntington Medical Research Institutes, Gene Therapy Program, Pasadena, CA, USA
- K.S. JEONG**, Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, S. Korea
- M. JHANWAR-UNIYAL**, Department of Neurosurgery, New York Medical College, Valhalla, NY, USA
- I. KISS**, Institute of Preventive Medicine, Medical School, University of Pécs, Pécs, Hungary
- E. KONDO**, Division of Molecular and Cellular Pathology Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan
- M. KOUTSILIERIS**, Department of Experimental Physiology, University of Athens Medical School, Athens, Greece
- G.R.F. KRUEGER**, Department of Anatomy II, Center for Anatomy, The University of Cologne Medical School, Cologne, Germany
- B. KRUSLIN**, Department of Pathology, Ljudevit Jurak University, Sestre milosrdnice University Hospital, Zagreb, Croatia
- N. KYPRIANOU**, Department of Urology, University of Kentucky, Lexington, KY, USA
- S.A. LAMPRECHT**, Division of Clinical Biochemistry, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel
- G. LANDBERG**, Department of Laboratory Medicine, Lund University, Lund, Sweden
- I. LELONG-REBEL**, Lab. de Biophotonique et Pharmacologie, Université de Strasbourg, Illkirch, France
- J. LEROY**, IRCAD, University of Strasbourg, France
- W. LICHTENEGGER**, Charité Campus Virchow-Klinikum, Berlin, Germany
- J. LYKKESFELDT**, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark
- P. MADARNAS**, Department of Pathology, University of Sherbrooke, Québec, Canada
- H. MAEDA**, BioDynamics Research Foundation, Kumamoto, Japan
- M. MAREEL**, Laboratory of Experimental Cancerology, State University, Ghent, Belgium
- L. MARGOLIS**, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA
- G. MARTORANA**, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy
- J. MOLNÁR**, Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
- S.L. MOOBERRY**, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
- N. MOTOHASHI**, Department of Medicinal Chemistry, Meiji Pharmaceutical University, Tokyo, Japan
- R.M. NAGLER**, Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, Israel
- S. NAKANO**, Graduate School of Health and Nutritional Sciences, Nakamura Gakuen University, Fukuoka, Japan
- M. NAKASHIMA**, Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
- R. NARAYANAN**, Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- M.B. NICHOLL**, South Texas Veterans Health Care System, San Antonio, TX, USA
- K. NILSSON**, Tumor Biology Laboratory, Department of Pathology, University Hospital, Uppsala, Sweden
- K.R. NORUM**, Institute for Nutrition Research, University of Oslo, Oslo, Norway
- K. OGAWA**, Department of Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
- M. PAGÉ**, Département de Biologie, Division de Biochimie, Université Laval, Québec, Canada
- C. POLYCHRONAKOS**, Department of Paediatrics and Human Genetics, McGill University Health Centre Research Institute, Montreal, QC, Canada
- M.-F. POUPON**, Institut Curie, Section de Recherche, Paris, France
- D. RADES**, Department of Radiation Oncology, University of Lübeck, Lübeck, Germany

- F.M. ROBERTSON**, *Virginia Commonwealth University, Clinical Research Services, Center for Clinical and Translational Research, Richmond Academy of Medicine, Richmond, VA, USA*
- D. RUBELLO**, *Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy*
- C.A. RUBIO**, *Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden*
- G.R. RUTTEMAN**, *Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands*
- H. SAKAGAMI**, *Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan*
- G. SAVA**, *Institutes of Biological Research, Fondazione Cellerio-Onlus, Trieste, Italy*
- D. SCHIFFER**, *Neuro-bio-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy*
- L.D. SHULTZ**, *The Jackson Laboratory, Bar Harbor, ME, USA*
- G. SICA**, *Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy*
- J.M. SIEGFRIED**, *Department of Pharmacology, MNPI Center, University of Minnesota, Minneapolis, MN, USA*
- J. SLANSKY**, *Integrated Department of Immunology, School of Medicine, University of Colorado Denver and National Jewish Health, Denver, CO, USA*
- R.M. SNAPKA**, *Department of Radiology, The Ohio State University, Columbus, OH, USA*
- G.-I. SOMA**, *Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan*
- P.P. SORDILLO**, *Department of Medical Oncology and Hematology, Lenox Hill Hospital, New York, NY, USA*
- T.A. SPRINGER**, *Department of Pathology, Harvard Medical School, Boston, MA, USA*
- D.D. SPYROPOULOS**, *Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA*
- K. SYRJÄNEN**, *Biohit Healthcare Oyj, Helsinki, Finland*
- G.C. TORRE**, *Centro Ippocrate, Vico Cosmelli 4, Finale Ligure (SV), Italy*
- B. TRIBUKAIT**, *Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden*
- J. VADGAMA**, *Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA*
- J.K. VISHWANATHA**, *Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA*
- W. WANG**, *Research Institute of Healthcare Science, University of Wolverhampton, Wolverhampton, UK*
- N. WATANABE**, *Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan*
- W. WEBER**, *Clinical Cancer Etiology Unit, Basel, Switzerland*
- L.M. WEINER**, *Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA*
- J.A. WERNER**, *Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany*
- S. YLÄ-HERTTUALA**, *Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland*
- H. YOSHIDA**, *Department of Pathology, Kagoshima University, Kagoshima, Japan*

Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 32, 2018.

- Academia Sinica Taiwan Biobank Stroke Biosignature Project,
China Medical University, Taichung, Taiwan, R.O.C.
- Aesculap AG, Tuttlingen, Germany
- Agri-Bio Industry Technology Development Program, Ministry
of Agriculture, Food and Rural Affairs (MAFRA), Sejong,
Republic of Korea
- Angiogenesis Research Center, Timisoara, Romania
- Atherosclerosis and Atherothrombosis Group, Romanian Society
of Cardiology, Bucharest, Romania
- Basic Science Research Program, National Research Foundation
of Korea (NRF), Ministry of Education, Science and
Technology, Seoul, Republic of Korea
- BIH-Charité Clinical Scientist Program, Charité
Universitätsmedizin Berlin and the Berlin Institute of Health,
Berlin, Germany
- BIOMAGIK Consortium, Meotec GmbH & Co. KG, Aachen,
Germany
- BIOMAGIK Consortium, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
- Bower Foundation, Ridgeland, MS, U.S.A.
- Bristol-Myers Squibb Co., Ltd, New York, NY, U.S.A.
- Bundesministerium für Bildung und Forschung (BMBF), Bonn,
Germany
- Cancer Society of Finland, Helsinki, Finland
- Center for Research and Development of Medical Diagnostic
Laboratories, Faculty of Associated Medical Sciences and
Graduate School, Khon Kaen University, Khon Kaen,
Thailand
- Central-Taiwan University of Science and Technology, Taichung,
Taiwan R.O.C.
- Chang Gung Medical Research Fund, Chang Gung University,
Taoyuan, Taiwan, R.O.C.
- Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
- Cheng Ching General Hospital, Taichung, Taiwan, R.O.C.
- Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.
- China Medical Board, Faculty of Public Health, Mahidol
University, Bangkok, Thailand
- China Medical University Hospital, Taichung, Taiwan,
R.O.C.
- Chula Research Scholar, Ratchadaphiseksomphot Endowment
Fund, Chulalongkorn University, Bangkok, Thailand
- Chulalongkorn University, Bangkok, Thailand
- Clinical Medicine Research Laboratory and Translational
Laboratory, National Yang-Ming University Hospital, Yilan,
Taiwan, R.O.C.
- Clinical Research Institute, National Kyushu Cancer Center,
Fukuoka, Japan
- Clinical Trial and Research Center of Excellence, Taipei, Taiwan,
R.O.C.
- Columbia University, New York, NY, U.S.A.
- Committee of Preventive Healthcare of Companion Animals,
Utrecht, the Netherlands
- Conceptual Development of Research Organization, Ministry of
Health, Prague, Czech Republic
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
(CNPq), Brasília, Brazil
- Copenhagen Center for Applied Animal Research (CALAR),
Copenhagen, Denmark
- Department of Biochemistry and Biotechnology, University of
Thessaly, Larisa, Greece
- Department of Biology, Division of Natural and Social Sciences,
Carthage College, Kenosha, WI, U.S.A.
- Department of Diagnostic Radiology, Udon Thani Cancer
Hospital, Nong Phai, Thailand
- Department of Education of Hunan Province, Changsha, China
- Department of Otorhinolaryngology, Head and Neck Surgery,
University Hospital Giessen and Marburg, Marburg, Germany
- Department of Pediatrics, University of Mississippi Medical
Center, Jackson, MS, U.S.A.
- Department of Radiation Oncology, Gunma University Graduate
School of Medicine, Gunma, Japan
- Department of Radiation Oncology, Osaka International Cancer
Institute, Osaka, Japan
- Department of Surgery, Rajavithi Hospital, Bangkok, Thailand
- Department of Surgical Oncology, Osaka City University
Graduate School of Medicine, Osaka, Japan
- Department of Veterinary Internal Medicine, University of
Tokyo, Tokyo, Japan
- Departments of Pathology, Kanagawa Cancer Centre, Yokohama,
Japan
- Division of Breast and Endocrine Surgery, Department of
General Surgical Science, Gunma University Graduate School
of Medicine, Gunma, Japan
- Division of Laboratory Animal Sciences, Natural Science Center
for Research and Education, Kagoshima University,
Kagoshima, Japan

Edanz Group, Fukuoka, Japan	Istanbul University Research Fund, Istanbul, Turkey
Editage, Cactus Communications, Tokyo, Japan	Ito Hospital, Tokyo, Japan
Einar och Inga Nilssons Foundation, Malmö, Sweden	János Bolyai Research Scholarship, Hungarian Academy of Sciences, Budapest, Hungary
Electron Microscopy Unit, Institute of Biotechnology, University of Helsinki, Engineering and Physical Sciences Research Counsil (EPSRC), Helsinki, Finland	Japan Health Sciences Foundation, Tokyo, Japan
European Commission, Brussels, Belgium	Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
European Regional Development Fund, Brussels, Belgium	Joint Research Laboratory, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
European Social Fund (ESF), European Commission, Brussels, Belgium	Kagoshima University, Kagoshima, Japan
EV Core, University of Helsinki, Helsinki, Finland	Kanagawa Standard Anti-cancer Therapy Support System, Kanagawa, Japan
Experimental Research Center of ELPEN Pharmaceuticals (E.R.C.E), Athens, Greece	Khon Kaen University Research Grant, Khon Kaen, Thailand
Faculty of Medicine, Vilnius University, Vilnius, Lithuania	KlinStrucMed Program, Else-Kröner-Foundation, Bad Homburg, Germany
Fundaçāo de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Ipatinga, Brazil	Kodama Memorial Fund for Medical Research, Japan
Fundaçāo de Amparo à Pesquisa do Estado de São Paulo (FAPESP) São Paulo, Brazil	Korea Health Technology R&D Project, Korean Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Seoul, Republic of Korea
Fundeni Clinical Institute, Bucharest, Romania	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPIET), Anyang, Republic of Korea
Genomics Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany	KRI Inc., Kyoto, Japan
Glennan Center for Geriatrics and Gerontology (EVMS), Norfolk, VA, U.S.A.	Kyushu University, Fukuoka, Japan
Grants for Support of the Promotion of Research, Yokohama City University, Yokohama, Japan	Liver Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan	Mackenzie Charitable Foundation, Toronto, ON, Canada
Hangzhou Science and Technology Development Fund, Hangzhou, P.R. China	Malmö University Hospital Cancer Foundation, Malmö, Sweden
Health Labor Sciences Research Grant, Ministry of Health, Labor and Welfare of Japan, Tokyo, Japan	Medical Research Core Facilities Center, Office of Research & Development at China Medical University, Taichung, Taiwan, R.O.C.
Hellenic Agricultural Organisation DEMETER, Athens, Greece	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
Hellenic Cardiological Society, Athens, Greece	Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan, R.O.C.
Helsinki University Central Hospital, Helsinki, Finland	Ministry of Health of the Czech Republic, Prague, Czech Republic
Hillman Animal Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, U.S.A.	Ministry of Science and Higher Education of Poland, Warsaw, Poland
Hirosaki University Graduate School of Medicine, Hirosaki, Japan	Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
IKY Fellowship of Excellence for Postgraduate Studies in Greece – Siemens Program, Athens, Greece	National Cancer Center Research Core Facility, Tokyo, Japan
InnoCan, Interreg Deutschland-Danmark, Sønderjylland, Denmark	National Health Research Institutes, Taipei, Taiwan R.O.C.
Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine in Vienna, Vienna, Austria	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and
Internal Research Program, Victor Babes University of Medicine and Pharmacy Timisoara, Timisoara, Romania	

- Human Services, Bethesda, MD, U.S.A.
- National Key Research and Development Program of China,
Beijing, P.R. China
- National Research Council of Thailand, Bangkok, Thailand
- National Taiwan University Hospital University, Taipei, Taiwan
R.O.C.
- National Yang-Ming University Hospital, Taipei, Taiwan R.O.C.
- New National Excellence Program, Ministry of Human
Capacities, Budapest, Hungary
- Next-Generation BioGreen 21 Program, Rural Development
Administration, Jeonju, Republic of Korea
- Oita Cancer Research Foundation, Yufu, Japan
- Ono Pharmaceutical Co., Ltd, Osaka, Japan
- Philipps-Universität Marburg, Marburg, Germany
- Project for Cancer Research and Therapeutic Evolution (P-
CREATE), Japan Agency for Medical Research and
Development (AMED), Tokyo, Japan
- Providence University, Taichung, Taiwan, R.O.C.
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
- Radium Hospital Foundation, Oslo, Norway
- Research Center of Medical Informatics, Kaohsiung Veterans
General Hospital, Kaohsiung, Taiwan, R.O.C.
- Research Fund of Istanbul University, Istanbul, Turkey
- Rosetrees Trust, Edgware, U.K.
- Royal Golden Jubilee (RGJ) Ph.D. Program Scholarship,
Thailand Research Fund, Bangkok, Thailand
- Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan,
R.O.C.
- Shin Nippon Biomedical Laboratories, Ltd., Tokyo, Japan
- Sigrid Juselius Foundation, Helsinki, Finland
- Slovak Academy of Sciences, Bratislava, Slovakia
- Smoking Research Foundation (SRF) for Biomedical Research
of Japan, Tokyo, Japan
- Suzuken Memorial Foundation, Nagoya, Japan
- Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
- Taipei Cathay General, Taipei, Taiwan, R.O.C.
- Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
- Taiwan Clinical Trial Consortium for Stroke, Taipei, Taiwan, R.O.C.
- Taiwan Ministry of Health and Welfare (MOHW), Taipei,
Taiwan, R.O.C.
- Takeda Science Foundation, Japan
- Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan, R.O.C.
- TCI Co., Ltd., Taipei, Taiwan, R.O.C.
- Tissue Bank, China Medical University, Taichung, Taiwan,
R.O.C.
- Translational Laboratory, Department of Medical Research,
Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
- Tumour and Angiogenesis Research Group, Democritus
University of Thrace, Alexandroupolis, Greece
- University Hospital in Pilzen (Faculty Hospital Pilzen-FNPI),
Pilsen, Czech Republic
- University of Auckland, Auckland, New Zealand
- University of Florida, Gainesville, Florida
- University of Pécs, Pécs, Hungary
- Victor Babes University of Medicine and Pharmacy Timisoara,
Timisoara, Romania
- Wilhelm-Sander Foundation, Munich, Germany
- Wroclaw Centre of Biotechnology, Leading National Research
Centre (KNOW), University of Wroclaw, Wroclaw, Poland
- Wroclaw Medical University, Wroclaw, Poland
- Yamaguchi University Gene Research Center, Yamaguchi, Japan
- Yilan National Yang-Ming University Hospital, Yilan, Taiwan,
R.O.C.

Contents, Volume 32, 2018

Number 1, January-February

Review

- Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer. E.S. WENZEL, A.T.K. SINGH
(Kenosha, WI, USA) 1

Experimental Studies

- Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE
(Utrecht, the Netherlands; Cambridge, UK) 7

- Effects of 2,3-Bis(4-hydroxyphenyl)-propionitrile on Induction of Polyovular Follicles in the Mouse Ovary. T. SATO, H. KIM, H. KAKUTA, T. IGUCHI (Yokohama, Japan) 19

- EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer. K. MASUDO, N. SUGANUMA, H. NAKAYAMA, T. OSHIMA, Y. RINO, H. IWASAKI, K. MATSUZU, K. SUGINO, K. ITO, T. KONDO, Y. NAKAMURA, M. YOSHIHARA, M. MASUDA, Y. MIYAGI
(Yokohama; Tokyo; Yamanashi, Japan) 25

- Effect of Benifuuki Tea on Cytochrome P450-mediated Metabolic Activity in Rats. T. HIRAI, Y. NISHIMURA, N. KURATA, H. NAMBA, M. IWASE, Y. GOMI, H. TSUCHIYA, T. YAMAKAWA, Y. KIUCHI (Tokyo; Fujiyoshida, Japan) 33

- The Association of MMP-8 Genotypes with Pterygium. P.-S. HU, W.-S. CHANG, A.-K. CHOU, N.-Y. HSIA, Y.-W. HUNG, C.-W. LIN, C.-W. WU, C.-Y. HUANG, M.-F. WU, C.-H. LIAO, C.-W. TSAI, D.-T. BAU, C.-L. GONG (Changhua; Taichung; Taoyuan, Taiwan, ROC) 41

- Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-based Case-control Study. Y.-R. LEE, N. TIEN, C.-L. LIN, H.-Y. SHEN, D.-T. BAU, Y.-P. LIM (Chiayi; Taichung, Taiwan, ROC) 47

- Effects of Dietary and Lighting Conditions on Diurnal Locomotor Activity and Body Temperature in Microminipigs. K. TAKEISHI, H. KAWAGUCHI, K. AKIOKA, M. NOGUCHI, E. ARIMURA, M. ABE, M. USHIKAI, S. OKITA, A. TANIMOTO, M. HORIUCHI (Kagoshima; Kanagawa, Japan) 55

- Three-Dimensional Printing-based Reconstruction of a Maxillary Bone Defect in a Dog Following Tumor Removal. S.E. KIM, K.M. SHIM, K. JANG, J.-H. SHIM, S.S. KANG (Gwangju; Siheung, Republic of Korea) 63

- Cycloartobiloxanthone Induces Human Lung Cancer Cell Apoptosis via Mitochondria-dependent Apoptotic Pathway. N. LOSUWANNARAK, B. SRITALARAK, P. CHANVORACHOTE (Bangkok, Thailand) 71

- Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer. I.S. BUJOR, A. CIOCA, R.A. CEAUŞU, F. VEACESLAV, C. NICĂ, A.M. CÎMPEAN, M. RAICA (Timisoara, Romania; Chisinau, Republic of Moldova) 79

Effect of Increased Intra-abdominal Pressure on Liver Histology and Hemodynamics: An Experimental Study. E.A. ANTONIOU, E. KAIRI, G.A. MARGONIS, N. ANDREATOS, K. SASAKI, C. DAMASKOS, N. GARMPIS, M. SAMAH, E. ARGYRA, G. POLYMENEAS, M.J. WEISS, T.M. PAWLIK, D. VOROS, G. KOURAKLIS (<i>Athens, Greece; Baltimore, MD, USA</i>)	85
Preventive Effects of Vitamin C on Diethylnitrosamine-induced Hepatotoxicity in <i>Smp30</i> Knockout Mice. Y.-S. SON, H.M.A. ULLAH, A.K. ELFADL, M.-J. CHUNG, S.-G. GHIM, Y.D. KIM, E.-J. LEE, K.-K. KANG, K.-S. JEONG (<i>Daegu, Republic of Korea</i>).....	93
Inhibition of Formation of Azoxymethane-induced Colonic Aberrant Crypt Foci in Rats by Edible Green Algae <i>Capsosiphon fulvescens</i> and Brown Algae <i>Hizikia fusiforme</i> . Y.-S. SON, H.M.A. ULLAH, A.K. ELFADL, S.-G. GHIM, M.-J. CHUNG, Y.D. KIM, E.-J. LEE, K.-K. KANG, K.-S. JEONG (<i>Daegu, Republic of Korea</i>).....	101
Silver Nanoparticles Alter Cell Adhesion and Proliferation of Sheep Primary Mesothelial Cells. Z.V. ARSENOPOLOU, I.A. TAITZOGLOU, P.-A. MOLYVDAS, K.I. GOURGOULIANIS, C. HATZOGLOU, S.G. ZAROGIANNIS (<i>Larissa; Thessaloniki, Greece</i>).....	109
Clinical Studies	
Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer. S.M. GLASER, R. KALASH, D.R. BONGIORNI, M.S. ROBERTS, G.K. BALASUBRAMANI, B.L. JACOBS, S. BERIWAL, D.E. HERON, J.S. GREENBERGER (<i>Pittsburgh, PA, USA</i>).....	113
Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control. M. TYRAN, N. CHARRIER, J. DARREON, A. MADROSZYK, A. TALLET, N. SALEM (<i>Marseille, France</i>)	121
Detection of Local Recurrence with 3-Tesla MRI After Radical Prostatectomy: A Useful Method for Radiation Treatment Planning? D. BUERGY, M. SERTDEMIR, A. WEIDNER, M. SHELAN, F. LOHR, F. WENZ, S.O. SCHÖENBERG, U.I. ATTENBERGER (<i>Mannheim; Karlsruhe, Germany; Bern, Switzerland</i>).....	125
MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer. C. STENE, A. POLISTENA, A. GABER, B. NODIN, B. OTTOCHIAN, D. ADAWI, N. AVENIA, K. JIRSTRÖM, L.B. JOHNSON (<i>Malmö, Sweden; Terni, Italy</i>)	133
Quality of Life in Patients with Bladder Cancer Undergoing Ileal Conduit: A Comparison of Women Versus Men. S. SIRACUSANO, C. D'ELIA, M.A. CERRUTO, O. SALEH, S. SERNI, M. GACCI, S. CICILIATO, A. SIMONATO, A. PORCARO, V. DE MARCO, R. TALAMINI, L. TOFFOLI, F. VISALLI, M. NIERO, C. LONARDI, C. IMBIMBO, P. VERZE, V. MIRONE, M. RACIOPPI, M. IAFRATE, G. CACCIAMANI, D. DE MARCHI, P. BASSI, W. ARTIBANI (<i>Verona; Bolzano; Florence; Trieste; Genoa; Aviano; Naples; Rome; Padua, Italy</i>)	139
Prognostic Impact of Splenectomy in Patients with Esophagogastric Junction Carcinoma. M. FUKUCHI, E. MOCHIKI, T. ISHIGURO, K. SAITO, H. NAITOH, Y. KUMAGAI, K. ISHIBASHI, H. ISHIDA (<i>Saitama; Gunma, Japan</i>).....	145
Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer. M. SHIBUTANI, K. MAEDA, H. NAGAHARA, T. FUKUOKA, Y. ISEKI, S. MATSUTANI, S. KASHIWAGI, H. TANAKA, K. HIRAKAWA, M. OHIRA (<i>Osaka, Japan</i>)	151

Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. P. BORGHETTI, M.L. BONÙ, E. ROCA, S. PEDRETTI, E. SALAH, A. BAIGUINI, D. GRECO, L. TRIGGIANI, M. MADDALO, N.G. LEVRA, F. ALONGI, S.M. MAGRINI, M. BUGLIONE (<i>Brescia; Negrar, Italy</i>)	159
Clinical and Prognostic Analysis of Hypopharyngeal Squamous Cell Carcinoma with Synchronous and Metachronous Multiple Malignancies. K. YAMAMOTO, K. TAKANO, A. KONDO, M. KUROSE, K. OBATA, T. HIMI (<i>Sapporo, Japan</i>)	165
The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. A. OSOEGAWA, H. HIRASHI, T. HASHIMOTO, Y. TAKUMI, M. ABE, H. TAKEUCHI, M. MIYAWAKI, T. OKAMOTO, K. SUGIO (<i>Yufu, Japan</i>)	171
Totally Implantable Central Venous Port Catheters: Radiation Exposure as a Function of Puncture Site and Operator Experience. M. JONCZYK, B. GEBAUER, R. ROTZINGER, D. SCHNAPAUFF, B. HAMM, F. COLLETTINI (<i>Berlin, Germany</i>)	179
Hypoxia Inducible Factor Expression and Angiogenesis – Analysis in the Pituitary Gland and Patterns of Death. M. KOUROUPI, E. SIVRIDIS, D. PAPAZOGLOU, M.I. KOUKOURAKIS, A. GIATROMANOLAKI (<i>Alexandroupolis, Greece</i>)	185
Rare Coexistence of Ileal Diverticulosis, Crohn's Disease and Small Bowel Adenocarcinoma: Report of a Case. E. SPARTALIS, N. GARMPIS, M. SPARTALIS, C. DAMASKOS, D. MORIS, A. ATHANASIOU, P. GKOLFAKIS, P. KORKOLOPOULOU, D. DIMITROULIS, D. MANTAS (<i>Athens, Greece; Columbus, OH, USA; Birmingham, UK</i>)	191
Influence of Obesity on the Course of Malignant Neoplastic Disease in Patients After Pulmonary Metastasectomy. A. RZECHONEK, P. BŁASIAK, G. PNIEWSKI, P. CIERPIKOWSKI, M. MOŚCIBRODZKA, M. ORNAT, J. GRZEGRZÓŁKA, A. BRZECKA (<i>Wroclaw, Poland</i>)	197
Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma. M.-H. LI, J.-T. TSAI, L.-L. TING, J.-C. LIN, Y.-C. LIU (<i>Taipei; Yilan; Taichung, Taiwan, ROC</i>)	203

Number 2, March-April

Reviews

<i>In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma.</i> S. DI STASO, L. AGNIFILI, S. CECANNECCHIA, A. DI GREGORIO, M. CIANCAGLINI (<i>L'Aquila; Chieti, Italy</i>)	211
<i>Non Lipomatous Benign Lesions Mimicking Soft-tissue Sarcomas: A Pictorial Essay.</i> A. CORAN, G. ORSATTI, F. CRIMM, M. RASTRELLI, A. DI MAGGIO, A. PONZONI, S. ATTAR, R. STRAMARE (<i>Padua, Italy</i>)	221

Experimental Studies

Protection of Differentiating Neuronal Cells from Amyloid β Peptide-induced Injury by Alkaline Extract of Leaves of <i>Sasa senanensis</i> Rehder. H. SAKAGAMI, M. TSUJI, M. TOMOMURA, Y. MASUDA, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, T. ABE, N. TAMURA, A. TOMOMURA, S. YOKOSE, H. TAKESHIMA, T. NATORI, M. HORIUCHI, T. FUJISAWA, Y. KIUCHI, K. OGUCHI, T. YASUI, H. OIZUMI, T. OIZUMI (<i>Saitama; Tokyo; Kanagawa, Japan</i>)	231
Plasma Electrolytic Oxidation of Titanium Implant Surfaces: Microgroove-Structures Improve Cellular Adhesion and Viability. P. HARTJEN, A. HOFFMANN, A. HENNINSEN, M. BARBECK, A. KOPP, L. KLUWE, C. PRECHT, O. QUATELA, R. GAUDIN, M. HEILAND, R.E. FRIEDRICH, C. KNIPFER, D. GRUBEANU, R. SMEETS, O. JUNG (<i>Hamburg; Aachen; Berlin; Idstein, Germany</i>)	241
The Impact of Exercise Training on Breast Cancer. K. SIEWIERSKA, I. MALICKA, C. KOBIERZYCKI, U. PASLAWSKA, M. CEGIELSKI, J. GRZEGORZOLKA, A. PIOTROWSKA, M. PODHORSKA-OKOLOW, P. DZIEGIEL, M. WOZNIEWSKI (<i>Wroclaw, Poland</i>)	249
Anti-inflammatory Activity of β -Carotene, Lycopene and Tri- <i>n</i> -butylborane, a Scavenger of Reactive Oxygen Species. A. KAWATA, Y. MURAKAMI, S. SUZUKI, S. FUJISAWA (<i>Sakado, Japan</i>)	255
Effects of Diets with Different Proportions of Protein/Carbohydrate on Retinal Manifestations in <i>db</i> Mice. E. ARIMURA, H. OKATANI, T. ARAKI, M. USHIKAI, M. NAKAKUMA, M. ABE, H. KAWAGUCHI, H. IZUMI, M. HORIUCHI (<i>Kagoshima, Japan</i>)	265
Inhibition of Systemic Hyaluronan Synthesis Exacerbates Murine Hepatic Carcinogenesis. K. MIKAMI, T. ENDO, N. SAWADA, G. IGARASHI, M. KIMURA, H. SAKURABA, S. FUKUDA (<i>Hirosaki, Japan</i>)	273
Amentoflavone Induces Apoptosis and Inhibits NF- κ B-modulated Anti-apoptotic Signaling in Glioblastoma Cells. T.-H. YEN, C.-L. HSIEH, T.-T. LIU, C.-S. HUANG, Y.-C. CHEN, Y.-C. CHUANG, S.-S. LIN, F.-T. HSU (<i>Taichung; Taipei; Yilan, Taiwan, ROC; Macau SAR, PR China</i>)	279
Tumor Necrosis Factor-Alpha (<i>TNF-α-308 G>A</i>) Polymorphism in High-grade Gliomas. S. OZDOGAN, C.K. YALTIRIK, S.G. YILMAZ, M. KAYA, A.H. DUZKALIR, N. DEMIREL, A. KAFADAR, T. ISBIR (<i>Istanbul; Zonguldak, Turkey</i>)	287
Novel Feed Including Olive Oil Mill Wastewater Bioactive Compounds Enhanced the Redox Status of Lambs. S. MAKRI, I. KAFANTARIS, S. SAVVA, P. NTANOU, D. STAGOS, I. ARGYROULIS, B. KOTSAMPASI, V. CHRISTODOULOU, K. GERASOPOULOS, K. PETROTOΣ, D. KOMIOTIS, D. KOURETAS (<i>Larissa; Thessaloniki; Giannitsa, Greece</i>)	291
Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer – A Single Centre Prospective Observational Study. C. CONSTANTINOU, S. PAPADOPOULOS, E. KARYDA, A. ALEXOPOULOS, N. AGNANTI, A. BATISTATOU, H. HARISIS (<i>London, UK; Athens; Ioannina, Greece</i>)	303
Expression of miR-208b and miR-499 in Greek Patients with Acute Myocardial Infarction. K. AGIANNITOPOULOS, P. PAVLOPOULOU, K. TSAMIS, K. BAMPALI, P. SAMARA, G. NASIOULAS, G. MERTZANOS, D. BABALIS, K. LAMNISSOU (<i>Athens, Greece</i>)	313
Reduced Peripheral Blood Mononuclear Cell ROCK1 and ROCK2 Levels in Obstructive Sleep Apnea Syndrome. Ş. AYDIN, C. ÖZDEMİR, C. İ. KÜÇÜKALI, S.N. SÖKÜCÜ, M. GİRİŞ, U. AKCAN, E. TÜZÜN (<i>Istanbul, Turkey</i>)	319

Clinical Studies

Does Marital Status Influence Levels of Anxiety and Depression Before Palliative Radiotherapy? C. NIEDER, T.A. KÄMPE (<i>Bodø; Tromsø, Norway</i>)	327
How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer? C. NIEDER, R. YOBUTA, B. MANNSÅKER, A. DALHAUG (<i>Bodø; Tromsø, Norway</i>)	331
Pulmonary Tumor Embolism Due to Squamous Cell Carcinoma of the Uterine Cervix: A Case Report. S. OKAZAKI, T. ABE, N. TAKAYANAGI, M. YASUDA, F. SAKAI, K. KOBAYASHI, S. KATO (<i>Hidaka; Maebashi; Kawagoe, Japan</i>).....	337
Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. H. ARIYASU, H. INABA, T. OTA, H. YAMAOKA, Y. FURUKAWA, H. IWAKURA, N. DOI, Y. YAMAMOTO, T. AKAMIZU (<i>Wakayama, Japan</i>)	345
The Difference in Prognostic Outcomes Between <i>De Novo</i> Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer. J. YAMAMURA, S. KAMIGAKI, J. FUJITA, H. OSATO, Y. KOMOIKE (<i>Osaka; Sayama, Japan</i>).....	353
Clinical Impact of a Surgical Energy Device in Advanced Ovarian Cancer Surgery Including Bowel Resection. G. VIZZIELLI, C. CONTE, M. ROMANO, A. FAGOTTI, B. COSTANTINI, C. LODOLI, S. GUELI ALLETTI, K. GABALLAH, F. PACELLI, A. ERCOLI, G. SCAMBIA, V. GALLOTTA (<i>Rome; Novara, Italy</i>)	359
DCLK1 Expression in Colorectal Polyps Increases with the Severity of Dysplasia. A. TAKIYAMA, T. TANAKA, S. KAZAMA, H. NAGATA, K. KAWAI, K. HATA, K. OTANI, T. NISHIKAWA, K. SASAKI, M. KANEKO, S. EMOTO, K. MURONO, H. TAKIYAMA, H. NOZAWA (<i>Tokyo; Saitama, Japan</i>)	365
Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis. S. DAROCHA, M. WILK, A. WALASZKOWSKA-CZYŻ, J. KĘPSKI, R. MAŃCZAK, M. KURZYNA, A. TORBICKI, S. SZMIT (<i>Otwock, Poland</i>)	373
Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases. D. RADES, O. BLANCK, M.T. KHOA, P.V. THAI, N.Q. HUNG, L. DZIGGEL, S.E. SCHILD (<i>Hanoi, Vietnam; Góstrow, Germany; Scottsdale, AZ, USA</i>)	381
Normal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases – A Case Report and Literature Review. N. BACALBASA, I. BALESCU, C. BALALAU, O. IONESCU, C. STOICA (<i>Bucharest, Romania; Marktredwitz, Germany</i>)	385
Cullin-1 and -2 Protein Expression in Colorectal Cancer: Correlation with Clinicopathological Variables. O. MICHAİL, D. MORIS, S. THEOCHARIS, J. GRINIATSOS (<i>Athens, Greece; Durham, NC, USA</i>).....	391
Increase in Serum Amylase and Resistive Index After Kidney Transplant Are Biomarkers of Delayed Graft Function. G. COMAI, O. BARALDI, V. CUNA, V. CORRADETTI, A. ANGELETTI, S. BRUNILDA, I. CAPELLI, M. CAPPUCCILLI, G. LA MANNA (<i>Bologna, Italy</i>)	397
Tear Film Osmolarity in Subjects with Acute Allergic Rhinoconjunctivitis. E. NITODA, A. LAVARIS, K. LAIOS, S. ANDROUDI, C.D. KALOGEROPOULOS, M. TSATSOS, C. DAMASKOS, N. GARMPIS, M.M. MOSCHOS (<i>Athens; Larissa; Ioannina, Greece; Southampton, UK</i>)	403

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer. Y. MIYAZAWA, Y. SEKINE, T. SYUTO, M. NOMURA, H. KOIKE, H. MATSUI, Y. SHIBATA, K. ITO, K. SUZUKI (<i>Maebashi, Japan</i>)	409
Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation. M. HU, J. TREVINO, L. YANG, D. CAO, X. LIU, J. LAI (<i>Gainesville, FL; St. Louis, MO, USA</i>)	413
The Influence of Cardiac Pacemaker Programming Modes on Exercise Capacity. B. CALOIAN, A.V. SITAR-TAUT, G.N. GUSETU, D. POP, D.T. ZDRENGHEA (<i>Cluj-Napoca, Romania</i>)	419
Differences in Urinary Amino Acid Patterns in Individuals with Different Types of Urological Tumor Urinary Amino Acid Patterns as Markers of Urological Tumors. K. DUSKOVA, S. VESELY, J.D.C. SILVA, N. CERNEI, O. ZITKA, Z. HEGER, V. ADAM, K. HAVLOVA, M. BABJUK (<i>Prague; Brno, Czech Republic</i>)	425
Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer. N. BACALBASA, I. BALESCU, C. BALALAU, O. IONESCU, C. STOICA (<i>Bucharest, Romania; Marktredwitz, Germany</i>)	431
<i>In Vivo</i> Scanning Laser Confocal Microscopy of Conjunctival Goblet Cells in Medically-controlled Glaucoma. S. DI STASO, L. AGNIFILI, M. CIANCAGLINI, G. MURANO, E. BORRELLI, L. MASTROPASQUA (<i>L'Aquila; Chieti, Italy</i>)	437
Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma. T. OTOSHI, Y. KATAOKA, S. KAKU, R. IKI, M. HIRABAYASHI (<i>Amagasaki, Japan</i>)	445

Number 3, May-June

Review

Considerations Regarding Embryo Culture Conditions: From Media to Epigenetics. M. SIMOPOULOU, K. SFAKIANOUDIS, A. RAPANI, P. GIANNELOU, G. ANIFANDIS, S. BOLARIS, A. PANTOU, M. LAMBROPOULOU, A. PAPPAS, E. DELIGEOROGLOU, K. PANTOS, M. KOUTSILIERIS (<i>Athens; Larissa; Alexandroupolis, Greece</i>)	451
---	-----

Experimental Studies

An Improved <i>In Vivo</i> Methodology to Visualise Tumour Induced Changes in Vasculature Using the Chick Chorionic Allantoic Membrane Assay. N. MANGIR, A. RAZA, J.W. HAYCOCK, C. CHAPPLE, S. MACNEIL (<i>Sheffield, UK</i>)	461
Zanamivir Diminishes Lung Damage in Influenza A Virus-infected Mice by Inhibiting Nitric Oxide Production. B. ZABLOCKIENĖ, T. KAČERGIUS, A. AMBROZAITIS, E. ŽURAUSKAS, M. BRATCHIKOV, L. JURGAUSKIENĖ, R. ZABLOCKIS, S. GRAVENSTEIN (<i>Vilnius, Lithuania; Norfolk, VA; Providence, RI, USA</i>)	473
<i>In Vitro</i> Anti-tumor Activity of Azulene Amide Derivatives. T. WADA, R. MARUYAMA, Y. IRIE, M. HASHIMOTO, H. WAKABAYASHI, N. OKUDAIRA, Y. UESAWA, H. KAGAYA, H. SAKAGAMI (<i>Saitama; Tokyo, Japan</i>)	479

The Association of <i>Matrix Metalloproteinase-1</i> Promoter Polymorphisms with Breast Cancer. C.-L. HSIAO, L.-C. LIU, T.-C. SHIH, Y.-L. LAI, S.-W. HSU, H.-C. WANG, S.-Y. PAN, T.-C. SHEN, C.-W. TSAI, W.-S. CHANG, C.-H. SU, T.-D. WAY, J.-G. CHUNG, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>).....	487
Invasion-inhibiting Effects of Gaseous Components in Cigarette Smoke on Mouse Rectal Carcinoma Colon-26 Cells. M. HATAI, N. YOSHIKAWA, E. KINOSHITA, S. HORIYAMA, S. KAGOTA, K. SHINOZUKA, K. NAKAMURA (<i>Nishinomiya, Japan</i>)	493
Activated Ductal Proliferation Induced by <i>N</i> -Nitrosobis (2-oxopropyl)amine in Fat-infiltrated Pancreas of KK-A ^y Mice. M. HORI, M. MUTOH, R. ISHIGAMORI, T. IMAI, M. TAKAHASHI (<i>Suita; Tokyo, Japan</i>)	499
Elevated EGF Levels in the Blood Serum of Dogs with Periodontal Diseases and Oral Tumours. A. SOBCZYŃSKA-RAK, B. ŹYLIŃSKA, I. POLKOWSKA, T. SZPONDER (<i>Lublin, Poland</i>)	507
Total Skin Electron Beam Therapy with Rotary Dual Technique as Palliative Treatment for Mycosis Fungoides. T. PIOTROWSKI, M. FUNDOWICZ, M. PAWLACZYK (<i>Poznan, Poland</i>)	517
Laminarin Promotes Immune Responses and Reduces Lactate Dehydrogenase But Increases Glutamic Pyruvic Transaminase in Normal Mice <i>In Vivo</i> . Y.-L. SHIH, S.-C. HSUEH, Y.-L. CHEN, J.-S. CHOU, H.-Y. CHUNG, K.-L. LIU, H.-W. JAIR, Y.-Y. CHUANG, H.-F. LU, J.-Y. LIU, J.-G. CHUNG (<i>Taipei; New Taipei City; Hsinchu; Miaoli; Taichung, Taiwan, ROC</i>)	523
Reduction of Potential Risk for Skin Toxicity in Megavoltage Radiotherapy Using a Novel Rigid Couch. M. TAMURA, H. MONZEN, K. MATSUMOTO, M. OKUMURA, H. DOI, Y. NISHIMURA (<i>Osaka-Sayama, Japan</i>).....	531
Effects of Medium Molecular Weight Heparinyl Arginine on Scorpion Venom-induced Pulmonary Edema in Rats. S. TAKEDA, T. TODA, K. NAKAMURA (<i>Osaka; Nishinomiya, Japan</i>).....	537
<i>In Vitro</i> Antitumor Activity of Alkylaminoguaiazulenes. M. UEHARA, H. MINEMURA, T. OHNO, M. HASHIMOTO, H. WAKABAYASHI, N. OKUDAIRA, H. SAKAGAMI (<i>Saitama, Japan</i>)	541
Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular Carcinoma <i>In Vitro</i> . K.-C. LEE, J.-J. TSAI, C.-W. TSENG, Y.-C. KUO, Y.-C. CHUANG, S.-S. LIN, F.-T. HSU (<i>Taichung; Yilan; Chia-Yi; Changhua; Taipei, Taiwan, ROC; Macau SAR, PR China</i>)	549
Association of Pro-apoptotic Bad Gene Expression Changes with Benign Thyroid Nodules. N. GÜL, B. TEMEL, D. USTEK, S. SIRMA-EKMEKÇİ, Y. KAPRAN, F. TUNCA, Y. GILES-ŞENYÜREK, U. ÖZBEK, F. ALAGÖL (<i>Istanbul, Turkey</i>)	555
Circulating microRNAs as Novel Biomarkers for Atherosclerosis. S.G. YILMAZ, S. ISBIR, A.T. KUNT, T. ISBIR (<i>Istanbul; Ankara, Turkey</i>)	561
Biodistribution, Pharmacokinetics and Efficacy of ¹⁸⁸ Re(I)-Tricarbonyl-Labeled Human Serum Albumin Microspheres in an Orthotopic Hepatoma Rat Model. L.-C. CHEN, W.-C. LEE, C.-L. HO, Y.-J. CHANG, S.-J. CHEN, C.-H. CHANG (<i>Taoyuan, Taiwan, ROC</i>)	567
Clinical Application of Bone Morphogenetic Protein-2 Microcarriers Fabricated by the Cryopolymerization of Gelatin Methacrylate for the Treatment of Radial Fracture in Two Dogs. J. PARK, S. KWON, N.S. HWANG, B.-J. KANG (<i>Chuncheon; Seoul, Republic of Korea</i>)	575

Clinical Studies

Diurnal Variation of Melatonin Concentration in the Cerebrospinal Fluid of Unanesthetized Microminipig. M. ABE, H. KAWAGUCHI, N. MIURA, K. AKIOKA, M. USHIKAI, S. OI, A. YUKAWA, T. YOSHIKAWA, H. IZUMI, M. HORIUCHI (<i>Kagoshima, Japan</i>)	583
Patient Height, Weight, BMI and Age as Predictors of Gracilis Muscle Free-Flap Mass in Lower Extremity Reconstruction. C.M. ORANGES, M. TREMP, W. WANG, S. MADDURI, P.G. DI SUMMA, R. WETTSTEIN, D.J. SCHAEFER, D.F. KALBERMATTEN (<i>Basel; Lausanne, Switzerland; Shanghai, PR China</i>).....	591
A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas. H. SOYAMA, M. MIYAMOTO, M. TAKANO, H. IWASHI, K. KATO, T. SAKAMOTO, M. KUWAHARA, H. ISHIBASHI, H. MATUURA, T. YOSHIKAWA, T. AOYAMA, H. TSUDA, K. FURUYA (<i>Tokorozawa, Japan</i>)	597
Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy. S. SATO, C. KUNISAKI, H. SUEMATSU, Y. TANAKA, H. MIYAMOTO, T. KOSAKA, N. YUKAWA, K. TANAKA, K. SATO, H. AKIYAMA, I. ENDO (<i>Yokohama, Japan</i>)	603
Meta-analysis of Robot-assisted <i>Versus</i> Laparoscopic Surgery for Rectal Cancer. H. OHTANI, K. MAEDA, S. NOMURA, O. SHINTO, Y. MIZUYAMA, H. NAKAGAWA, H. NAGAHARA, M. SHIBUTANI, T. FUKUOKA, R. AMANO, K. HIRAKAWA, M. OHIRA (<i>Osaka, Japan</i>)	611
The Use of TissuGlu® Surgical Adhesive for Mastectomy With or Without Lymphonodectomy. R. OHLINGER, L. GIERON, R. RUTKOWSKI, T. KOHLMANN, M. ZYGMUNT, J. UNGER (<i>Greifswald, Germany</i>).....	625
Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder. D. RADES, L. DZIGGEL, L. MANIG, S. JANSSEN, M.T. KHOA, V.N. DUONG, V.H. KHIEM, S.E. SCHILD (<i>Lübeck; Hannover, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i>)	633
Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. M. KAWANO, S. KAINO, S. AMANO, S. SHINODA, S. SUENAGA, M. SEN-YO, I. SAKAIDA (<i>Yamaguchi, Japan</i>)	637
The Feasibility and Efficacy of Laparoscopic Extended Total Mesorectal Excision for Locally Advanced Lower Rectal Cancer. T. NONAKA, A. FUKUDA, K. MAEKAWA, S. NAGAYOSHI, T. TOKUNAGA, M. TAKATSUKI, T. KITAJIMA, K. TANIGUCHI, H. FUJIOKA (<i>Nagasaki, Japan</i>)	643
Fat-forming Solitary Fibrous Tumor of the Kidney – A Case Report and Literature Review. N. BACALBASA, I. BALESCU, G. JINESCU, M. MARCU, A. CONTOLENCU, D. POP, D. DOBRITOIU, O. IONESCU, P. IONESCU, C. STOICA (<i>Bucharest; Constanta, Romania; Marktredwitz, Germany</i>).....	649
Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. S. KOKKALI, E.-S. TRIPODAKI, M. DRIZOU, D. STEFANOU, E. MAGOU, D. ZYLIS, M. KAPIRIS, D. NASI, C. GEORGANTA, A. ARDAVANIS (<i>Athens, Greece</i>)	653
Laparoscopic Left Hepatectomy for Ruptured Hepatocellular Carcinoma Controlled After Transcatheter Arterial Embolization: Case Report and Review of the Literature. S. YOSHIYA, K. IWAKI, A. SAKAI, S. FUJITA, T. KAWASAKI, F. YOSHIZUMI, S. HIROSHIGE, M. OKAMOTO, K. FUKUZAWA, A. MOTOHIRO, Y. MAEHARA (<i>Oita; Fukuoka, Japan</i>)	659

Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer. M. TOMITA, T. AYABE, R. MAEDA, K. NAKAMURA (Kiyotake, Japan)	663
Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. N. IIMORI, S. KASHIWAGI, Y. ASANO, W. GOTO, K. TAKADA, K. TAKAHASHI, T. HATANO, T. TAKASHIMA, S. TOMITA, H. MOTOMURA, K. HIRAKAWA, M. OHIRA (Osaka, Japan)	669
cDNA Microarray Analysis and Influx Transporter OATP1B1 in Liver Cells After Exposure to Gadoxetate Disodium, a Gadolinium-based Contrast Agent in MRI Liver Imaging. C.-C. LU, W.-K. CHEN, J.-H. CHIANG, Y.-F. TSAI, Y.-N. JUAN, P.-C. LIN, Y.-S. TYAN, J.-S. YANG (Hualien; Tainan; Chiayi; Taipei; Taichung, Taiwan, ROC)	677
Superficial Spreading-type Gastric Cancer with <i>Situs Inversus Totalis</i> . T. NAMIKAWA, S. TSUDA, K. FUJISAWA, J. IWABU, S. UEMURA, S. TSUJII, H. MAEDA, H. KITAGAWA, M. KOBAYASHI, K. HANAZAKI (Kochi, Japan)	685
Clinical Implications of Transbronchial Biopsy for Surgically-resected Non-small Cell Lung Cancer. M. YASUKAWA, N. SAWABATA, T. KAWAGUCHI, N. KAWAI, S. TANIGUCHI (Nara, Japan)	691
Celiac Trunk Stenosis Treated by Resection and Splenic Patch Reconstruction – A Case Report and Literature Review. N. BACALBASA, I. BALESCU, V. BRASOVEANU (Bucharest, Romania)	699
Surgical Management of a Giant Pheochromocytoma. A. AFANEH, M. YANG, A. HAMZA, E. SCHERVISH, R. BERRI (Detroit, MI, USA)	703

Number 4, July-August

Experimental Studies

Photodynamic Therapy with Pyoktanin Blue and Diode Laser for Elimination of <i>Enterococcus faecalis</i> . Y. MASUDA, H. SAKAGAMI, M. HORIIKE, H. KADOKURA, T. YAMASAKI, P.R. KLOKKEVOLD, H.H. TAKEI, S. YOKOSE (Saitama, Japan; Los Angeles, CA, USA)	707
Transdermal Fentanyl Solution Provides Long-term Analgesia in the Hind-paw Incisional Model of Postoperative Pain in Male Rats. J. CLEMENSEN, L.V. RASMUSSEN, K.S.P. ABELSON (Copenhagen, Denmark)	713
High Consumption of Green Tea Suppresses Urinary Tract Recurrence of Urothelial Cancer via Down-regulation of Human Antigen-R Expression in Never Smokers. T. YASUDA, Y. MIYATA, Y. NAKAMURA, Y. SAGARA, T. MATSUO, K. OHBA, H. SAKAI (Nagasaki, Japan)	721
Expression of p16 and SATB1 in Invasive Ductal Breast Cancer – A Preliminary Study. C. KOBIERZYCKI, J. GRZEGRZOLKA, N. GLATZEL-PLUCINSKA, A. PIOTROWSKA, A. WOJNAR, B. SMOLARZ, H. ROMANOWICZ, P. DZIEGIEL (Wroclaw; Lodz, Poland)	731
Antibacterial and Resistance Modifying Activities of <i>Nigella sativa</i> Essential Oil and its Active Compounds Against <i>Listeria monocytogenes</i> . A. MOUWAKEH, Á. TELBISZ, G. SPENGLER, C. MOHÁCSI-FARKAS, G. KISKÓ (Budapest; Szeged, Hungary)	737

Partial Protection of Paclitaxel-induced Neurotoxicity by Antioxidants. Y. HARA, H. SAKAGAMI, H. SHI, T. ABE, N. TAMURA, H. TAKESHIMA, N. HORIE, T. KANEKO, H. SHIRATSUCHI, T. KANEKO (Tokyo; Saitama, Japan; Shanghai, PR China)	745
Effect of Oligomeric Proanthocyanidin on the Antioxidant Status and Lung Function of Patients with Chronic Obstructive Pulmonary Disease. M.-C. LU, M.-D. YANG, P.-C. LI, H.-Y. FANG, H.-Y. HUANG, Y.-C. CHAN, D.-T. BAU (Taichung, Taiwan, ROC)	753
Enzyme-treated Asparagus Extract Down-regulates Heat Shock Protein 27 of Pancreatic Cancer Cells. T. SHIMADA, Y. NANIMOTO, B. BARON, T. KITAGAWA, K. TOKUDA, Y. KURAMITSU (Ube; Tobetsu, Japan; Msida, Malta)	759
Change in Anticancer Drug Sensitivity During Neuronal Differentiation of PC12 Cells. H. SAKAGAMI, Y. HARA, H. SHI, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, T. ABE, N. TAMURA, H. TAKESHIMA, N. HORIE, T. KANEKO, H. SHIRATSUCHI, T. KANEKO (Saitama; Tokyo, Japan; Shanghai, PR China)	765
<i>In Vivo</i> Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model. I.H. JUNG, D.H. KIM, D.K. YOO, S.Y. BAEK, S.H. JEONG, D.E. JUNG, S.W. PARK, Y.-Y. CHUNG (Seoul, Republic of Korea)	771
Laminarin Promotes Immune Responses and Normalizes Glutamic Oxaloacetic Transaminase and Glutamic Pyruvic Transaminase Levels in Leukemic Mice <i>In Vivo</i> . H.-S. SHANG, Y.-L. SHIH, C.-P. CHEN, M.-H. LEE, H.-F. LU, P.-Y. CHOU, N.-C. LIAO, Y.-L. CHEN, S.-C. HSUEH, J.-G. CHUNG (Taipei; New Taipei; Changhua; Hsinchu; Taichung, Taiwan, ROC)	783
Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model. A.M. CIMPEAN, D. LALOŠEVIĆ, V. LALOŠEVIĆ, P. BANOVIĆ, M. RAICA, O.A. MEDERLE (Timisoara, Romania; Novi Sad, Serbia)	791
Accelerated Wound Healing on the Skin Using a Film Dressing with β -Glucan Paramylon. K. YASUDA, M. OGUSHII, A. NAKASHIMA, Y. NAKANO, K. SUZUKI (Tokyo; Osaka, Japan)	799
Effects of Dietary Grape Pomace Supplementation on Performance, Carcass Traits and Meat Quality of Lambs. I. KAFANTARIS, B. KOTSAMPASI, V. CHRISTODOULOU, S. MAKRI, D. STAGOS, K. GERASOPOULOS, K. PETROTOΣ, P. GOULAS, D. KOURETAS (Larissa; Giannitsa, Greece)	807
A Study of Short- and Long-term mRNA Levels of the <i>Retn</i> , <i>Iapp</i> , and <i>Drd5</i> Genes in Obese Mice Induced with High-fat Diet. O. TIMIRCI-KAHRAMAN, U. YILMAZ, N. YILMAZ, A. CEVIK, C. HOROZOGLU, F. CELIK, M.O. GOKCE, A. ERGEN, A. MELEKOGLU, U. ZEYBEK (Istanbul; Kastamonu, Turkey)	813
Clinical Studies	
Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients. M.A. STRUNK, E.M. ZOPF, J. STECK, S. HAMACHER, M. HALLEK, F.T. BAUMANN (Cologne, Germany; Melbourne, Australia)	819
A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy. D. RADES, L. DZIGGEL, S.E. SCHILD (Lübeck, Germany; Scottsdale, AZ, USA)	825

Effects of Nutritional Intervention on the Survival of Patients with Cardiopulmonary Failure Undergoing Extracorporeal Membrane Oxygenation Therapy. M.-C. LU, M.-D. YANG, P.-C. LI, H.-Y. FANG, H.-Y. HUANG, Y.-C. CHAN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	829
Expression of SOX9 Is Related to Prognosis in Patients with Oesophageal Squamous Cell Carcinoma. N. HIGO, H. OKUMURA, Y. UCHIKADO, I. OMOTO, K. SASAKI, Y. KITA, D. RYOSUKE, M. NODA, T. OWAKI, S. ISHIGAMI, S. NATSUGOE (<i>Kagoshima, Japan</i>)	835
Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis. M. RUSSILLO, G. FERRETTI, A. VIDIRI, S. GASPARRO, F. COGNETTI, D. PELLEGRINI, A. FABI (<i>Rome, Italy</i>)	839
Objective Comparison Using Guideline-based Query of Conventional Radiological Reports and Structured Reports. M.E. MAROS, R. WENZ, A. FÖRSTER, M.F. FROELICH, C. GRODEN, W.H. SOMMER, S.O. SCHÖNBERG, T. HENZLER, H. WENZ (<i>Mannheim; Munich, Germany; London, UK</i>)	843
Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease. K. KASHIWABARA, H. SEMBA, S. FUJII, S. TSUMURA (<i>Kumamoto, Japan</i>)	851
Human Emotions on the Onset of Cardiovascular and Small Vessel Related Diseases. C. VLACHAKIS, K. DRAGOUMANI, S. RAFTOPOULOU, M. MANTAIOU, L. PAPAGEORGIOU, S. CHAMPERIS TSANIRAS, V. MEGALOOIKONOMOU, D. VLACHAKIS (<i>Athens; Patras, Greece</i>)	859
Novel Potential Biomarkers for <i>Opisthorchis viverrini</i> Infection and Associated Cholangiocarcinoma. N. AKSORN, S. ROYTRAKUL, S. KITTISENACHAI, K. LEELAWAT, P. CHANVORACHOTE, S. TOPANURAK, S. HAMANO, U. LEK-UTHAI (<i>Bangkok; Pathum Thani, Thailand; Nagasaki, Japan</i>)	871
Cardiotoxicity Assessment After Different Adjuvant Hypofractionated Radiotherapy Concurrently Associated with Trastuzumab in Early Breast Cancer. E. BONZANO, M. GUENZI, R. CORVÒ (<i>Genoa, Italy</i>)	879
Impact of Ultrasonic Scalpels for Liver Parenchymal Transection on Postoperative Bleeding and Bile Leakage. I.D. KOSTAKIS, N. MACHAIRAS, Z. GAROUFALIA, A. PRODRIMIDOU, G.C. SOTIROPOULOS (<i>Athens, Greece</i>)	883
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. K. NAKAHAMA, A. TAMIYA, S.-I. ISA, Y. TANIGUCHI, T. SHIROYAMA, H. SUZUKI, T. INOUE, M. TAMIYA, T. HIRASHIMA, F. IMAMURA, S. ATAGI (<i>Osaka, Japan</i>)	887
Comparison of Anterolateral Thigh and Radial Forearm Free Flaps in Head and Neck Reconstruction. C.M. ORANGES, B. LING, M. TREMP, R. WETTSTEIN, D.F. KALBERMATTEN, D.J. SCHAEFER (<i>Basel, Switzerland</i>)	893
Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor. H. IWAMOTO, K. IZUMI, A. NATSAGDORJ, T. MAKINO, T. NOHARA, K. SHIGEHARA, Y. KADONO, A. MIZOKAMI (<i>Kanazawa, Japan</i>)	899
Under-stage and Overlook of Peritoneal Spread from Bladder Urothelial Carcinoma. C.-C. LIAW, C.-K. CHUANG, Y.-H. CHANG, J.W.-C. CHANG, T.-Y. LIAO, Y.-H. JUAN (<i>Taoyuan, Taiwan, ROC</i>)	905

Successful Resection of a Non-functional Paraganglioma with Celiac Trunk Invasion Followed by Common Hepatic Artery Reimplantation – A Case Report and Literature Review. N. BACALBASA, I. BADESCU, A. TANASE, I. BREZAN, M. VILCU, V. BRASOVEANU (<i>Bucharest, Romania</i>)	911
Spleno-pancreatectomy <i>En Bloc</i> with Parcelar Gastrectomy for Splenic Artery Aneurysm – A Case Report and Literature Review. N. BACALBASA, I. BADESCU, A. TANASE, M. PAUTOV, I. BREZAN, M. VILCU, V. BRASOVEANU (<i>Bucharest, Romania</i>)	915
Acute Heart Failure in the Emergency Department: Respiratory Rate as a Risk Predictor. E. SINIORAKIS, S. ARVANITAKIS, C. TSITSIMPIKOU, K. TSAROUHAS, P. TZEVELEKOS, S. PANTA, F. AIVALIOTI, C. ZAMPELIS, F. TRIPOSKIADIS, S. LIMBERI (<i>Athens; Larissa, Greece</i>)	921
Relationship Between p16 Expression and Prognosis in Patients with Oropharyngeal Cancer Undergoing Surgery. K. KIDA, T. TERADA, N. UWA, Y. OMORI, T. FUJII, Y. TOMITA, K. TSUZUKI, H. NISHIKAWA, M. SAKAGAMI (<i>Hyogo; Osaka; Tokyo, Japan</i>)	927
Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer. M. KOIZUMI, T. YAMADA, S. SHINJI, Y. YOKOYAMA, G. TAKAHASHI, T. IWAI, K. TAKEDA, K. HARA, K. OHTA, E. UCHIDA, H. YOSHIDA (<i>Tokyo, Japan</i>)	937
Correlation Between Contrast-enhanced Ultrasound Characteristics (Qualitative and Quantitative) and Pathological Prognostic Factors in Breast Cancer. I. VRAKA, E. PANOURGIAS, E. SIFAKIS, A. KOUREAS, P. GALANIS, D. DELLAPORTAS, A. GOULIAMOS, A. ANTONIOU (<i>Athens, Greece; Stockholm, Sweden</i>)	945
Increase of Serum Kallikrein-8 Level After Long-term Telbivudine Treatment. H.-E. WANG, C.-L. LIN, T.-L. PAN, C.-T. YEH (<i>Taoyuan; Keelung, Taiwan, ROC</i>)	955
Clinical Advantage of Chest-wall Post-mastectomy Radiation Therapy Without Bolus. S. SHIBA, M. OKAMOTO, H. KIYOHARA, N. OKANO, Y. YOSHIMOTO, H. MURATA, D. IRIE, H. KATOH, T. NAKANO (<i>Gunma; Chiba; Nara; Yokohama, Japan</i>)	961
Association Between Secondary Peritoneal Hydatidosis and Peritoneal Carcinomatosis from Ovarian Cancer – A Case Report. N. BACALBASA, I. BADESCU, I. BREZAN, M. VILCU, V. BRASOVEANU (<i>Bucharest, Romania</i>)	967
Susceptibility Vessel Sign on T2*-Weighted Gradient Echo Imaging in Lacunar Infarction. M. AL-ZGHLOUL, H. WENZ, M. MAROS, J. BΦHME, C. GRODEN, A. FΦRSTER (<i>Mannheim, Germany</i>)	973

Number 5, September-October

Reviews

Vitamin D in Cardiovascular Disease. A. NITSA, M. TOUTOUZA, N. MACHAIRAS, A. MARIOLIS, A. PHILIPPOU, M. KOUTSILERIS (<i>Athens; Areropolis, Greece</i>)	977
From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis. A.R. ALRAFIAH (<i>Jeddah, Saudi Arabia</i>)	983

Cysts and Pseudocysts of the Oral Cavity: Revision of the Literature and a New Proposed Classification. D. MENDITTI, L. LAINO, M. DI DOMENICO, G. TROIANO, M. GUGLIELMOTTI, S. SAVA, A. MEZZOGIORNO, A. BALDI (<i>Naples, Italy</i>)	999
<i>Experimental Studies</i>	
Evaluation of Different Formulations and Routes for the Delivery of the Ionizing Radiation Mitigator GS-Nitroxide (JP4-039). M.W. EPPERLY, P. WIPF, R. FISHER, D. FRANICOLA, J. BEUMER, S. LI, R.M. BRAND, L.D. FALO Jr, G. ERDOS, J.S. GREENBERGER (<i>Pittsburgh, PA, USA</i>)	1009
Ultrasound Microbubble Delivery Targeting Intraplaque Neovascularization Inhibits Atherosclerotic Plaque in an APOE-deficient Mouse Model. H. YUAN, H. HU, J. SUN, M. SHI, H. YU, C. LI, Y. SUN, Z. YANG, R.M. HOFFMAN (<i>Hangzhou; Nanjing, PR China; San Diego, CA, USA</i>)	1025
Chronic Nicotine Exposure Reduces Antioxidant Function of Simvastatin in Renal Proximal Tubule Cells. I. ARANY, T. FÜLÖP, M. DIXIT (<i>Jackson, MS; Charleston, SC, USA</i>)	1033
Association of Polymorphisms in DNA Repair Gene XRCC3 with Asthma in Taiwan. W.-Y. HSIAO, C.-W. TSAI, W.-S. CHANG, S. WANG, C.-Y. CHAO, W.-C. CHEN, T.-C. SHEN, T.-C. HSIA, D.-T. BAU (<i>Taichung, Taiwan, ROC; Xi'an, PR China</i>)	1039
Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer. C.-H. LIAO, W.-S. CHANG, C.-W. TSAI, P.-S. HU, H.-C. WU, S.-W. HSU, G.-L. CHEN, T.-C. YUEH, T.-C. SHEN, T.-C. HSIA, D.-T. BAU (<i>Taichung; Taipei; Changhua, Taiwan, ROC</i>)	1045
Carcinogenic Pesticide Control via Hijacking Endosymbiosis; The Paradigm of DSB-A from <i>Wolbachia pipiensis</i> for the Management of <i>Otiorhynchus singularis</i> . T. KOSTAROPOULOS, L. PAPAGEORGIOU, S. CHAMPERIS TSANIRAS, D. VLACHAKIS, E. ELIOPoulos (<i>Athens; Patras, Greece; London, UK</i>)	1051
Interaction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin. J. STANIČOVÁ, V. VEREBOVÁ, J. BENEŠ (<i>Košice, Slovakia; Prague, Czech Republic</i>)	1063
Characterisation of a Mouse Model of Breast Cancer with Metabolic Syndrome. L.A. BUSS, A. MANDANI, E. PHILLIPS, N.J.A. SCOTT, M.J. CURRIE, G.U. DACHS (<i>Christchurch, New Zealand</i>)	1071
Antitumor Activity of Betulinic Acid and Betulin in Canine Cancer Cell Lines. J. ZHAO, R. LI, A. PAWLAK, M. HENKLEWSKA, A. SYSAK, L. WEN, J.-E. YI, B. OBMIŃSKA-MRUKOWICZ (<i>Changsha, PR China; Wrocław, Poland</i>)	1081
Fermented Lingonberry Juice Inhibits Oral Tongue Squamous Cell Carcinoma Invasion <i>In Vitro</i> Similarly to Curcumin. D. HOORNSTRA, J. VESTERLIN, P. PÄRNÄNEN, A. AL-SAMADI, A. ZLOTOGORSKI-HURVITZ, M. VERED, T. SALO (<i>Helsinki; Oulu, Finland; Tel Aviv; Tel Hashomer, Israel</i>)	1089
Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-κB Activation. K.-C. LEE, W.-T. CHEN, Y.-C. LIU, S.-S. LIN, F.-T. HSU (<i>Taichung; Yilan; Kaohsiung; Taipei, Taiwan, ROC</i>)	1097

Endothelial Lipase Gene Polymorphism (584 C/T) in Coronary Artery Patients Among a Turkish Population. L.A. SOLIM, I.A. GENCAN, B. ÇELIK, A. ATAACAR, U. KOH, B. BÜYÜKÖREN, G. GÜNGÖR, S. ISBIR (<i>Istanbul, Turkey</i>)	1105
Vertical Bone Augmentation Using Three-dimensionally Printed Cap in the Rat Calvarial Partial Defect. J.-M. KIM, J.-H. KIM, B.-H. LEE, S.H. CHOI (<i>Seoul; Cheongju; Cheonan, Republic of Korea</i>).....	1111
Lauryl Gallate Induces Apoptotic Cell Death through Caspase-dependent Pathway in U87 Human Glioblastoma Cells <i>In Vitro</i> . C.-C. LIU, W.-W. LIN, C.-C. WU, S.-L. HSU, C.-Y. WANG, J.-G. CHUNG, C.-S. CHIANG (<i>Hsinchu; Taichung, Taiwan, ROC</i>)	1119
Bufalin Enhances Immune Responses in Leukemic Mice Through Enhancing Phagocytosis of Macrophage <i>In Vivo</i> . Y.-L. SHIH, J.-S. CHOU, Y.-L. CHEN, S.-C. HSUEH, H.-Y. CHUNG, M.-H. LEE, C.-P. CHEN, M.-Z. LEE, H.-T. HOU, H.-F. LU, K.-W. CHEN, J.-G. CHUNG (<i>Taipei; New Taipei; Hsinchu; Houlung; Changhua; Taichung, Taiwan, ROC</i>).....	1129
Antitumor Ability of KT2 Peptide Derived from Leukocyte Peptide of Crocodile Against Human HCT116 Colon Cancer Xenografts. P. MARAMING, S. MAIJAROEN, S. KLAYNONGSRUANG, P. BOONSIRI, S. DADUANG, J.-G. CHUNG, J. DADUANG (<i>Khon Kaen, Thailand; Taichung, Taiwan, ROC</i>).....	1137
Clinical Studies	
Cellular Phone Irradiation of the Head Affects Heart Rate Variability Depending on Inspiration/Expiration Ratio. S. BIRES, A. NIMETH, Z. AJTAY, I. KISS, B. NIMETH, L. HEJJEL (<i>Pécs, Hungary</i>)	1145
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small Cell Lung Cancer: Phase II Study. K. YAMAGUCHI, T. MASUDA, K. FUJITAKA, K. MIWATA, S. SAKAMOTO, Y. HORIMASU, K. HAMAI, S. MIYAMOTO, T. NAKASHIMA, Y. OKAMOTO, H. IWAMOTO, N. ISHIKAWA, Y. MIYATA, M. OKADA, H. HAMADA, N. HATTORI (<i>Hiroshima, Japan</i>)	1155
Standardized Screening and Psycho-oncological Treatment of Orthopedic Cancer Patients. F. LENZE, C. KIRCHHOFF, F. POHLIG, C. KNEBEL, H. RECHL, B. MARTEN-MITTAG, P. HERSCHBACH, R.V. EISENHART-ROTHE, U. LENZE (<i>Munich, Germany</i>)	1161
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma. Y. NEGI, K. KURIBAYASHI, N. FUNAGUCHI, H. DOI, K. MIKAMI, T. MINAMI, T. TAKUWA, T. YOKOI, S. HASEGAWA, T. KIJIMA (<i>Hyogo, Japan</i>)	1169
EGF Level in Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas in Dogs After Administering Tamoxifen. A. SOBCZYŃSKA-RAK, B. ŻYLIŃSKA, Ł. JAROSZ, A. BRODZKI, M. TATAR (Lublin, Poland)	1175
R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy. H. KAMACHI, Y. TSURUGA, T. ORIMO, K. WAKAYAMA, S. SHIMADA, A. NAGATSU, H. YOKOO, T. KAMIYAMA, N. KATOH, A. TAKETOMI (<i>Sapporo, Japan</i>).....	1183
Peak of Standardized Uptake Value in Oral Cancer Predicts Survival Adjusting for Pathological Stage. H. SUZUKI, T. TAMAKI, M. NISHIO, S. BEPPU, N. MUKOYAMA, N. HANAI, D. NISHIKAWA, Y. KOIDE, Y. HASEGAWA (<i>Nagoya, Japan</i>)	1193

T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations. Y. KOGURE, F. SHIGEMATSU, M. OKI, H. SAKA (<i>Nagoya, Japan</i>)	1199
A Case of a Pregnant Woman Diagnosed as Having <i>ALK</i> -rearranged Lung Adenocarcinoma. M. KOMURA, S. YAGISHITA, K. NAKAMURA, N. ARANO, T. TAKESHIGE, K. MURAKI, O. NAGASHIMA, H. IZUMI, S. TOMITA, S. SASAKI, K. TAKAHASHI (<i>Urayasu; Tokyo, Japan</i>)	1205
Pathological Complete Response by S-1 Chemotherapy in Advanced Gastric Cancer. T. NAMIKAWA, N. ISHIDA, S. TSUDA, K. FUJISAWA, E. MUNEKAGE, J. IWABU, M. MUNEKAGE, S. UEMURA, S. TSUJII, H. MAEDA, H. KITAGAWA, M. KOBAYASHI, K. HANAZAKI (<i>Kochi, Japan</i>)	1211
Reconstruction of Inferior Right Hepatic Veins in Living Donor Liver Transplantation. N. BACALBASA, I. BALESCU, M. PAUTOV, J. BREZEAN, M. VILCU, V. BRASOVEANU (<i>Bucharest, Romania</i>)	1217
Mechanical Thrombectomy of Large Artery Occlusion Is Beneficial in Octogenarians. S. KARHI, O. NERG, T. MIETTINEN, E. MÄKIPAAKKANEN, M. TAINA, H. MANNINEN, R. VANNINEN, P. JÄKÄLÄ (<i>Kuopio, Finland</i>)	1223
Ovarian Teratoma or Uterine Malformation? PET/MRI as a Novel Useful Tool in NMDAR Encephalitis. F. CRIMÌ, G. CAMPORESE, C. LACOGNATA, G. FANELLI, D. CECCHIN, M. ZOCCARATO (<i>Padua, Italy</i>)	1231
High-risk Stage II Colorectal Cancers Carry an Equivalent Risk of Peritoneal Recurrence to Stage III. H. NOZAWA, K. KAWAI, K. HATA, T. TANAKA, T. NISHIKAWA, K. OTANI, K. SASAKI, M. KANEKO, S. EMOTO, K. MURONO (<i>Tokyo, Japan</i>)	1235
An Adult Patient with Early Pre-B Acute Lymphoblastic Leukemia with t(12;17)(p13;q21)/ZNF384-TAF15. N. GEORGAKOPOULOS, P. DIAMANTOPOULOS, F. MICCI, N. GIANNAKOPOULOU, K. ZERVAKIS, A. DIMITRAKOPOULOU, N.-A. VINIOU (<i>Athens, Greece; Oslo, Norway</i>)	1241
The Impact on the Long-term Outcomes of Hormonal Status After Hepatic Resection for Breast Cancer Liver Metastases. N. BACALBASA, I. BALESCU, V. ILIE, R. FLOREA, A. SOROP, V. BRASOVEANU, I. BREZEAN, M. VILCU, S. DIMA, I. POPESCU (<i>Bucharest, Romania</i>)	1247
Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders. E. ZAPPULO, M.P. RICCIO, S. BINDA, L. PELLEGRINELLI, F. PREGLIASCO, A.R. BUONOMO, B. PINCHERA, G. D'URSO, C. BRAVACCIO, G. BORGIA, I. GENTILE (<i>Naples; Milan, Italy</i>)	1255
Transcutaneous Carbon Dioxide Treatment Affects Heart Rate Variability – A Pilot Study. Z. KRESKA, B. NÉMETH, I. KISS, I. PÉTER, Z. AJTAY, L. HEJJEL (<i>Harkány; Pécs, Hungary</i>)	1259
Refractive Nightmares Revisited: Calcification of a Multifocal Intraocular Lens. M.M. MOSCHOS, K. LAIOS, A. LAVARIS, C. DAMASKOS, N. GARMPIS, A. THABIT, D. LAKE, S. HAMADA, A. GARMPI, Z. GATZIOUFAS (<i>Athens, Greece; East Grinstead, UK</i>)	1265
The Importance of Concurrent Chemotherapy for T1 Esophageal Cancer: Role of FDG-PET/CT for Local Control. I. OGINO, S. WATANABE, K. HIRASAWA, T. MISUMI, M. HATA, C. KUNISAKI (<i>Yokohama, Japan</i>)	1269
	1695

Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients. A. EL-BALAT, I. SCHMEIL, T. KARN, U. HOLTRICH, L. MAVROVA-RISTESKA, A. RODY, A. YOUSSEF, L.C. HANKER (<i>Frankfurt; Lübeck, Germany; Bologna, Italy</i>).....	1275
Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer. A.C. LOHMAN, I. VAN RIJN, C.L. LINDHARDT, R. VONTHEIN, D. RADES, N.H. HOLLÄNDER (<i>Naestved; Kolding; Sorø, Denmark; Lübeck, Germany</i>).....	1283

Number 6, November-December

Reviews

Treatment of Articular Cartilage Defects: Focus on Tissue Engineering. B. ŹYLIŃSKA, P. SILMANOWICZ, A. SOBCZYŃSKA-RAK, Ł. JAROSZ, T. SZPONDER (<i>Lublin, Poland</i>)	1289
Can Complete Axillary Node Dissection Be Safely Omitted in Patients with Early Breast Cancer When the Sentinel Node Biopsy Is Positive for Malignancy? An Update for Clinical Practice. R. GERA, A. KASEM, K. MOKBEL (<i>London, UK</i>)	1301

Experimental Studies

Cytotoxicity and Pro-/Anti-inflammatory Properties of Cinnamates, Acrylates and Methacrylates Against RAW264.7 Cells. Y. MURAKAMI, A. KAWATA, S. SUZUKI, S. FUJISAWA (<i>Sakado, Japan</i>)	1309
Virome Analysis Reveals No Association of Head and Neck Vascular Anomalies with an Active Viral Infection. N. FRANKE, M. BETTE, A. MARQUARDT, T. BRIESE, W.I. LIPKIN, C. KURZ, J. EHRENREICH, E. MACK, B. BAYING, V. BENEX, F.R. RODEPETER, A. NEFF, A. TEYMOORTASH, B. EIVAZI, U. GEISTHOFF, B.A. STUCK, U. BAKOWSKY, R. MANDIC (<i>Marburg; Heidelberg, Germany; New York City, NY, USA</i>)	1323
Expression of Circulating <i>miR-155</i> , <i>miR-21</i> , <i>miR-221</i> , <i>miR-30a</i> , <i>miR-34a</i> and <i>miR-29a</i> : Comparison of Colonic and Rectal Cancer. E. OROSZ, I. KISS, Z. GYÖNGYI, T. VARJAS (<i>Budapest; Pécs, Hungary</i>).....	1333
Geranylgeraniol Induces PPAR γ Expression and Enhances the Biological Effects of a PPAR γ Agonist in Adipocyte Lineage Cells. T. MATSUBARA, N. TAKAKURA, M. URATA, Y. MURAMATSU, M. TSUBOI, K. YASUDA, W.N. ADDISON, M. ZHANG, K. MATSUO, C. NAKATOMI, Y. SHIGEYAMA-TADA, T. KANEUJI, A. NAKAMICHI, S. KOKABU (<i>Kitakyushu; Miyazaki, Japan; Montreal, QC, Canada</i>).....	1339
The Neutrophil Response to Rabbit Antimicrobial Extract After Implantation of Biomaterial into a Bone/Cartilage Defect. T. SZPONDER, J. WESSELY-SZPONDER, A. SOBCZYŃSKA-RAK (<i>Lublin, Poland</i>)	1345
Blocking of Type 1 Angiotensin II Receptor Inhibits T-lymphocyte Activation and IL-2 Production. S. TAWINWUNG, N. PETPIROON, P. CHANVORACHOTE (<i>Bangkok, Thailand</i>)	1353

Magnolol Induces Apoptosis and Inhibits ERK-modulated Metastatic Potential in Hepatocellular Carcinoma Cells. L.-Y. KUAN, W.-L. CHEN, J.-H. CHEN, F.-T. HSU, T.-T. LIU, W.-T. CHEN, K. WANG, W.-C. CHEN, Y.-C. LIU, W.-S. WANG (<i>Taipei; Taichung; Yilan; Kaohsiung; Keelung; Chiayi; Changhua, Taiwan, ROC</i>)	1361
Feasibility and Characteristics of Pressurized Aerosol Chemotherapy (PAC) in the Bladder as a Therapeutic Option in Early-stage Urinary Bladder Cancer. A. MIKOLAJCZYK, V. KHOSRAWIPOUR, J. SCHUBERT, M. PLOCIENNIK, K. NOWAK, C. FAHR, H. CHAUDHRY, T. KHOSRAWIPOUR (<i>Wroclaw, Poland; Dortmund; Freiburg; Duesseldorf, Germany; Irvine, CA, USA</i>)	1369
Banana Flower Extract Suppresses Benign Prostatic Hyperplasia by Regulating the Inflammatory Response and Inducing G ₁ Cell-cycle Arrest. L.-C. LIU, Y.-H. LIN, Y.-C. LIN, C.-T. HO, C.-M. HUNG, T.-D. WAY, D.-T. BAU (<i>Taichung; Taipei; Hualien; Kaohsiung, Taiwan, ROC; New Brunswick, NJ, USA</i>)	1373
How Much Ischemia Can the Severely Steatotic Rat Liver Tolerate? I.D. KOSTAKIS, N. SIKALIAS, K. ALEXIOU, L. MOUNTZALIA, A. PAPALOIS, T. KARATZAS (<i>Athens; Pikermi, Greece</i>)	1381
The Involvement of Granulosa Cells in the Regulation by Gonadotropins of <i>Cyp17a1</i> in Theca Cells. H. KAKUTA, T. IGUCHI, T. SATO (<i>Yokohama, Japan</i>)	1387
Change in Amino Acid Pools During Neuronal Differentiation of PC12 Cells. A. SANO, H. SHI, R. SUZUKI, Y. SHIRATAKI, H. SAKAGAMI (<i>Saitama, Japan; Shanghai, PR China</i>)	1403
Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome. S. TAKADA, T. MIYASHITA, Y. YAMAMOTO, S. KANOU, S. MUNESUE, Y. OHBATAKE, S. NAKANUMA, K. OKAMOTO, S. SAKAI, J. KINOSHITA, I. MAKINO, K. NAKAMURA, H. TAJIMA, H. TAKAMURA, I. NINOMIYA, S. FUSHIDA, T. OHTA (<i>Kanazawa, Japan</i>)	1409
Evaluation of Porcine Hybrid Bone Block for Bone Grafting in Dentistry. S.E. KIM, E. LEE, K. JANG, K.M. SHIM, S.S. KANG (<i>Gwangju, Republic of Korea</i>)	1419
Geranylgeraniol-induced Myogenic Differentiation of C2C12 Cells. T. MATSUBARA, M. URATA, T. NAKAJIMA, M. FUKUZAKI, R. MASUDA, Y. YOSHIMOTO, W.N. ADDISON, C. NAKATOMI, K. MORIKAWA, M. ZHANG, K. SAEKI, Y. TAKAHASHI, A. NAKAMICHI, S. KOKABU (<i>Kitakyushu; Morioka, Japan; Montreal, QC, Canada</i>)	1427
Exercise Training Attenuates the Development of Cardiac Autonomic Dysfunction in Diabetic Rats. I. NAKOS, N.P.E. KADOGLOU, P. GKEKA, A.T. TZALLAS, N. GIANNAKEAS, D.G. TSALIKAKIS, M. KATSIMPOULAS, G. MANTZIARAS, N. KOSTOMITSOPoulos, C.D. LIAPIS, J. KAKISIS (<i>Athens; Arta; Kozani, Greece; London, UK</i>)	1433
Healing Effect of Platelet-rich Plasma on Decellularized Tracheal Allotransplantation in Rabbits. S.J. JANG, M.-H. PARK, T.-K. LEE, S.H. CHOI (<i>Cheongju, Republic of Korea</i>)	1443
Application of Platelet-rich Plasma and Tricalcium Phosphate in the Treatment of Commminuted Fractures in Animals. T. SZPONDER, J. WESSELY-SZPONDER, A. SOBCZYŃSKA-RAK, B. ŹYLIŃSKA, R.P. RADZKI, I. POLKOWSKA (<i>Lublin, Poland</i>)	1449

Clinical Studies

Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD. P. FLECHSIG, O. HURAL, M. KREUTER, M. EICHHORN, G. HEUSSEL, C. SACHPEKIDIS, H.-U. KAUCZOR, U. HABERKORN, C.P. HEUSSEL, M. EICHINGER (<i>Heidelberg, Germany</i>)	1457
Clinical and Radiological Mid- to Long-term Outcomes Following Ankle Fusion. I.E. GAEDKE, U. WIEBKING, P.F. O'LOUGHLIN, C. KRETTEK, R. GAULKE (<i>Hannover, Germany; Cork, Ireland</i>)	1463
Preliminary Report: Multiple Clusters of Proliferating Cells in Non-dysplastic Corrupted Colonic Crypts Underneath Conventional Adenomas. C.A. RUBIO (<i>Stockholm, Sweden</i>)	1473
The Evolving Role of Pre-pectoral ADM-assisted Approach in Implant-based Immediate Breast Reconstruction Following Conservative Mastectomy: An Overview of the Literature and Description of Technique. U. WAZIR, K. MOKBEL (<i>London, UK</i>)	1477
Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer. M. TREDER, R.P. VOGELSANG, S. JANSSEN, S.E. SCHILD, N.H. HOLLÄNDER, D. RADES (<i>Lübeck; Hannover, Germany; Køge; Naestved, Denmark; Scottsdale, AZ, USA</i>)	1481
Inverse Relationship Between Polio Incidence in the US and Colorectal Cancer. S. LEHRER, P.H. RHEINSTEIN (<i>New York, NY; Severna Park, MD, USA</i>)	1485
Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. S. SHU, M. IIMORI, R. NAKANISHI, T. JOGO, H. SAEKI, E. OKI, Y. MAEHARA (<i>Fukuoka; Kamakura, Japan</i>)	1491
Correlation Between Dosimetric Parameters and Acute Dermatitis of Post-operative Radiotherapy in Breast Cancer Patients. T. TAKENAKA, H. YAMAZAKI, G. SUZUKI, N. AIBE, K. MASUI, D. SHIMIZU, T. NISHIMURA, A. NAKASHIMA, T. OGATA, K. MATSUSHITA, K. YOSHIDA, K. YAMADA (<i>Kyoto; Osaka, Japan</i>)	1499
Histological Grade: Analysis of Prognosis of Non-small Cell Lung Cancer After Complete Resection. M. YASUKAWA, N. SAWABATA, T. KAWAGUCHI, N. KAWAI, T. NAKAI, C. OHBAYASHI, S. TANIGUCHI (<i>Kashihara, Japan</i>)	1505
A Comparison of the Body Composition Changes Between Laparoscopy-assisted and Open Total Gastrectomy for Gastric Cancer. T. AOYAMA, T. YOSHIKAWA, Y. MAEZAWA, K. KANO, K. HARA, T. SATO, T. HAYASHI, T. YAMADA, H. CHO, T. OGATA, H. TAMAGAWA, N. YUKAWA, Y. RINO, M. MASUDA, T. OSHIMA (<i>Kanagawa; Yokohama, Japan</i>)	1513
Spleen Dose–Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer. T. SAITO, R. TOYA, N. YOSHIDA, T. SHONO, T. MATSUYAMA, S. NINOMURA, T. WATAKABE, Y. SASAKI, H. BABA, N. OYA (<i>Kumamoto, Japan</i>)	1519
Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma. N.S. AMARAL, V. RESENDE, J.S. DOS SANTOS, L.F. LIMA, D.C. MORAES, E. FRIEDMAN, L. DE MARCO, L. BASTOS-RODRIGUES (<i>Belo Horizonte; Ribeirão Preto, Brazil; Tel-Hashomer, Israel</i>)	1527

CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. C.-P. HSU, L.-Y. LEE, J.-T. HSU, Y.-P. HSU, Y.-T. WU, S.-Y. WANG, C.-N. YEH, T.-C. CHEN, T.-L. HWANG (<i>Taoyuan, Taiwan; ROC</i>).....	1533
Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. K. TAKADA, G. TOYOKAWA, K. AZUMA, S. TAKAMORI, T. JOGO, F. HIRAI, T. TAGAWA, A. KAWAHARA, J. AKIBA, I. OKAMOTO, Y. NAKANISHI, Y. ODA, T. HOSHINO, Y. MAEHARA (<i>Fukuoka; Kurume, Japan</i>)	1541
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma – A Pilot Study. S. SVOBODOVA, M. KARLIKOVÁ, O. TOPOLCAN, L. PECEN, M. PESTOVA, O. KOTT, V. TRESKA, D. SLOUKA, R. KUCERA (<i>Prague; Pilsen, Czech Republic</i>)	1551
Transcutaneous Carbon Dioxide Treatment Is Capable of Reducing Peripheral Vascular Resistance in Hypertensive Patients. B. NÉMETH, I. KISS, B. AJTAY, I. PÉTER, Z. KRESKA, A. CZIRÁKI, I.G. HORVÁTH, Z. AJTAY (<i>Pécs; Harkány, Hungary</i>).....	1555
CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer. H. LEE, H.J. LEE, I.H. SONG, W.S. BANG, S.-H. HEO, G. GONG, I.A. PARK (<i>Seoul, Republic of Korea</i>).....	1561
Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma. R. ZABLOCKIS, E. ŽURAUSKAS, E. DANILA, V. GRUSLYS (<i>Vilnius, Lithuania</i>)	1571
Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer. H. YOSHIOKA, Y. KOGURE, M. ANDO, C. KITAGAWA, M. IWASAKU, T. NIWA, H. SAKA (<i>Kurashiki; Nagoya; Hirakata; Kyoto; Yokohama, Japan</i>)	1581
Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer. H. YOSHIDA, Y.H. KIM, H. OZASA, Y. SAKAMORI, T. TSUJI, T. NOMIZO, Y. YASUDA, T. YAMAMOTO, H. AJIMIZU, T. HIRAI (<i>Kyoto, Japan</i>).....	1587
Surgical Margin Status of Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Radical Intent: Risk Factors for the Survival Impact of Positive Margins. C.-C. LAI, S.-Y. WANG, C.-H. LIAO, J.-T. HSU, K.-C. CHIANG, T.-S. YEH, T.-L. HWANG, C.-N. YEH (<i>Taoyuan; Keelung, Taiwan, ROC</i>). .	1591
The Assessment of Left Ventricle Function and Subclinical Atherosclerosis in Patients with Acute Myeloid Leukemia. A. MILITARU, A. AVRAM, A.M. CIMPEAN, M. IURCIUC, P. MATUSZ, D. LIGHEZAN, M. MILITARU (<i>Timisoara, Romania</i>).....	1599
Calcium Phosphate Cement Paste Injection as a Fiducial Marker of Cervical Cancer. I. OGINO, M. KITAGAWA, S. WATANABE, H. YOSHIDA, M. HATA (<i>Yokohama, Japan</i>)	1609
mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma – A German Single-center Real-world Experience. M. SCHWAB, R. HOFMANN, H. HEERS, A. HEGELE (<i>Marburg, Germany</i>).....	1617
Ischemic Damage Represents the Main Risk Factor for Biliary Stricture After Liver Transplantation: A Follow-Up Study in a Danish Population. B. LATTANZI, P. OTT, A. RASMUSSEN, K.R. KUDSK, M. MERLI, G.E. VILLADSEN (<i>Rome, Italy; Aarhus; Copenhagen, Denmark</i>)	1623
	1699

Greek Version of the Connor-Davidson Resilience Scale: Psychometric Properties in a Sample of 546 Subjects. E. TSIGKAROPOULOU, A. DOUZENIS, N. TSITAS, P. FERENTINOS, I. LIAPPAS, I. MICHOPoulos (<i>Athens, Greece</i>)	1629
Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Breast Cancer with Liver-predominant Metastatic Disease. J.-H. HSIAO, H.-T. CHANG, Y.-D. TSENG, C.-L. CHIANG, I.-S. CHEN, Y.-C. CHEN, P.-M. CHANG, B.-W. WANG (<i>Kaohsiung, Taiwan, ROC</i>)	1635
Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer. S. NARIHIRO, K. SUWA, T. USHIGOME, M. OHTSU, S. RYU, Y. SHIMOYAMA, T. OKAMOTO, K. YANAGI (<i>Tokyo, Japan</i>)	1643
Diagnostic Accuracy of Muscle Biopsy and Electromyography in 123 Patients with Neuromuscular Disorders. V.C. CONSTANTINIDES, M.M. PAPAHATZAKI, G.K. PAPADIMAS, N. KARANDREAS, T. ZAMBELIS, P. KOKOTIS, P. MANDA (<i>Athens, Greece</i>)	1647
The Relationship Between Sepsis-induced Immunosuppression and Serum Toll-like Receptor 9 Level. N. ATALAN, L. ACAR, N. YAPICI, T. KUDSIOGLU, A. ERGEN, S.G. YILMAZ, T. ISBIR (<i>Istanbul, Turkey</i>)	1653
Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms. C.B. DE CAMPOS, G.E. LAVALLE, L.N. MONTEIRO, G.R.A. PÊGAS, S.L. FIALHO, D. BALABRAM, G.D. CASSALI (<i>Belo Horizonte; Jaboticabal; Vitória, Brazil</i>)	1659
The Preoperative Geriatric Nutritional Risk Index Predicts Postoperative Complications in Elderly Patients with Gastric Cancer Undergoing Gastrectomy. S. KUSHIYAMA, K. SAKURAI, N. KUBO, Y. TAMAMORI, T. NISHII, A. TACHIMORI, T. INOUE, K. MAEDA (<i>Osaka, Japan</i>)	1667
Index	1673

Subject Index

(Figures refer to page numbers)

- ¹³C-NMR spectra, cinnamates, (meth)acrylates, cytotoxicity, pro-/anti-inflammatory properties, RAW264.7 cells, cox2, nos2 and Ho1 mRNA, β-carbon, 1309
- ¹⁸⁸Re-HSAM, biodistribution, pharmacokinetics, GP7TB orthotopic hepatoma model, therapeutic evaluation, 567
- ¹⁸F-FDG-PET/CT, oral squamous cell carcinoma, sUVpeak, overall survival, uICC8th, 1193
- ¹⁸F-fluorodeoxyglucose positron emission computed tomography (¹⁸F-FDG-PET/CT), malignant pleural mesothelioma, early clinical stage, extrapleural pneumonectomy (EPP), pleurectomy or decortication (P/D), biphasic, 1169
- 3D printing, pCL/β-TCP scaffold, oral tumor, dog, 63
- 3D spheroid, oral cancer cells, anti-invasive, anti-proliferative, 1089
- 4-methyl-umbelliferon, hepatocellular carcinoma, hyaluronan, 273
- ACTH, PD-1, CTLA-4, malignant melanoma, pituitary gland, thyroid gland, irAEs, 345
- Acute allergic rhinoconjunctivitis, artificial tears, tear osmolarity, 403
- Acute myocardial infarction, biomarkers, greek population, microRNAs, plasma, 313
- Adenocarcinoma, lung cancer, pathology, prognostic factors, 1571
- Adenohypophysis, neurohypophysis, hIF1α, hIF2α, VEGF, CD31, 185
- Adipogenesis, diabetes, statin, antidiabetic drug, geranylgeranylation, 1339
- Adjuvant treatment, hypofractionated radiotherapy (HRT), trastuzumab, breast cancer cardiotoxicity, 879
- Adrenal, pheochromocytoma, paraganglionoma, kidney, endocrine, 211
- Adrenal, pheochromocytoma, paraganglionoma, kidney, endocrine, 703
- Advanced-stage ovarian cancer, diaphragmatic resection, diaphragmatic peritonectomy, 431
- Adverse events, glaucoma, prostaglandin analogues, side effects, medical therapy, benzalkonium chloride, *in vivo* confocal microscopy, review, 211
- AFP, PIVKA-II, hepatocellular carcinoma, biomarkers, predictive, 1551
- Age, gender, genotype, MMP-8, polymorphism, pterygium, taiwan, 41
- Age, height, weight, BMI, muscle mass predictors, lower extremity reconstruction, gracilis muscle, free flap, 591
- Airway obstruction, interstitial lung disease, lung cancer, nivolumab, risk factor, 887
- Alectinib, lung cancer, pregnancy, anaplastic lymphoma kinase, fetus, 1205
- Alectinib, non-small cell lung cancer, aLK-positive, ceritinib, 1587
- Alginate, biomaterial, carbon fibers, antimicrobial peptides, neutrophils, 1345
- Alginate, biomaterial, carbon fibers, antimicrobial peptides, neutrophils, 1345
- ALK-positive, non-small cell lung cancer, alectinib, ceritinib, 1587
- ALK, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, PDL-1 and c-MYC, 303
- Alkylaminoguaiazulene, alkylation, morpholine backbone, cytotoxicity, tumor specificity, apoptosis, 541
- Alkylation, alkylaminoguaiazulene, morpholine backbone, cytotoxicity, tumor specificity, apoptosis, 541
- Allotransplantation, decellularized trachea, platelet-rich plasma, rabbit, 1443
- Amentoflavone, glioblastoma, and NF-κB, apoptosis, 279
- Amentoflavone, hepatocellular carcinoma, extracellular signal-regulated kinase, nuclear factor-kappaB, bioluminescence imaging, 1097
- Amentoflavone, hepatocellular carcinoma, NF-κB, ERK, 549
- Amino acid concentration, neuronal differentiation, PC12 cells, NGF, urea, taurine, aspartic acid, overlay isolation method, 1403
- Amino acids, prostate cancer, renal cell carcinoma, urinary bladder cancer, 425
- Amrubicin, small cell lung cancer, refractory, relapsed, phase II, 1581
- Amylase, resistive index, delayed graft function, kidney transplant, 397
- Amyloid β-peptide, nerve cell, NGF, differentiation, protection, hormesis, bamboo leaf extract, 231
- Amyotrophic lateral sclerosis, motor neuron diseases, mouse models, C9ORF72, FUS, SOD1, TARDBP, review, 983
- Analgesia, laboratory rats, pain, transdermal, fentanyl, 713
- Anaplastic lymphoma kinase, lung cancer, pregnancy, alectinib, fetus, 1205
- And NF-κB, glioblastoma, amentoflavone, apoptosis, 279

- Androgen synthesis, theca cell, cyp17a1, luteinizing hormone, granulosa cell, PCOS, 1387
- Androgen-deprivation therapy, prostate cancer, bone mineral density, chronic kidney disease, 409
- Aneuploidy, cell-cycle checkpoints, cancer, regulation, cyclins, cyclin-dependent kinases, review, 1
- Angiogenesis, breast cancer, microvessels, vascular proliferation, immunohistochemistry, 79
- Angiogenesis, tumour intravasation, tumour thrombus, prostate cancer, melanoma, 461
- Angiotensin, t-lymphocyte, IL-2, candesartan, ERK, 1353
- Animal, cartilage, treatment, regeneration, biomaterial, tissue engineering, review, 1289
- Ankle fusion, osteoarthritis, insurance status, revision surgery, long-term follow-up, 1463
- Anterolateral thigh flap, head and neck cancer, free-flap transfer, reconstructive surgery, radial forearm flap, 893
- Anti-invasive, oral cancer cells, anti-proliferative, 3D spheroid, 1089
- Anti-proliferative, oral cancer cells, anti-invasive, 3D spheroid, 1089
- Anti-tuberculosis, isoniazid (INH), rifampin (RIF), hyperlipidemia, population-based case-control study, 47
- Anticancer activity, colorectal cancer, KT2 peptide, xenograft, apoptosis, 1137
- Anticancer drug, neurotoxicity, differentiation stage, PC12, NGF, 745
- Anticancer drug, neurotoxicity, differentiation stage, PC12, NGF, 765
- Antidiabetic drug, diabetes, adipogenesis, statin, geranylgeranylation, 1339
- Antimicrobial activity, *N. sativa* essential oil, *Listeria monocytogenes*, resistance modifying activity, 737
- Antimicrobial peptides, biomaterial, alginate, carbon fibers, neutrophils, 1345
- Antimicrobial peptides, biomaterial, alginate, carbon fibers, neutrophils, 1345
- Antioxidant, simvastatin, nicotine, renal, HO1, mnSOD, CREB, ERK, p66shc, 1033
- Antiproliferative activity, betulin acid, betulin, apoptosis, cell cycle, canine lymphoma, canine osteosarcoma, 1081
- Anxiety, palliative radiotherapy, edmonton symptom assessment system, depression, marital status, 327
- Aortic augmentation index, carbon dioxide therapy, aortic pulse-wave velocity, aortic stiffness, 1555
- Aortic pulse-wave velocity, carbon dioxide therapy, aortic augmentation index, aortic stiffness, 1555
- Aortic stiffness, carbon dioxide therapy, aortic pulse-wave velocity, aortic augmentation index, 1555
- ApoE, metabolic syndrome, breast cancer, hyperlipidaemia, arKO, 1071
- Apoptosis, alkylaminoguaiazulene, alkylation, morpholine backbone, cytotoxicity, tumor specificity, 541
- Apoptosis, azulene amides, cytotoxicity, tumor specificity, hydrophobicity, molecular shape, 479
- Apoptosis, benign thyroid nodules, bad, bcl-2, bax, gene expression, 555
- Apoptosis, betulin acid, betulin, antiproliferative activity, cell cycle, canine lymphoma, canine osteosarcoma, 1081
- Apoptosis, colorectal cancer, anticancer activity, KT2 peptide, xenograft, 1137
- Apoptosis, cycloartobiloxanthone, lung cancer, mitochondria-dependent apoptotic pathway, BAX, MCL1, 71
- Apoptosis, glioblastoma, amentoflavone, and NF- κ B, 279
- Apoptosis, magnolol, extracellular-signal-regulated kinase, hepatocellular carcinoma, 1361
- Apoptotic cell death, lauryl gallate, caspase pathway, human glioblastoma U87 cells, 1119
- AR, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- ArKO, metabolic syndrome, breast cancer, hyperlipidaemia, apoE, 1071
- Arterial stiffness, chemotherapy, cardiotoxicity, myocardial dysfunction, subclinical atherosclerosis, LV function, 1599
- Artificial tears, acute allergic rhinoconjunctivitis, tear osmolarity, 403
- Aspartic acid, neuronal differentiation, PC12 cells, NGF, amino acid concentration, urea, taurine, overlay isolation method, 1403
- Asthma, genotype, single nucleotide polymorphism, XRCC3, taiwan, 1039
- Atherosclerosis, biomarker, miRNA221, miRNA222, miRNA122a, 561
- Atherosclerosis, cardiovascular disease, matrix metalloproteinases, vitamin D, vitamin D receptor, review, 977
- Atherosclerosis, ultrasound, targeted microbubble, intraplaque neovascularization, 1025
- Autopsy, pulmonary tumor embolism, uterine cervical cancer, 337
- Axillary dissection, sentinel lymph node biopsy, early breast cancer, axillary radiotherapy, evidence-based medicine, clinical practice update, review, 1301
- Axillary radiotherapy, sentinel lymph node biopsy, early breast cancer, axillary dissection, evidence-based medicine, clinical practice update, review, 1301
- Azoxymethane, colorectal cancer, *Capsosiphon fulvescens*, *Hizikia fusiforme*, rat, 101

- Azulene amides, cytotoxicity, tumor specificity, hydrophobicity, molecular shape, apoptosis, 479
- B-carbon, cinnamates, (meth)acrylates, cytotoxicity, pro-/anti-inflammatory properties, RAW264.7 cells, cox2, nos2 and Ho1 mRNA, ¹³C-NMR spectra, 1309
- β -Carotene, lycopene, tri-n-butyl borane, LPS, RAW264.7 cells, COX2, NOS2, HMOX1, 255
- B-glucan, paramylon, wound dressing, cytokine, 799
- B-tri-calcium phosphate, platelet-rich plasma, comminuted fracture, bone healing, 1449
- Bad, benign thyroid nodules, apoptosis, bcl-2, bax, gene expression, 555
- Balneotherapy, carbon dioxide treatment, rehabilitation, heart rate variability, 1259
- Bamboo leaf extract, nerve cell, NGF, differentiation, amyloid β -peptide, protection, hormesis, 231
- Banana flower extract, benign prostatic hyperplasia, G0/G1 arrest, cyclooxygenase-2, prostaglandin E2, 1373
- Bax, benign thyroid nodules, apoptosis, bad, bcl-2, gene expression, 555
- BAX, cycloartobiloxanthone, lung cancer, apoptosis, mitochondria-dependent apoptotic pathway, MCL1, 71
- Bcl-2, benign thyroid nodules, apoptosis, bad, bax, gene expression, 555
- Benifuuki tea, cytochrome P450, pharmacokinetics, food-drug interactions, CYP2D, CYP3A, 33
- Benign prostatic hyperplasia, banana flower extract, G0/G1 arrest, cyclooxygenase-2, prostaglandin E2, 1373
- Benign thyroid nodules, apoptosis, bad, bcl-2, bax, gene expression, 555
- Benzalkonium chloride, glaucoma, prostaglandin analogues, side effects, adverse events, medical therapy, *in vivo* confocal microscopy, review, 211
- BEP, germ cell tumor, neutropenia, pegfilgrastim, 899
- Bernese Mountain Dog, canine, histiocytic sarcoma, histo(patho)logy, cytology, immunohistochemistry, flatcoated Retriever, comparative pathology, 7
- Betulin acid, betulin, antiproliferative activity, apoptosis, cell cycle, canine lymphoma, canine osteosarcoma, 1081
- Betulin, betulin acid, antiproliferative activity, apoptosis, cell cycle, canine lymphoma, canine osteosarcoma, 1081
- Bevacizumab, salvage therapy, non-squamous cell lung cancer, osteonecrosis of the jaw, 1155
- BHK 21/C13 cell line, chick embryo chorioallantoic membrane, experimental therapy, phenotype characterization, 791
- Bile leakage, liver parenchymal transection, liver resection, hepatectomy, ultrasonic scalpel, lotus, harmonic, bleeding, 883
- Bile, *Opisthorchis viverrini*, cholangiocarcinoma, proteomics, biomarkers, 871
- Biliary complication, liver transplantation, strictures, cytomegalovirus, hepatic artery stenosis, 1623
- Biodegradability, porcine hybrid bone block, collagen, hydroxyapatite, bone regeneration, 1419
- Biodistribution, pharmacokinetics, GP7TB orthotopic hepatoma model, therapeutic evaluation, ¹⁸⁸Re-HSAM, 567
- Bioluminescence imaging, amentoflavone, hepatocellular carcinoma, extracellular signal-regulated kinase, nuclear factor-kappaB, 1097
- Biomarker, atherosclerosis, miRNA221, miRNA222, miRNA122a, 561
- Biomarker, circulating microRNA, colon, rectum, human, 1333
- Biomarkers, acute myocardial infarction, greek population, microRNAs, plasma, 313
- Biomarkers, *Opisthorchis viverrini*, cholangiocarcinoma, proteomics, bile, 871
- Biomarkers, PIVKA-II, AFP, hepatocellular carcinoma, predictive, 1551
- Biomaterial, alginate, carbon fibers, antimicrobial peptides, neutrophils, 1345
- Biomaterial, alginate, carbon fibers, antimicrobial peptides, neutrophils, 1345
- Biomaterial, animal, cartilage, treatment, regeneration, tissue engineering, review, 1289
- Biopsy, muscle, electromyography, neuromuscular disorders, 1647
- Biphasic, malignant pleural mesothelioma, ¹⁸F-fluorodeoxyglucose positron emission computed tomography (18F-FDG-PET/CT), early clinical stage, extrapleural pneumonectomy (EPP), pleurectomy or decortication (P/D), 1169
- Biweekly, pancreatic cancer, modified regimen, convenient, nab-paclitaxel, gemcitabine, 653
- Bladder cancer, genotype, MMP-7, polymorphism, Taiwan, 1045
- Bladder cancer, quality of life, ileal conduit, orthotopic neobladder, radical cystectomy, 139
- Bladder cancer, urothelial carcinoma, peritoneum, computed tomography, therapy, 905
- Bleeding, liver parenchymal transection, liver resection, hepatectomy, ultrasonic scalpel, lotus, harmonic, bile leakage, 883
- Blood transfusion, esophagogastric junction carcinoma, splenectomy, venous invasion, 145
- BMI, height, weight, age, muscle mass predictors, lower extremity reconstruction, gracilis muscle, free flap, 591

- Body composition, lean body mass, laparoscopy-assisted total gastrectomy, open total gastrectomy, surgical stress, 1513
- Bone healing, platelet-rich plasma, comminuted fracture, β -tri-calcium phosphate, 1449
- Bone marrow, treatment-related lymphopenia, chemoradiotherapy, spleen, dose–volume parameters, 1519
- Bone mineral density, prostate cancer, androgen-deprivation therapy, chronic kidney disease, 409
- Bone morphogenetic protein-2, cryopolymerization, dog, gelatin methacrylate hydrogel, radial fracture, 575
- Bone regeneration, porcine hybrid bone block, collagen, hydroxyapatite, biodegradability, 1419
- Bone tumor, sarcoma, psychosocial distress, distress screening, cancer, pO-Bado, 1161
- Brachytherapy, prostate cancer, cost effectiveness, prostatectomy, radiotherapy, integrated delivery and finance system, 113
- BRAF, pancreatic cancer, KRAS, EGFR, PIK3CA, CDKN2A, TP53, ethnicity, 1527
- Brain metastases, radiosurgery, fractionated stereotactic radiotherapy, survival, scoring-system, validation, 381
- Brain metastasis, pertuzumab, metastatic breast cancer, 839
- Breast cancer cardiotoxicity, hypofractionated radiotherapy (HRT), trastuzumab, adjuvant treatment, 879
- Breast cancer patients, white blood cell counts, neutrophil counts, chemotherapy, new device, preliminary results, 1283
- Breast cancer therapy, mastectomy, seroma formation, postoperative complications, dead space reduction, surgical adhesive, tissuGlu, 625
- Breast cancer, breast reconstruction, dermal matrix, pectoral muscle, 1477
- Breast cancer, contrast-enhanced ultrasound, prognosis, qualitative analysis, quantitative analysis, 945
- Breast cancer, *de novo* stage IV patients, recurrent, hER2-negative, hR-positive, 353
- Breast cancer, dendritic cell, cD11c, tumor-infiltrating lymphocyte, 1561
- Breast cancer, dermatitis, radiation therapy, mastectomy, 961
- Breast cancer, genotype, MMP-1, polymorphism, Taiwan, 487
- Breast cancer, liver metastases, hormonal receptor, HER2 status, 1247
- Breast cancer, liver metastasis, hepatic arterial infusion chemotherapy (HAIC), LMBC, heavily-pretreated patients, 1635
- Breast cancer, metabolic syndrome, hyperlipidaemia, apoE, arKO, 1071
- Breast cancer, microvessels, vascular proliferation, immunohistochemistry, angiogenesis, 79
- Breast cancer, neutrophil-to-lymphocyte ratio, endocrine therapy, stage IV, predictive marker, 669
- Breast cancer, p16, SATB1, ki-67, TMA, tissue microarray, proliferation, 731
- Breast cancer, physical training, n-methyl-N-nitrosourea, 249
- Breast cancer, post-operative radiotherapy, radiation dermatitis, dosimetric parameter, 1499
- Breast cancer, TIVAD, venous access system, complication, thrombosis, 1275
- Breast neoplasm, exercise, martial arts, physical activity, quality of life, kyusho Jitsu, 819
- Breast reconstruction, breast cancer, dermal matrix, pectoral muscle, 1477
- Bufalin, leukemia WEHI-3 cells, macrophage, natural killer cells, phagocytosis, 1129
- C-kit, triple-negative breast cancer, p53, p63, ki67, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- C-Reactive protein-to-albumin ratio, malignant pleural mesothelioma, neutrophil-to-lymphocyte ratio, prognostic factor, 445
- C2C12 cells, sarcopenia, myogenesis, statin, geranylgeranylation, 1427
- C57BL/6J, gene expression, retn, iapp, drd5, 813
- C9ORF72, amyotrophic lateral sclerosis, motor neuron diseases, mouse models, FUS, SOD1, TARDBP, review, 983
- Caiman®, ovarian cancer, energy device, surgery, 359
- Calcium phosphate cement, injectable fiducial marker, cone beam computed tomography, magnetic resonance imaging, cervical cancer, 1609
- Cancer of the bladder, cerebral metastases, whole-brain irradiation, prognostic tool, estimation of survival, 633
- Cancer stem cell, colorectal adenoma, colorectal cancer, colorectal polyp, doublecortin-like kinase 1, 365
- Cancer, cell-cycle checkpoints, regulation, cyclins, cyclin-dependent kinases, aneuploidy, review, 1
- Cancer, sarcoma, psychosocial distress, distress screening, bone tumor, pO-Bado, 1161
- Candesartan, angiotensin, t-lymphocyte, IL-2, ERK, 1353
- Canine lymphoma, betulin acid, betulin, antiproliferative activity, apoptosis, cell cycle, canine osteosarcoma, 1081
- Canine osteosarcoma, betulin acid, betulin, antiproliferative activity, apoptosis, cell cycle, canine lymphoma, 1081
- Canine, histiocytic sarcoma, histo(patho)logy, cytology, immunohistochemistry, bernese Mountain Dog, flatcoated Retriever, comparative pathology, 7
- Canine, mammary gland, metastasis, thalidomide, metronomic chemotherapy, 1659

- Capsosiphon fulvescens*, azoxymethane, colorectal cancer, *Hizikia fusiforme*, rat, 101
- Carbon couch, skin toxicity, surface dose, HM couch, 531
- Carbon dioxide therapy, aortic pulse-wave velocity, aortic augmentation index, aortic stiffness, 1555
- Carbon dioxide treatment, rehabilitation, balneotherapy, heart rate variability, 1259
- Carbon fibers, biomaterial, alginate, antimicrobial peptides, neutrophils, 1345
- Carbon fibers, biomaterial, alginate, antimicrobial peptides, neutrophils, 1345
- Cardiac autonomic dysfunction, diabetis, ECG, 1433
- Cardiac pacemaker, pacemaker programming modes, single-chamber pacing, dual-chamber pacing, rate responsive function, exercise capacity, 419
- Cardio-oncology, recurrent pericardial effusion, pericardiocentesis, cisplatin, 373
- Cardiopulmonary failure patients, extracorporeal membrane oxygenation therapy, nutritional intervention, 829
- Cardiotoxicity, chemotherapy, myocardial dysfunction, arterial stiffness, subclinical atherosclerosis, LV function, 1599
- Cardiovascular disease, atherosclerosis, matrix metalloproteinases, vitamin D, vitamin D receptor, review, 977
- Cartilage, animal, treatment, regeneration, biomaterial, tissue engineering, review, 1289
- Caspase pathway, lauryl gallate, apoptotic cell death, human glioblastoma U87 cells, 1119
- CD-RISC, resilience, psychometric properties, validity, greek version, 1629
- CD11c, breast cancer, dendritic cell, tumor-infiltrating lymphocyte, 1561
- CD31, adenohypophysis, neurohypophysis, hIF1 α , hIF2 α , VEGF, 185
- CD44, early recurrence, pancreatic cancer, surgery, 1533
- CDKN2A, pancreatic cancer, KRAS, EGFR, BRAF, PIK3CA, TP53, ethnicity, 1527
- CDNA microarray, gadoxetate disodium, chang liver cells, influx transporter OATP1B1, 677
- Celiac axis stenosis, median arcuate ligament syndrome, splenic artery patch, 699
- Celiac trunk resection, retroperitoneal tumor, paraganglioma, hepatic artery reinsertion, 911
- Cell adhesion, cell proliferation, mesothelial, pleura, silver nanoparticles, 109
- Cell adhesion, plasma electrolytic oxidation (PEO), *in vitro* cytocompatibility, surface topography, 241
- Cell cycle, betulin acid, betulin, antiproliferative activity, apoptosis, canine lymphoma, canine osteosarcoma, 1081
- Cell proliferation, cell adhesion, mesothelial, pleura, silver nanoparticles, 109
- Cell-cycle checkpoints, cancer, regulation, cyclins, cyclin-dependent kinases, aneuploidy, review, 1
- Cellular phone, heart rate variability, heart rate asymmetry, microwave radiation, 1145
- Cerebral infarction, cerebrovascular stroke, thrombectomy, elderly, octogenarian, endovascular procedures, 1223
- Cerebral metastases, cancer of the bladder, whole-brain irradiation, prognostic tool, estimation of survival, 633
- Cerebrospinal fluid, intrathecal catheter, melatonin, swine, minipig, 583
- Cerebrovascular stroke, thrombectomy, elderly, octogenarian, endovascular procedures, cerebral infarction, 1223
- Ceritinib, non-small cell lung cancer, aLK-positive, alectinib, 1587
- Cervical cancer, calcium phosphate cement, injectable fiducial marker, cone beam computed tomography, magnetic resonance imaging, 1609
- Chang liver cells, gadoxetate disodium, cDNA microarray, influx transporter OATP1B1, 677
- Chemoradiotherapy, neoadjuvant, pancreatic cancer, gemcitabine, R0 resection, 1183
- Chemoradiotherapy, treatment-related lymphopenia, spleen, bone marrow, dose-volume parameters, 1519
- Chemotherapeutic outcome, colorectal cancer, tumor-infiltrating lymphocytes, 151
- Chemotherapy, breast cancer patients, white blood cell counts, neutrophil counts, new device, preliminary results, 1283
- Chemotherapy, cardiotoxicity, myocardial dysfunction, arterial stiffness, subclinical atherosclerosis, LV function, 1599
- Chemotherapy, drug-induced interstitial lung disease, re-administration, EGFR-TKI, corticosteroid, 851
- Chemotherapy, gastric cancer, complete response, S-1, preoperative therapy, 1211
- Chemotherapy, TAS-102, unresectable colorectal carcinoma, 1643
- Chick embryo chorioallantoic membrane, BHK 21/C13 cell line, experimental therapy, phenotype characterization, 791
- Cholangiocarcinoma, NK cell, xenograft nude mouse model, 771
- Cholangiocarcinoma, *Opisthorchis viverrini*, proteomics, bile, biomarkers, 871
- Chronic kidney disease, prostate cancer, androgen-deprivation therapy, bone mineral density, 409
- Chronic obstructive pulmonary disease, oxidative status, lipid profiles, lung function, oligomeric proanthocyanidin, 753
- Cinnamates, (meth)acrylates, cytotoxicity, pro-/anti-inflammatory properties, RAW264.7 cells, cox2, nos2 and Ho1 mRNA, ¹³C-NMR spectra, β -carbon, 1309

- Circulating microRNA, colon, rectum, biomarker, human, 1333
- Cisplatin, recurrent pericardial effusion, pericardiocentesis, cardio-oncology, 373
- CK 5/6, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- CK17, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- Classification, cysts, pseudo-cysts, cytokeratin, oral cavity, diagnosis, review, 999
- Claudin 7, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, CK 5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- Clinical outcome, oropharyngeal cancer, surgery, human papillomavirus, p16, 927
- Clinical practice update, sentinel lymph node biopsy, early breast cancer, axillary radiotherapy, axillary dissection, evidence-based medicine, review, 1301
- CMet, triple-negative breast cancer, p53, p63, c-kit, ki67, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- Collagen, porcine hybrid bone block, hydroxyapatite, biodegradability, bone regeneration, 1419
- Colon, circulating microRNA, rectum, biomarker, human, 1333
- Colon, crypts, stem cells, morphology, proliferation, 1473
- Colorectal adenoma, cancer stem cell, colorectal cancer, colorectal polyp, doublecortin-like kinase 1, 365
- Colorectal cancer, anticancer activity, KT2 peptide, xenograft, apoptosis, 1137
- Colorectal cancer, azoxymethane, *Capsosiphon fulvescens*, *Hizikia fusiforme*, rat, 101
- Colorectal cancer, cancer stem cell, colorectal adenoma, colorectal polyp, doublecortin-like kinase 1, 365
- Colorectal cancer, cullins, cullin-1, cullin-2, prognosis, 391
- Colorectal cancer, high-risk stage II, stage III, peritoneal metastasis, 1235
- Colorectal cancer, polio virus, the Cancer Genome Atlas, PVR gene, 1485
- Colorectal cancer, tumor-infiltrating lymphocytes, chemotherapeutic outcome, 151
- Colorectal polyp, cancer stem cell, colorectal adenoma, colorectal cancer, doublecortin-like kinase 1, 365
- Comminuted fracture, platelet-rich plasma, β-tri-calcium phosphate, bone healing, 1449
- Comparative pathology, canine, histiocytic sarcoma, histo(patho)logy, cytology, immunohistochemistry, bernese Mountain Dog, flatcoated Retriever, 7
- Complete response, gastric cancer, chemotherapy, S-1, preoperative therapy, 1211
- Complication, TIVAD, venous access system, thrombosis, breast cancer, 1275
- Complications, gastric cancer, elderly, outcomes, GNRI, 1667
- Computed tomography, bladder cancer, urothelial carcinoma, peritoneum, therapy, 905
- Concurrent chemoradiotherapy, local control, T1 esophageal cancer, FDG-PET/CT, 1269
- Conditions, embryo culture media, trends, epigenetics, review, 451
- Cone beam computed tomography, calcium phosphate cement, injectable fiducial marker, magnetic resonance imaging, cervical cancer, 1609
- Conjunctiva, *in vivo* laser scanning confocal microscopy, goblet cells, open-angle glaucoma, glaucoma therapy, ocular surface, 437
- Contrast-enhanced ultrasound, breast cancer, prognosis, qualitative analysis, quantitative analysis, 945
- Convenient, pancreatic cancer, modified regimen, nab-paclitaxel, gemcitabine, biweekly, 653
- Coronary artery disease, LIPG (584 C/T), polymorphism, 1105
- Coronary heart disease, emotional intelligence, emotions, diabetes melitus, obesity, 859
- Corticosteroid, drug-induced interstitial lung disease, re-administration, chemotherapy, EGFR-TKI, 851
- Cosine similarity score, data mining, report quality, structured reporting, objective comparison, text mining, 843
- Cost effectiveness, prostate cancer, prostatectomy, brachytherapy, radiotherapy, integrated delivery and finance system, 113
- Cox2, cinnamates, (meth)acrylates, cytotoxicity, pro-/anti-inflammatory properties, RAW264.7 cells, nos2 and Ho1 mRNA, 13C-NMR spectra, β-carbon, 1309
- COX2, β-Carotene, lycopene, tri-n-butyl borane, LPS, RAW264.7 cells, NOS2, HMOX1, 255
- CREB, simvastatin, nicotine, renal, antioxidant, HO1, mnSOD, ERK, p66shc, 1033
- Crohn's disease, ileal diverticulosis, small bowel adenocarcinoma, 191
- Cryopolymerization, bone morphogenetic protein-2, dog, gelatin methacrylate hydrogel, radial fracture, 575
- Crypts, colon, stem cells, morphology, proliferation, 1473
- CSE, nicotine- and tar-removed cigarette smoke extract, mouse rectal carcinoma Colon-26 cells, invasion, methyl vinyl ketone, MVK, 493
- CT, PD-L2, lung adenocarcinoma, 1541
- CTLA-4, PD-1, malignant melanoma, ACTH, pituitary gland, thyroid gland, irAEs, 345

- Cullin-1, cullins, cullin-2, colorectal cancer, prognosis, 391
 Cullin-2, cullins, cullin-1, colorectal cancer, prognosis, 391
 Cullins, cullin-1, cullin-2, colorectal cancer, prognosis, 391
 Curative resection, pancreatic adenocarcinoma, surgical margin, 1591
 Cyclin-dependent kinases, cell-cycle checkpoints, cancer, regulation, cyclins, aneuploidy, review, 1
 Cyclins, cell-cycle checkpoints, cancer, regulation, cyclin-dependent kinases, aneuploidy, review, 1
 Cycloartobiloxanthone, lung cancer, apoptosis, mitochondria-dependent apoptotic pathway, BAX, MCL1, 71
 Cyclooxygenase-2, banana flower extract, benign prostatic hyperplasia, G0/G1 arrest, prostaglandin E2, 1373
 Cyp17a1, theca cell, luteinizing hormone, granulosa cell, PCOS, androgen synthesis, 1387
 CYP2D, cytochrome P450, benifuuki tea, pharmacokinetics, food-drug interactions, CYP3A, 33
 CYP3A, cytochrome P450, benifuuki tea, pharmacokinetics, food-drug interactions, CYP2D, 33
 Cysts, pseudo-cysts, cytokeratin, oral cavity, diagnosis, classification, review, 999
 Cytochrome P450, benifuuki tea, pharmacokinetics, food-drug interactions, CYP2D, CYP3A, 33
 Cytokeratin, cysts, pseudo-cysts, oral cavity, diagnosis, classification, review, 999
 Cytokine, β -glucan, paramylon, wound dressing, 799
 Cytology, canine, histiocytic sarcoma, histo(patho)logy, immunohistochemistry, bernese Mountain Dog, flatcoated Retriever, comparative pathology, 7
 Cytomegalovirus, liver transplantation, biliary complication, strictures, hepatic artery stenosis, 1623
 Cytotoxicity, alkylaminoguaiazulene, alkylation, morpholine backbone, tumor specificity, apoptosis, 541
 Cytotoxicity, azulene amides, tumor specificity, hydrophobicity, molecular shape, apoptosis, 479
 Cytotoxicity, cinnamates, (meth)acrylates, pro-/anti-inflammatory properties, RAW264.7 cells, cox2, nos2 and Ho1 mRNA, 13C-NMR spectra, β -carbon, 1309
 Data mining, report quality, structured reporting, objective comparison, text mining, cosine similarity score, 843
 Db Mice, renin-angiotensin system, optical coherence tomography, diabetic retinopathy, 265
 DBS, herpes simplex, neonatal herpes, neurobiology, etiology, 1255
De novo stage IV patients, breast cancer, recurrent, hER2-negative, hR-positive, 353
 Dead space reduction, breast cancer therapy, mastectomy, seroma formation, postoperative complications, surgical adhesive, tissuGlu, 625
 Debulking surgery, peritoneal carcinomatosis, peritoneal hydatidosis, 967
 Decellularized trachea, allotransplantation, platelet-rich plasma, rabbit, 1443
 Delayed graft function, amylase, resistive index, kidney transplant, 397
 Dendritic cell, breast cancer, cD11c, tumor-infiltrating lymphocyte, 1561
 Depression, palliative radiotherapy, edmonton symptom assessment system, anxiety, marital status, 327
 Dermal matrix, breast reconstruction, breast cancer, pectoral muscle, 1477
 Dermatitis, breast cancer, radiation therapy, mastectomy, 961
 Diabetes melitus, emotional intelligence, emotions, coronary heart disease, obesity, 859
 Diabetes, adipogenesis, statin, antidiabetic drug, geranylgeranylation, 1339
 Diabetic retinopathy, db Mice, renin-angiotensin system, optical coherence tomography, 265
 Diabetis, cardiac autonomic dysfunction, ECG, 1433
 Diagnosis, cysts, pseudo-cysts, cytokeratin, oral cavity, classification, review, 999
 Diaphragmatic peritonectomy, advanced-stage ovarian cancer, diaphragmatic resection, 431
 Diaphragmatic resection, advanced-stage ovarian cancer, diaphragmatic peritonectomy, 431
 Diethylnitrosamine, vitamin C, hepatocellular carcinoma, smp30 KO mice, 93
 Diethylstilbestrol, polyovular follicle, estrogen receptor β , ovary, 19
 Differentiation stage, neurotoxicity, anticancer drug, PC12, NGF, 745
 Differentiation stage, neurotoxicity, anticancer drug, PC12, NGF, 765
 Differentiation, nerve cell, NGF, amyloid β -peptide, protection, hormesis, bamboo leaf extract, 231
 Diffuse large B cell Lymphoma, stomach, plasmablastic lymphoma, ommunohistochemistry, *in situ* hybridization, 413
 Diode laser, photodynamic therapy, pyoktanin blue, root canal irrigants, 707
 Disease-free interval, obesity paradox, pulmonary metastases, metastasectomy, overall survival, 197
 Distal spleno-pancreatectomy, splenic artery aneurysm, resection, 915
 Distress screening, sarcoma, psychosocial distress, cancer, bone tumor, pO-Bado, 1161
 Diurnal rhythm, lighting conditions, mealtime, swine model, working environments, 55

- DNA damage response, immune checkpoint inhibitor, lung squamous cell carcinoma, 171
- DNA, hypericin, emodin, serum albumins, interaction, thermal stability, 1063
- Dog, 3D printing, pCL/β-TCP scaffold, oral tumor, 63
- Dog, bone morphogenetic protein-2, cryopolymerization, gelatin methacrylate hydrogel, radial fracture, 575
- Dog, EGF, epidermal growth factor, perianal tumours, tamoxifen, 1175
- Dog, epidermal growth factor, EGF, paradontopathy, oral cavity tumour, 507
- Dose area product, totally implantable central venous port systems, radiation exposure, fluoroscopy time, training, 179
- Dose–volume parameters, treatment-related lymphopenia, chemoradiotherapy, spleen, bone marrow, 1519
- Dosimetric parameter, breast cancer, post-operative radiotherapy, radiation dermatitis, 1499
- Double *EGFR* mutation, lung adenocarcinoma, epidermal growth factor receptor mutation, radiotherapy, 203
- Doublecortin-like kinase 1, cancer stem cell, colorectal adenoma, colorectal cancer, colorectal polyp, 365
- Downstaging, high rectal cancer, preoperative chemoradiation, prognostic factors, 1481
- Drd5*, gene expression, C57BL/6J, retn, iapp, 813
- Drug design, *Wolbachia Pipiensis*, *Otiorhynchus singularis*, DSB-A, pest control, 1051
- Drug-induced interstitial lung disease, re-administration, chemotherapy, *EGFR*-TKI, corticosteroid, 851
- DSB-A, *Wolbachia pipiensis*, *Otiorhynchus singularis*, pest control, drug design, 1051
- Dual-chamber pacing, cardiac pacemaker, pacemaker programming modes, single-chamber pacing, rate responsive function, exercise capacity, 419
- Early breast cancer, sentinel lymph node biopsy, axillary radiotherapy, axillary dissection, evidence-based medicine, clinical practice update, review, 1301
- Early clinical stage, malignant pleural mesothelioma, 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG-PET/CT), extrapleural pneumonectomy (EPP), pleurectomy or decortication (P/D), biphasic, 1169
- Early recurrence, CD44, pancreatic cancer, surgery, 1533
- Early-stage cancer, pressurized aerosol chemotherapy, PAC, urinary bladder carcinoma, penetration, intravesical chemotherapy, PIPAC, 1369
- ECG, cardiac autonomic dysfunction, diabetis, 1433
- Edmonton symptom assessment system, palliative radiotherapy, anxiety, depression, marital status, 327
- EGF, dog, epidermal growth factor, paradontopathy, oral cavity tumour, 507
- EGF, epidermal growth factor, perianal tumours, dog, tamoxifen, 1175
- EGFR* mutation, T790M, non-small cell lung carcinoma, rebiopsy, 1199
- EGFR*-TKI, drug-induced interstitial lung disease, re-administration, chemotherapy, corticosteroid, 851
- EGFR*, pancreatic cancer, KRAS, BRAF, PIK3CA, CDKN2A, TP53, ethnicity, 1527
- EGFR*, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, ALK, PDL-1 and c-MYC, 303
- Elderly, cerebrovascular stroke, thrombectomy, octogenarian, endovascular procedures, cerebral infarction, 1223
- Elderly, gastric cancer, outcomes, complications, GNRI, 1667
- Electromyography, muscle, biopsy, neuromuscular disorders, 1647
- Embryo culture media, conditions, trends, epigenetics, review, 451
- Emergency, heart failure, heart rate, respiratory rate, 921
- Emodin, hypericin, DNA, serum albumins, interaction, thermal stability, 1063
- Emotional intelligence, emotions, coronary heart disease, diabetes melitus, obesity, 859
- Emotions, emotional intelligence, coronary heart disease, diabetes melitus, obesity, 859
- Encephalitis, PET/MRI, NMDAR, ovarian teratoma, uterine malformation, 1231
- Endocrine therapy, neutrophil-to-lymphocyte ratio, stage IV, breast cancer, predictive marker, 669
- Endocrine, pheochromocytoma, paraganglionoma, adrenal, kidney, 211
- Endocrine, pheochromocytoma, paraganglionoma, adrenal, kidney, 703
- Endoscopic ultrasonography-guided-fine needle aspiration, pancreatic cancer, heat shock protein 27, gemcitabine, 637
- Endovascular procedures, cerebrovascular stroke, thrombectomy, elderly, octogenarian, cerebral infarction, 1223
- Energy device, ovarian cancer, surgery, caiman®, 359
- Epidermal growth factor receptor mutation, lung adenocarcinoma, radiotherapy, double *EGFR* mutation, 203
- Epidermal growth factor, dog, EGF, paradontopathy, oral cavity tumour, 507
- Epidermal growth factor, EGF, perianal tumours, dog, tamoxifen, 1175
- Epigenetics, embryo culture media, conditions, trends, review, 451

- Epigenetics, thyroid cancer, EZH2, prognostic factor, 25
- ERK, amentoflavone, hepatocellular carcinoma, NF-κB, 549
- ERK, angiotensin, t-lymphocyte, IL-2, candesartan, 1353
- ERK, simvastatin, nicotine, renal, antioxidant, HO1, mnSOD, CREB, p66shc, 1033
- Esophageal cancer, sarcopenia, prognosis, nutritional support, 603
- Esophagogastric junction carcinoma, splenectomy, venous invasion, blood transfusion, 145
- Estimated glomerular filtration rate, kallikrein-8, telbivudine, 955
- Estimation of survival, cancer of the bladder, cerebral metastases, whole-brain irradiation, prognostic tool, 633
- Estrogen receptor β , polyovular follicle, diethylstilbestrol, ovary, 19
- ETAS, HSP27, pancreatic cancer, HSP70, 759
- Ethnicity, pancreatic cancer, KRAS, EGFR, BRAF, PIK3CA, CDKN2A, TP53, 1527
- Etiology, herpes simplex, neonatal herpes, neurobiology, DBS, 1255
- Evidence-based medicine, sentinel lymph node biopsy, early breast cancer, axillary radiotherapy, axillary dissection, clinical practice update, review, 1301
- Exercise capacity, cardiac pacemaker, pacemaker programming modes, single-chamber pacing, dual-chamber pacing, rate responsive function, 419
- Exercise, breast neoplasm, martial arts, physical activity, quality of life, kyusho Jitsu, 819
- Experimental therapy, BHK 21/C13 cell line, chick embryo chorioallantoic membrane, phenotype characterization, 791
- Extended TME, locally advanced lower rectal cancer, laparoscopic surgery, 643
- Extracellular signal-regulated kinase, amentoflavone, hepatocellular carcinoma, nuclear factor-kappaB, bioluminescence imaging, 1097
- Extracellular-signal-regulated kinase, magnolol, apoptosis, hepatocellular carcinoma, 1361
- Extracorporeal membrane oxygenation therapy, cardiopulmonary failure patients, nutritional intervention, 829
- Extrapleural pneumonectomy (EPP), malignant pleural mesothelioma, 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG-PET/CT), early clinical stage, pleurectomy or decortication (P/D), biphasic, 1169
- EZH2, thyroid cancer, prognostic factor, epigenetics, 25
- Fat-forming solitary fibrous tumor, kidney, nephrectomy, 649
- Fatty acids, grape pomace, lambs, meat quality, polyphenols, 807
- Fatty infiltration, type 2 diabetes mellitus, mouse, proliferation, pancreatic cancer, 499
- Fatty liver disease, liver, steatosis, rats, ischemia, ischemia-reperfusion injury, 1381
- FDG-PET/CT, local control, T1 esophageal cancer, concurrent chemoradiotherapy, 1269
- FDG/PET-CT, lung cancer, staging, interstitial lung disease, 1457
- Feasibility, rectal cancer, neoadjuvant chemotherapy, FOLFOX, 937
- Fentanyl, laboratory rats, pain, analgesia, transdermal, 713
- Fetus, lung cancer, pregnancy, anaplastic lymphoma kinase, alemtuzumab, 1205
- Flatcoated Retriever, canine, histiocytic sarcoma, histo(patho)logy, cytology, immunohistochemistry, bernese Mountain Dog, comparative pathology, 7
- Fluoroscopy time, totally implantable central venous port systems, radiation exposure, dose area product, training, 179
- FOLFOX, rectal cancer, neoadjuvant chemotherapy, feasibility, 937
- Food-drug interactions, cytochrome P450, benifuuki tea, pharmacokinetics, CYP2D, CYP3A, 33
- Fractionated stereotactic radiotherapy, radiosurgery, brain metastases, survival, scoring-system, validation, 381
- Free flap, height, weight, BMI, age, muscle mass predictors, lower extremity reconstruction, gracilis muscle, 591
- Free-flap transfer, head and neck cancer, reconstructive surgery, anterolateral thigh flap, radial forearm flap, 893
- FUS, amyotrophic lateral sclerosis, motor neuron diseases, mouse models, C9ORF72, SOD1, TARDBP, review, 983
- G0/G1 arrest, banana flower extract, benign prostatic hyperplasia, cyclooxygenase-2, prostaglandin E2, 1373
- Gadoxetate disodium, chang liver cells, cDNA microarray, influx transporter OATP1B1, 677
- Gastric cancer, complete response, chemotherapy, S-1, preoperative therapy, 1211
- Gastric cancer, elderly, outcomes, complications, GNRI, 1667
- Gastric cancer, HER2, trastuzumab, 1491
- Gelatin methacrylate hydrogel, bone morphogenetic protein-2, cryopolymerization, dog, radial fracture, 575
- Gemcitabine, neoadjuvant, chemoradiotherapy, pancreatic cancer, R0 resection, 1183
- Gemcitabine, pancreatic cancer, heat shock protein 27, endoscopic ultrasonography-guided-fine needle aspiration, 637
- Gemcitabine, pancreatic cancer, modified regimen, convenient, nab-paclitaxel, biweekly, 653
- Gender, age, genotype, MMP-8, polymorphism, pterygium, Taiwan, 41
- Gene expression, benign thyroid nodules, apoptosis, bad, bcl-2, bax, 555

- Gene expression, C57BL/6J, retn, iapp, drd5, 813
- Genotype, age, gender, MMP-8, polymorphism, pterygium, Taiwan, 41
- Genotype, asthma, single nucleotide polymorphism, *XRCC3*, Taiwan, 1039
- Genotype, bladder cancer, *MMP-7*, polymorphism, Taiwan, 1045
- Genotype, breast cancer, *MMP-1*, polymorphism, Taiwan, 487
- Geranylgeranylation, diabetes, adipogenesis, statin, antidiabetic drug, 1339
- Geranylgeranylation, sarcopenia, myogenesis, statin, C2C12 cells, 1427
- Geriatrics, palliation, radiotherapy, prognostication, lung cancer, 331
- Germ cell tumor, BEP, neutropenia, pegfilgrastim, 899
- Glaucoma therapy, *in vivo* laser scanning confocal microscopy, conjunctiva, goblet cells, open-angle glaucoma, ocular surface, 437
- Glaucoma, prostaglandin analogues, side effects, adverse events, medical therapy, benzalkonium chloride, *in vivo* confocal microscopy, review, 211
- Glioblastoma, amentoflavone, and NF-κB, apoptosis, 279
- Glutamic oxaloacetic transaminase, laminarin, leukemia BALB/c mice, glutamic pyruvic transaminase, immune response, 783
- Glutamic pyruvic transaminase, laminarin, immune responses, lactate dehydrogenase, 523
- Glutamic pyruvic transaminase, laminarin, leukemia BALB/c mice, glutamic oxaloacetic transaminase, immune response, 783
- GNRI, gastric cancer, elderly, outcomes, complications, 1667
- Goblet cells, *in vivo* laser scanning confocal microscopy, conjunctiva, open-angle glaucoma, glaucoma therapy, ocular surface, 437
- GP7TB orthotopic hepatoma model, biodistribution, pharmacokinetics, therapeutic evaluation, ¹⁸⁸Re-HSAM, 567
- Gracilis muscle, height, weight, BMI, age, muscle mass predictors, lower extremity reconstruction, free flap, 591
- Granulosa cell, theca cell, cyp17a1, luteinizing hormone, PCOS, androgen synthesis, 1387
- Grape pomace, fatty acids, lambs, meat quality, polyphenols, 807
- GRE, susceptibility vessel sign, t2*-weighted images, lacunar infarction, 973
- Greek population, acute myocardial infarction, biomarkers, microRNAs, plasma, 313
- Greek version, resilience, psychometric properties, validity, CD-RISC, 1629
- Green tea, urothelial cancer, human antigen-R, smoking, recurrence, 721
- Gynecological malignancies, single brain metastasis, local therapies, survival score, personalized care, 825
- Harmonic, liver parenchymal transection, liver resection, hepatectomy, ultrasonic scalpel, lotus, bile leakage, bleeding, 883
- Head and neck cancer, free-flap transfer, reconstructive surgery, anterolateral thigh flap, radial forearm flap, 893
- Head and neck, virome, vascular anomaly, 1323
- Heart failure, heart rate, respiratory rate, emergency, 921
- Heart rate asymmetry, heart rate variability, cellular phone, microwave radiation, 1145
- Heart rate variability, carbon dioxide treatment, rehabilitation, balneotherapy, 1259
- Heart rate variability, heart rate asymmetry, cellular phone, microwave radiation, 1145
- Heart rate, heart failure, respiratory rate, emergency, 921
- Heat shock protein 27, pancreatic cancer, gemcitabine, endoscopic ultrasonography-guided-fine needle aspiration, 637
- Heavily-pretreated patients, liver metastasis, breast cancer, hepatic arterial infusion chemotherapy (HAIC), LMBC, 1635
- Height, weight, BMI, age, muscle mass predictors, lower extremity reconstruction, gracilis muscle, free flap, 591
- Hematopoietic stem cell transplantation, sinusoidal obstruction syndrome, recombinant human soluble thrombomodulin, liver transplantation, oxaliplatin-based chemotherapy, 1409
- Hepatectomy, liver parenchymal transection, liver resection, ultrasonic scalpel, lotus, harmonic, bile leakage, bleeding, 883
- Hepatic arterial infusion chemotherapy (HAIC), liver metastasis, breast cancer, LMBC, heavily-pretreated patients, 1635
- Hepatic artery reinsertion, retroperitoneal tumor, paraganglioma, celiac trunk resection, 911
- Hepatic artery stenosis, liver transplantation, biliary complication, strictures, cytomegalovirus, 1623
- Hepatocellular carcinoma, amentoflavone, extracellular signal-regulated kinase, nuclear factor-kappaB, bioluminescence imaging, 1097
- Hepatocellular carcinoma, amentoflavone, NF-κB, ERK, 549
- Hepatocellular carcinoma, hyaluronan, 4-methyl-umbelliferone, 273
- Hepatocellular carcinoma, magnolol, extracellular-signal-regulated kinase, apoptosis, 1361
- Hepatocellular carcinoma, PIVKA-II, AFP, biomarkers, predictive, 1551
- Hepatocellular carcinoma, vitamin C, diethylnitrosamine, *smp30* KO mice, 93

- HER2 status, breast cancer, liver metastases, hormonal receptor, 1247
- HER2-negative, breast cancer, *de novo* stage IV patients, recurrent, hR-positive, 353
- HER2, gastric cancer, trastuzumab, 1491
- Herpes simplex, neonatal herpes, neurobiology, DBS, etiology, 1255
- HIF1 α , adenohypophysis, neurohypophysis, hIF2 α , VEGF, CD31, 185
- HIF2 α , adenohypophysis, neurohypophysis, hIF1 α , VEGF, CD31, 185
- High rectal cancer, preoperative chemoradiation, downstaging, prognostic factors, 1481
- High-grade gliomas, tumor necrosis factor, polymorphism, 287
- High-risk stage II, colorectal cancer, stage III, peritoneal metastasis, 1235
- Histiocytic sarcoma, canine, histo(patho)logy, cytology, immunohistochemistry, bernese Mountain Dog, flatcoated Retriever, comparative pathology, 7
- Histo(patho)logy, canine, histiocytic sarcoma, cytology, immunohistochemistry, bernese Mountain Dog, flatcoated Retriever, comparative pathology, 7
- Histological grade, non-small cell lung carcinoma, prognosis, 1505
- Hizikia fusiforme*, azoxymethane, colorectal cancer, *Capsosiphon fulvescens*, rat, 101
- HM couch, skin toxicity, surface dose, carbon couch, 531
- HMOX1, β -carotene, lycopene, tri-*n*-butyl borane, LPS, RAW264.7 cells, COX2, NOS2, 255
- HO1, simvastatin, nicotine, renal, antioxidant, mnSOD, CREB, ERK, p66shc, 1033
- Hormesis, nerve cell, NGF, differentiation, amyloid β -peptide, protection, bamboo leaf extract, 231
- Hormonal receptor, breast cancer, liver metastases, HER2 status, 1247
- HR-positive, breast cancer, *de novo* stage IV patients, recurrent, hER2-negative, 353
- HSP27, ETAS, pancreatic cancer, HSP70, 759
- HSP70, HSP27, ETAS, pancreatic cancer, 759
- Human antigen-R, green tea, urothelial cancer, smoking, recurrence, 721
- Human glioblastoma U87 cells, lauryl gallate, apoptotic cell death, caspase pathway, 1119
- Human papillomavirus, oropharyngeal cancer, surgery, p16, clinical outcome, 927
- Human, circulating microRNA, colon, rectum, biomarker, 1333
- Hyaluronan, hepatocellular carcinoma, 4-methyl-umbelliferone, 273
- Hydrophobic, intraocular, lens, multifocal, opacification, 1265
- Hydrophobicity, azulene amides, cytotoxicity, tumor specificity, molecular shape, apoptosis, 479
- Hydroxyapatite, porcine hybrid bone block, collagen, biodegradability, bone regeneration, 1419
- Hypericin, emodin, DNA, serum albumins, interaction, thermal stability, 1063
- Hyperlipidaemia, metabolic syndrome, breast cancer, apoE, arKO, 1071
- Hyperlipidemia, anti-tuberculosis, isoniazid (INH), rifampin (RIF), population-based case-control study, 47
- Hypofractionated radiotherapy (HRT), trastuzumab, breast cancer cardiotoxicity, adjuvant treatment, 879
- Hypopharyngeal cancer, synchronous cancer, squamous cell carcinoma, oesophageal cancer, 165
- Iapp*, gene expression, C57BL/6J, retn, drd5, 813
- IL-2, angiotensin, t-lymphocyte, candesartan, ERK, 1353
- Ileal conduit, bladder cancer, quality of life, orthotopic neobladder, radical cystectomy, 139
- Ileal diverticulosis, crohn's disease, small bowel adenocarcinoma, 191
- Immune checkpoint inhibitor, DNA damage response, lung squamous cell carcinoma, 171
- Immune response, laminarin, leukemia BALB/c mice, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, 783
- Immune responses, laminarin, glutamic pyruvic transaminase, lactate dehydrogenase, 523
- Immunohistochemistry, breast cancer, microvessels, vascular proliferation, angiogenesis, 79
- Immunohistochemistry, canine, histiocytic sarcoma, histo(patho)logy, cytology, bernese Mountain Dog, flatcoated Retriever, comparative pathology, 7
- Immunosuppression, sepsis, TLR9, toll-like receptors, 1653
- In situ* hybridization, stomach, diffuse large B cell Lymphoma, plasmablastic lymphoma, ommunohistochemistry, 413
- In vitro* cytocompatibility, plasma electrolytic oxidation (PEO), surface topography, cell adhesion, 241
- In vivo* confocal microscopy, glaucoma, prostaglandin analogues, side effects, adverse events, medical therapy, benzalkonium chloride, review, 211
- In vivo* laser scanning confocal microscopy, conjunctiva, goblet cells, open-angle glaucoma, glaucoma therapy, ocular surface, 437
- Inferior right hepatic vein, phleboplasty, living donor liver transplantation, 1217
- Inflammation, matrilysin, matrix metalloproteinases, rectal cancer, radiotherapy, 133
- Influenza virus, lung pathology, nitric oxide, zanamivir, 473

- Influx transporter OATP1B1, gadoxetate disodium, chang liver cells, cDNA microarray, 677
- Inguinal lymph node metastases, normal size ovarian cancer, lymphatic spread, 385
- Injectable fiducial marker, calcium phosphate cement, cone beam computed tomography, magnetic resonance imaging, cervical cancer, 1609
- Insurance status, ankle fusion, osteoarthritis, revision surgery, long-term follow-up, 1463
- Integrated delivery and finance system, prostate cancer, cost effectiveness, prostatectomy, brachytherapy, radiotherapy, 113
- Interaction, hypericin, emodin, DNA, serum albumins, thermal stability, 1063
- Interstitial lung disease, airway obstruction, lung cancer, nivolumab, risk factor, 887
- Interstitial lung disease, lung cancer, staging, FDG/PET-CT, 1457
- Intra-abdominal hypertension, porcine model, liver histology and hemodynamics, 85
- Intraocular, hydrophobic, lens, multifocal, opacification, 1265
- Intraplaque neovascularization, ultrasound, targeted microbubble, atherosclerosis, 1025
- Intrathecal catheter, cerebrospinal fluid, melatonin, swine, minipig, 583
- Intravesical chemotherapy, pressurized aerosol chemotherapy, PAC, urinary bladder carcinoma, penetration, early-stage cancer, PIPAC, 1369
- Invasion, nicotine- and tar-removed cigarette smoke extract, CSE, mouse rectal carcinoma Colon-26 cells, methyl vinyl ketone, MVK, 493
- Ionizing irradiation, radiation mitigation, JP4-039, 1009
- IrAEs, PD-1, CTLA-4, malignant melanoma, ACTH, pituitary gland, thyroid gland, 345
- Ischemia-reperfusion injury, liver, steatosis, fatty liver disease, rats, ischemia, 1381
- Ischemia, liver, steatosis, fatty liver disease, rats, ischemia-reperfusion injury, 1381
- Isoniazid (INH), anti-tuberculosis, rifampin (RIF), hyperlipidemia, population-based case-control study, 47
- JP4-039, ionizing irradiation, radiation mitigation, 1009
- Kallikrein-8, estimated glomerular filtration rate, telbivudine, 955
- Ki-67, p16, SATB1, TMA, tissue microarray, proliferation, breast cancer, 731
- Ki67, triple-negative breast cancer, p53, p63, c-kit, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- Kidney transplant, amylase, resistive index, delayed graft function, 397
- Kidney, fat-forming solitary fibrous tumor, nephrectomy, 649
- Kidney, pheochromocytoma, paraganglioma, adrenal, endocrine, 211
- Kidney, pheochromocytoma, paraganglioma, adrenal, endocrine, 703
- KRAS, pancreatic cancer, EGFR, BRAF, PIK3CA, CDKN2A, TP53, ethnicity, 1527
- KT2 peptide, colorectal cancer, anticancer activity, xenograft, apoptosis, 1137
- Kyusho Jitsu, breast neoplasm, exercise, martial arts, physical activity, quality of life, 819
- Laboratory rats, pain, analgesia, transdermal, fentanyl, 713
- Lactate dehydrogenase, laminarin, immune responses, glutamic pyruvic transaminase, 523
- Lacunar infarction, susceptibility vessel sign, t2*-weighted images, GRE, 973
- Lambs, fatty acids, grape pomace, meat quality, polyphenols, 807
- Lambs, oxidative stress markers, olive mill wastewater, polyphenols, 291
- Laminarin, immune responses, glutamic pyruvic transaminase, lactate dehydrogenase, 523
- Laminarin, leukemia BALB/c mice, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, immune response, 783
- Laparoscopic hepatectomy, laparoscopic liver resection, left lobectomy, ruptured HCC, TAE, 659
- Laparoscopic liver resection, laparoscopic hepatectomy, left lobectomy, ruptured HCC, TAE, 659
- Laparoscopic surgery, locally advanced lower rectal cancer, extended TME, 643
- Laparoscopic surgery, rectal cancer, robot-assisted surgery, meta-analysis, 611
- Laparoscopy-assisted total gastrectomy, body composition, lean body mass, open total gastrectomy, surgical stress, 1513
- Lauryl gallate, apoptotic cell death, caspase pathway, human glioblastoma U87 cells, 1119
- Lean body mass, body composition, laparoscopy-assisted total gastrectomy, open total gastrectomy, surgical stress, 1513
- Left lobectomy, laparoscopic hepatectomy, laparoscopic liver resection, ruptured HCC, TAE, 659
- Lens, hydrophobic, intraocular, multifocal, opacification, 1265
- Leukemia BALB/c mice, laminarin, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, immune response, 783
- Leukemia WEHI-3 cells, bufalin, macrophage, natural killer cells, phagocytosis, 1129
- Lighting conditions, diurnal rhythm, mealtime, swine model, working environments, 55

- LIPG* (584 C/T), coronary artery disease, polymorphism, 1105
 Lipid profiles, oxidative status, chronic obstructive pulmonary disease, lung function, oligomeric proanthocyanidin, 753
Listeria monocytogenes, *N. sativa* essential oil, antimicrobial activity, resistance modifying activity, 737
 Liver histology and hemodynamics, intra-abdominal hypertension, porcine model, 85
 Liver metastases, breast cancer, hormonal receptor, HER2 status, 1247
 Liver metastasis, breast cancer, hepatic arterial infusion chemotherapy (HAIC), LMBC, heavily-pretreated patients, 1635
 Liver parenchymal transection, liver resection, hepatectomy, ultrasonic scalpel, lotus, harmonic, bile leakage, bleeding, 883
 Liver resection, liver parenchymal transection, hepatectomy, ultrasonic scalpel, lotus, harmonic, bile leakage, bleeding, 883
 Liver transplantation, biliary complication, strictures, cytomegalovirus, hepatic artery stenosis, 1623
 Liver transplantation, sinusoidal obstruction syndrome, recombinant human soluble thrombomodulin, hematopoietic stem cell transplantation, oxaliplatin-based chemotherapy, 1409
 Liver, steatosis, fatty liver disease, rats, ischemia, ischemia-reperfusion injury, 1381
 Living donor liver transplantation, inferior right hepatic vein, phleboplasty, 1217
 LMBC, liver metastasis, breast cancer, hepatic arterial infusion chemotherapy (HAIC), heavily-pretreated patients, 1635
 Local control, lung cancer, SBRT, pET-computed tomographic, 121
 Local control, T1 esophageal cancer, concurrent chemoradiotherapy, FDG-PET/CT, 1269
 Local therapies, gynecological malignancies, single brain metastasis, survival score, personalized care, 825
 Locally advanced lower rectal cancer, laparoscopic surgery, extended TME, 643
 Long-term follow-up, ankle fusion, osteoarthritis, insurance status, revision surgery, 1463
 Lotus, liver parenchymal transection, liver resection, hepatectomy, ultrasonic scalpel, harmonic, bile leakage, bleeding, 883
 Lower extremity reconstruction, height, weight, BMI, age, muscle mass predictors, gracilis muscle, free flap, 591
 LPS, β -Carotene, lycopene, tri-*n*-butyl borane, RAW264.7 cells, COX2, NOS2, HMOX1, 255
 Lung adenocarcinoma, CT, PD-L2, 1541
 Lung adenocarcinoma, epidermal growth factor receptor mutation, radiotherapy, double EGFR mutation, 203
 Lung biopsy, non-small cell lung cancer, prognosis, 691
 Lung cancer, adenocarcinoma, pathology, prognostic factors, 1571
 Lung cancer, airway obstruction, interstitial lung disease, nivolumab, risk factor, 887
 Lung cancer, cycloartobiloxanthone, apoptosis, mitochondria-dependent apoptotic pathway, BAX, MCL1, 71
 Lung cancer, palliation, radiotherapy, geriatrics, prognostication, 331
 Lung cancer, pregnancy, anaplastic lymphoma kinase, alectinib, fetus, 1205
 Lung cancer, SBRT, pET-computed tomographic, local control, 121
 Lung cancer, staging, interstitial lung disease, FDG/PET-CT, 1457
 Lung function, oxidative status, chronic obstructive pulmonary disease, lipid profiles, oligomeric proanthocyanidin, 753
 Lung pathology, influenza virus, nitric oxide, zanamivir, 473
 Lung squamous cell carcinoma, immune checkpoint inhibitor, DNA damage response, 171
 Luteinizing hormone, theca cell, cyp17a1, granulosa cell, PCOS, androgen synthesis, 1387
 LV function, chemotherapy, cardiotoxicity, myocardial dysfunction, arterial stiffness, subclinical atherosclerosis, 1599
 Lycopene, β -carotene, tri-*n*-butyl borane, LPS, RAW264.7 cells, COX2, NOS2, HMOX1, 255
 Lymphatic spread, normal size ovarian cancer, inguinal lymph node metastases, 385
 Macrophage, bufalin, leukemia WEHI-3 cells, natural killer cells, phagocytosis, 1129
 Magnetic resonance imaging, calcium phosphate cement, injectable fiducial marker, cone beam computed tomography, cervical cancer, 1609
 Magnolol, extracellular-signal-regulated kinase, apoptosis, hepatocellular carcinoma, 1361
 Malignant melanoma, PD-1, CTLA-4, ACTH, pituitary gland, thyroid gland, irAEs, 345
 Malignant pleural mesothelioma, 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG-PET/CT), early clinical stage, extrapleural pneumonectomy (EPP), pleurectomy or decortication (P/D), biphasic, 1169
 Malignant pleural mesothelioma, c-Reactive protein-to-albumin ratio, neutrophil-to-lymphocyte ratio, prognostic factor, 445
 Mammary gland, canine, metastasis, thalidomide, metronomic chemotherapy, 1659
 Marital status, palliative radiotherapy, edmonton symptom assessment system, anxiety, depression, 327

- Martial arts, breast neoplasm, exercise, physical activity, quality of life, kyusho Jitsu, 819
- Mastectomy, breast cancer therapy, seroma formation, postoperative complications, dead space reduction, surgical adhesive, tissuGlu, 625
- Mastectomy, breast cancer, dermatitis, radiation therapy, 961
- Matrilysin, matrix metalloproteinases, rectal cancer, radiotherapy, inflammation, 133
- Matrix metalloproteinases, atherosclerosis, cardiovascular disease, vitamin D, vitamin D receptor, review, 977
- Matrix metalloproteinases, matrilysin, rectal cancer, radiotherapy, inflammation, 133
- MCL1, cycloartobiloxanthone, lung cancer, apoptosis, mitochondria-dependent apoptotic pathway, BAX, 71
- Mealtime, diurnal rhythm, lighting conditions, swine model, working environments, 55
- Meat quality, fatty acids, grape pomace, lambs, polyphenols, 807
- Median arcuate ligament syndrome, celiac axis stenosis, splenic artery patch, 699
- Medical therapy, glaucoma, prostaglandin analogues, side effects, adverse events, benzalkonium chloride, *in vivo* confocal microscopy, review, 211
- Medium molecular weight heparinyl arginine (MHR), scorpion venom, pulmonary edema, 537
- Melanoma, angiogenesis, tumour intravasation, tumour thrombus, prostate cancer, 461
- Melatonin, intrathecal catheter, cerebrospinal fluid, swine, minipig, 583
- Mesothelial, cell adhesion, cell proliferation, pleura, silver nanoparticles, 109
- Meta-analysis, rectal cancer, robot-assisted surgery, laparoscopic surgery, 611
- Metabolic syndrome, breast cancer, hyperlipidaemia, apoE, arKO, 1071
- Metastasectomy, obesity paradox, pulmonary metastases, disease-free interval, overall survival, 197
- Metastasis, canine, mammary gland, thalidomide, metronomic chemotherapy, 1659
- Metastatic breast cancer, pertuzumab, brain metastasis, 839
- (meth)acrylates, cinnamates, cytotoxicity, pro-/anti-inflammatory properties, RAW264.7 cells, cox2, nos2 and Ho1 mRNA, 13C-NMR spectra, β-carbon, 1309
- Methyl vinyl ketone, nicotine- and tar-removed cigarette smoke extract, CSE, mouse rectal carcinoma Colon-26 cells, invasion, MVK, 493
- Metronomic chemotherapy, canine, mammary gland, metastasis, thalidomide, 1659
- MicroRNAs, acute myocardial infarction, biomarkers, greek population, plasma, 313
- Microvessels, breast cancer, vascular proliferation, immunohistochemistry, angiogenesis, 79
- Microwave radiation, heart rate variability, heart rate asymmetry, cellular phone, 1145
- Mimics, sarcoma, MRI, review, 221
- Minipig, intrathecal catheter, cerebrospinal fluid, melatonin, swine, 583
- miRNA122a, atherosclerosis, biomarker, *miRNA221, miRNA222*, 561
- miRNA221, atherosclerosis, biomarker, *miRNA222, miRNA122a*, 561
- miRNA222, atherosclerosis, biomarker, *miRNA221, miRNA122a*, 561
- Mitochondria-dependent apoptotic pathway, cycloartobiloxanthone, lung cancer, apoptosis, BAX, MCL1, 71
- MMP-1*, breast cancer, genotype, polymorphism, Taiwan, 487
- MMP-7*, bladder cancer, genotype, polymorphism, Taiwan, 1045
- MMP-8, age, gender, genotype, polymorphism, pterygium, Taiwan, 41
- MnSOD, simvastatin, nicotine, renal, antioxidant, HO1, CREB, ERK, p66shc, 1033
- Modified regimen, pancreatic cancer, convenient, nab-paclitaxel, gemcitabine, biweekly, 653
- Molecular shape, azulene amides, cytotoxicity, tumor specificity, hydrophobicity, apoptosis, 479
- Morpholine backbone, alkylaminoguaiazulene, alkylation, cytotoxicity, tumor specificity, apoptosis, 541
- Morphology, colon, crypts, stem cells, proliferation, 1473
- Motor neuron diseases, amyotrophic lateral sclerosis, mouse models, *C9ORF72, FUS, SOD1, TARDBP*, review, 983
- Mouse models, amyotrophic lateral sclerosis, motor neuron diseases, *C9ORF72, FUS, SOD1, TARDBP*, review, 983
- Mouse rectal carcinoma Colon-26 cells, nicotine- and tar-removed cigarette smoke extract, CSE, invasion, methyl vinyl ketone, MVK, 493
- Mouse, fatty infiltration, type 2 diabetes mellitus, proliferation, pancreatic cancer, 499
- MRI, prostate carcinoma, radiation therapy, salvage treatment, radical prostatectomy, 125
- MRI, sarcoma, mimics, review, 221
- Multifocal, hydrophobic, intraocular, lens, opacification, 1265
- Muscle mass predictors, height, weight, BMI, age, lower extremity reconstruction, gracilis muscle, free flap, 591
- Muscle, biopsy, electromyography, neuromuscular disorders, 1647
- MVK, nicotine- and tar-removed cigarette smoke extract, CSE, mouse rectal carcinoma Colon-26 cells, invasion, methyl vinyl ketone, 493

- Mycosis fungoides, radiotherapy, progression free survival, overall survival, toxicity, 517
- Myocardial dysfunction, chemotherapy, cardiotoxicity, arterial stiffness, subclinical atherosclerosis, LV function, 1599
- Myogenesis, sarcopenia, statin, geranylgeranylation, C2C12 cells, 1427
- N-methyl-N-nitrosourea, breast cancer, physical training, 249
- N. sativa* essential oil, *Listeria monocytogenes*, antimicrobial activity, resistance modifying activity, 737
- Nab-paclitaxel, pancreatic cancer, modified regimen, convenient, gemcitabine, biweekly, 653
- Natural killer cells, bufalin, leukemia WEHI-3 cells, macrophage, phagocytosis, 1129
- Neoadjuvant chemotherapy, rectal cancer, FOLFOX, feasibility, 937
- Neoadjuvant, chemoradiotherapy, pancreatic cancer, gemcitabine, R0 resection, 1183
- Neonatal herpes, herpes simplex, neurobiology, DBS, etiology, 1255
- Nephrectomy, fat-forming solitary fibrous tumor, kidney, 649
- Nerve cell, NGF, differentiation, amyloid β -peptide, protection, hormesis, bamboo leaf extract, 231
- Neurobiology, herpes simplex, neonatal herpes, DBS, etiology, 1255
- Neurohypophysis, adenohypophysis, hIF1 α , hIF2 α , VEGF, CD31, 185
- Neuromuscular disorders, muscle, biopsy, electromyography, 1647
- Neuronal differentiation, PC12 cells, NGF, amino acid concentration, urea, taurine, aspartic acid, overlay isolation method, 1403
- Neurotoxicity, anticancer drug, differentiation stage, PC12, NGF, 745
- Neurotoxicity, anticancer drug, differentiation stage, PC12, NGF, 765
- Neutropenia, BEP, germ cell tumor, pegfilgrastim, 899
- Neutrophil counts, breast cancer patients, white blood cell counts, chemotherapy, new device, preliminary results, 1283
- Neutrophil-to-lymphocyte ratio, c-Reactive protein-to-albumin ratio, malignant pleural mesothelioma, prognostic factor, 445
- Neutrophil-to-lymphocyte ratio, endocrine therapy, stage IV, breast cancer, predictive marker, 669
- Neutrophils, biomaterial, alginate, carbon fibers, antimicrobial peptides, 1345
- Neutrophils, biomaterial, alginate, carbon fibers, antimicrobial peptides, 1345
- New device, breast cancer patients, white blood cell counts, neutrophil counts, chemotherapy, preliminary results, 1283
- NF- κ B, amentoflavone, hepatocellular carcinoma, ERK, 549
- NGF, nerve cell, differentiation, amyloid β -peptide, protection, hormesis, bamboo leaf extract, 231
- NGF, neuronal differentiation, PC12 cells, amino acid concentration, urea, taurine, aspartic acid, overlay isolation method, 1403
- NGF, neurotoxicity, anticancer drug, differentiation stage, PC12, 745
- NGF, neurotoxicity, anticancer drug, differentiation stage, PC12, 765
- Nicotine- and tar-removed cigarette smoke extract, CSE, mouse rectal carcinoma Colon-26 cells, invasion, methyl vinyl ketone, MVK, 493
- Nicotine, simvastatin, renal, antioxidant, HO1, mnSOD, CREB, ERK, p66shc, 1033
- Nitric oxide, influenza virus, lung pathology, zanamivir, 473
- Nivolumab, airway obstruction, interstitial lung disease, lung cancer, risk factor, 887
- NK cell, cholangiocarcinoma, xenograft nude mouse model, 771
- NMDAR, PET/MRI, encephalitis, ovarian teratoma, uterine malformation, 1231
- Non-small cell lung cancer, aLK-positive, alectinib, ceritinib, 1587
- Non-small cell lung cancer, lung biopsy, prognosis, 691
- Non-small cell lung cancer, systemic immune-inflammation index, surgery, prognosis, 663
- Non-small cell lung carcinoma, EGFR mutation, T790M, rebiopsy, 1199
- Non-small cell lung carcinoma, histological grade, prognosis, 1505
- Non-squamous cell lung cancer, bevacizumab, salvage therapy, osteonecrosis of the jaw, 1155
- Normal size ovarian cancer, lymphatic spread, inguinal lymph node metastases, 385
- Nos2 and Ho1 mRNA, cinnamates, (meth)acrylates, cytotoxicity, pro-/anti-inflammatory properties, RAW264.7 cells, cox2, 13C-NMR spectra, β -carbon, 1309
- NOS2, β -Carotene, lycopene, tri-*n*-butyl borane, LPS, RAW264.7 cells, COX2, HMOX1, 255
- NSCLC, TKI, stereotactic radiotherapy, 159
- Nuclear factor-kappaB, amentoflavone, hepatocellular carcinoma, extracellular signal-regulated kinase, bioluminescence imaging, 1097
- Nutritional intervention, cardiopulmonary failure patients, extracorporeal membrane oxygenation therapy, 829
- Nutritional support, sarcopenia, esophageal cancer, prognosis, 603
- Obesity paradox, pulmonary metastases, metastasectomy, disease-free interval, overall survival, 197

- Obesity, emotional intelligence, emotions, coronary heart disease, diabetes melitus, 859
- Objective comparison, data mining, report quality, structured reporting, text mining, cosine similarity score, 843
- Obstructive sleep apnea syndrome, rho-associated protein kinase, ROCK, triglycerides, polysomnography, sleep, 319
- Octogenarian, cerebrovascular stroke, thrombectomy, elderly, endovascular procedures, cerebral infarction, 1223
- Ocular surface, *in vivo* laser scanning confocal microscopy, conjunctiva, goblet cells, open-angle glaucoma, glaucoma therapy, 437
- Oesophageal cancer, hypopharyngeal cancer, synchronous cancer, squamous cell carcinoma, 165
- Oesophageal cancer, SOX9, prognosis, 835
- Oligomeric proanthocyanidin, oxidative status, chronic obstructive pulmonary disease, lipid profiles, lung function, 753
- Olive mill wastewater, oxidative stress markers, lambs, polyphenols, 291
- Ommunohistochemistry, stomach, diffuse large B cell Lymphoma, plasmablastic lymphoma, *in situ* hybridization, 413
- Opacification, hydrophobic, intraocular, lens, multifocal, 1265
- Open total gastrectomy, body composition, lean body mass, laparoscopy-assisted total gastrectomy, surgical stress, 1513
- Open-angle glaucoma, *in vivo* laser scanning confocal microscopy, conjunctiva, goblet cells, glaucoma therapy, ocular surface, 437
- Opisthorchis viverrini*, cholangiocarcinoma, proteomics, bile, biomarkers, 871
- Optical coherence tomography, *db* Mice, renin-angiotensin system, diabetic retinopathy, 265
- Oral cancer cells, anti-invasive, anti-proliferative, 3D spheroid, 1089
- Oral cavity tumour, dog, epidermal growth factor, EGF, paradontopathy, 507
- Oral cavity, cysts, pseudo-cysts, cytokeratin, diagnosis, classification, review, 999
- Oral squamous cell carcinoma, 18F-FDG-PET/CT, sUVpeak, overall survival, uICC8th, 1193
- Oral tumor, 3D printing, pCL/β-TCP scaffold, dog, 63
- Oropharyngeal cancer, surgery, human papillomavirus, p16, clinical outcome, 927
- Orthotopic neobladder, bladder cancer, quality of life, ileal conduit, radical cystectomy, 139
- Osteoarthritis, ankle fusion, insurance status, revision surgery, long-term follow-up, 1463
- Osteonecrosis of the jaw, bevacizumab, salvage therapy, non-squamous cell lung cancer, 1155
- Otiorhynchus singularis*, *Wolbachia pipiensis*, DSB-A, pest control, drug design, 1051
- Outcomes, gastric cancer, elderly, complications, GNRI, 1667
- Ovarian cancer, energy device, surgery, caiman®, 359
- Ovarian endometrioid carcinoma, ovarian high-grade serous carcinoma, prognosis, World Health Organization 2014 criteria, 597
- Ovarian high-grade serous carcinoma, ovarian endometrioid carcinoma, prognosis, World Health Organization 2014 criteria, 597
- Ovarian teratoma, PET/MRI, NMDAR, encephalitis, uterine malformation, 1231
- Ovary, polyovular follicle, diethylstilbestrol, estrogen receptor β, 19
- Overall survival, mycosis fungoides, radiotherapy, progression free survival, toxicity, 517
- Overall survival, obesity paradox, pulmonary metastases, metastectomy, disease-free interval, 197
- Overall survival, oral squamous cell carcinoma, 18F-FDG-PET/CT, sUVpeak, uICC8th, 1193
- Overlay isolation method, neuronal differentiation, PC12 cells, NGF, amino acid concentration, urea, taurine, aspartic acid, 1403
- Oxaliplatin-based chemotherapy, sinusoidal obstruction syndrome, recombinant human soluble thrombomodulin, hematopoietic stem cell transplantation, liver transplantation, 1409
- Oxidative status, chronic obstructive pulmonary disease, lipid profiles, lung function, oligomeric proanthocyanidin, 753
- Oxidative stress markers, olive mill wastewater, lambs, polyphenols, 291
- P16, oropharyngeal cancer, surgery, human papillomavirus, clinical outcome, 927
- P16, SATB1, ki-67, TMA, tissue microarray, proliferation, breast cancer, 731
- P53, triple-negative breast cancer, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- P63, triple-negative breast cancer, p53, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- P66shc, simvastatin, nicotine, renal, antioxidant, HO1, mnSOD, CREB, ERK, 1033
- PAC, pressurized aerosol chemotherapy, urinary bladder carcinoma, penetration, early-stage cancer, intravesical chemotherapy, PIPAC, 1369
- Pacemaker programming modes, cardiac pacemaker, single-chamber pacing, dual-chamber pacing, rate responsive function, exercise capacity, 419

- Pain, laboratory rats, analgesia, transdermal, fentanyl, 713
- Palliation, radiotherapy, geriatrics, prognostication, lung cancer, 331
- Palliative radiotherapy, edmonton symptom assessment system, anxiety, depression, marital status, 327
- Pancreatic adenocarcinoma, surgical margin, curative resection, 1591
- Pancreatic cancer, CD44, early recurrence, surgery, 1533
- Pancreatic cancer, fatty infiltration, type 2 diabetes mellitus, mouse, proliferation, 499
- Pancreatic cancer, heat shock protein 27, gemcitabine, endoscopic ultrasonography-guided-fine needle aspiration, 637
- Pancreatic cancer, HSP27, ETAS, HSP70, 759
- Pancreatic cancer, KRAS, EGFR, BRAF, PIK3CA, CDKN2A, TP53, ethnicity, 1527
- Pancreatic cancer, modified regimen, convenient, nab-paclitaxel, gemcitabine, biweekly, 653
- Pancreatic cancer, neoadjuvant, chemoradiotherapy, gemcitabine, R0 resection, 1183
- Parodontopathy, dog, epidermal growth factor, EGF, oral cavity tumour, 507
- Paraganglioma, retroperitoneal tumor, celiac trunk resection, hepatic artery reinsertion, 911
- Paraganglioma, pheochromocytoma, adrenal, kidney, endocrine, 211
- Paraganglioma, pheochromocytoma, adrenal, kidney, endocrine, 703
- Paramylon, β -glucan, wound dressing, cytokine, 799
- Pathology, lung cancer, adenocarcinoma, prognostic factors, 1571
- PC12 cells, neuronal differentiation, NGF, amino acid concentration, urea, taurine, aspartic acid, overlay isolation method, 1403
- PC12, neurotoxicity, anticancer drug, differentiation stage, NGF, 745
- PC12, neurotoxicity, anticancer drug, differentiation stage, NGF, 765
- PCL/ β -TCP scaffold, 3D printing, oral tumor, dog, 63
- PCOS, theca cell, cyp17a1, luteinizing hormone, granulosa cell, androgen synthesis, 1387
- PD-1, CTLA-4, malignant melanoma, ACTH, pituitary gland, thyroid gland, irAEs, 345
- PD-L2, CT, lung adenocarcinoma, 1541
- PDL-1 and c-MYC, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, ALK, 303
- Pectoral muscle, breast reconstruction, breast cancer, dermal matrix, 1477
- Pegfilgrastim, BEP, germ cell tumor, neutropenia, 899
- Penetration, pressurized aerosol chemotherapy, PAC, urinary bladder carcinoma, early-stage cancer, intravesical chemotherapy, PIPAC, 1369
- Perianal tumours, EGF, epidermal growth factor, dog, tamoxifen, 1175
- Pericardiocentesis, recurrent pericardial effusion, cisplatin, cardio-oncology, 373
- Peritoneal carcinomatosis, peritoneal hydatidosis, debulking surgery, 967
- Peritoneal hydatidosis, peritoneal carcinomatosis, debulking surgery, 967
- Peritoneal metastasis, colorectal cancer, high-risk stage II, stage III, 1235
- Peritoneum, bladder cancer, urothelial carcinoma, computed tomography, therapy, 905
- Personalized care, gynecological malignancies, single brain metastasis, local therapies, survival score, 825
- Pertuzumab, metastatic breast cancer, brain metastasis, 839
- Pest control, *Wolbachia pipiensis*, *Otiorhynchus singularis*, DSB-A, drug design, 1051
- PET-computed tomographic, lung cancer, SBRT, local control, 121
- PET/MRI, NMDAR, encephalitis, ovarian teratoma, uterine malformation, 1231
- Phagocytosis, bufalin, leukemia WEHI-3 cells, macrophage, natural killer cells, 1129
- Pharmacokinetics, biodistribution, GP7TB orthotopic hepatoma model, therapeutic evaluation, ^{188}Re -HSAM, 567
- Pharmacokinetics, cytochrome P450, benifuuki tea, food-drug interactions, CYP2D, CYP3A, 33
- Phase II, amrubicin, small cell lung cancer, refractory, relapsed, 1581
- Phenotype characterization, BHK 21/C13 cell line, chick embryo chorioallantoic membrane, experimental therapy, 791
- Pheochromocytoma, paraganglioma, adrenal, kidney, endocrine, 211
- Pheochromocytoma, paraganglioma, adrenal, kidney, endocrine, 703
- Phleboplasty, inferior right hepatic vein, living donor liver transplantation, 1217
- Photodynamic therapy, pyoktanin blue, diode laser, root canal irrigants, 707
- Physical activity, breast neoplasm, exercise, martial arts, quality of life, kyusho Jitsu, 819
- Physical training, breast cancer, n-methyl-N-nitrosourea, 249
- PIK3CA, pancreatic cancer, KRAS, EGFR, BRAF, CDKN2A, TP53, ethnicity, 1527

- PIPAC, pressurized aerosol chemotherapy, PAC, urinary bladder carcinoma, penetration, early-stage cancer, intravesical chemotherapy, 1369
- Pituitary gland, PD-1, CTLA-4, malignant melanoma, ACTH, thyroid gland, irAEs, 345
- PIVKA-II, AFP, hepatocellular carcinoma, biomarkers, predictive, 1551
- Plasma electrolytic oxidation (PEO), *in vitro* cytocompatibility, surface topography, cell adhesion, 241
- Plasma, acute myocardial infarction, biomarkers, greek population, microRNAs, 313
- Plasmablastic lymphoma, stomach, diffuse large B cell Lymphoma, immunohistochemistry, *in situ* hybridization, 413
- Platelet-rich plasma, comminuted fracture, β -tri-calcium phosphate, bone healing, 1449
- Platelet-rich plasma, decellularized trachea, allotransplantation, rabbit, 1443
- Pleura, cell adhesion, cell proliferation, mesothelial, silver nanoparticles, 109
- Pleurectomy or decortication (P/D), malignant pleural mesothelioma, 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG-PET/CT), early clinical stage, extrapleural pneumonectomy (EPP), biphasic, 1169
- PO-Bado, sarcoma, psychosocial distress, distress screening, cancer, bone tumor, 1161
- Polio virus, colorectal cancer, the Cancer Genome Atlas, PVR gene, 1485
- Polymorphism, age, gender, genotype, MMP-8, pterygium, Taiwan, 41
- Polymorphism, bladder cancer, genotype, *MMP-7*, Taiwan, 1045
- Polymorphism, breast cancer, genotype, *MMP-1*, Taiwan, 487
- Polymorphism, coronary artery disease, *LIPG* (584 C/T), 1105
- Polymorphism, tumor necrosis factor, high-grade gliomas, 287
- Polyovular follicle, diethylstilbestrol, estrogen receptor β , ovary, 19
- Polyphenols, fatty acids, grape pomace, lambs, meat quality, 807
- Polyphenols, oxidative stress markers, olive mill wastewater, lambs, 291
- Polysomnography, obstructive sleep apnea syndrome, rho-associated protein kinase, ROCK, triglycerides, sleep, 319
- Population-based case-control study, anti-tuberculosis, isoniazid (INH), rifampin (RIF), hyperlipidemia, 47
- Porcine hybrid bone block, collagen, hydroxyapatite, biodegradability, bone regeneration, 1419
- Porcine model, intra-abdominal hypertension, liver histology and hemodynamics, 85
- Post-operative radiotherapy, breast cancer, radiation dermatitis, dosimetric parameter, 1499
- Postoperative complications, breast cancer therapy, mastectomy, seroma formation, dead space reduction, surgical adhesive, tissuGlu, 625
- Pre-B acute lymphoblastic leukemia, t(12;17)(q13;q21), ZNF384/TAF, 1241
- Predictive marker, neutrophil-to-lymphocyte ratio, endocrine therapy, stage IV, breast cancer, 669
- Predictive, PIVKA-II, AFP, hepatocellular carcinoma, biomarkers, 1551
- Pregnancy, lung cancer, anaplastic lymphoma kinase, alectinib, fetus, 1205
- Preliminary results, breast cancer patients, white blood cell counts, neutrophil counts, chemotherapy, new device, 1283
- Preoperative chemoradiation, high rectal cancer, downstaging, prognostic factors, 1481
- Preoperative therapy, gastric cancer, complete response, chemotherapy, S-1, 1211
- Pressurized aerosol chemotherapy, PAC, urinary bladder carcinoma, penetration, early-stage cancer, intravesical chemotherapy, PIPAC, 1369
- Printing, vertical bone augmentation, three-dimension, rat calvarial partial defec, 1111
- Pro-/anti-inflammatory properties, cinnamates, (meth)acrylates, cytotoxicity, RAW264.7 cells, cox2, nos2 and Ho1 mRNA, 13C-NMR spectra, β -carbon, 1309
- Prognosis, breast cancer, contrast-enhanced ultrasound, qualitative analysis, quantitative analysis, 945
- Prognosis, cullins, cullin-1, cullin-2, colorectal cancer, 391
- Prognosis, non-small cell lung cancer, lung biopsy, 691
- Prognosis, non-small cell lung carcinoma, histological grade, 1505
- Prognosis, ovarian endometrioid carcinoma, ovarian high-grade serous carcinoma, World Health Organization 2014 criteria, 597
- Prognosis, sarcopenia, esophageal cancer, nutritional support, 603
- Prognosis, SOX9, oesophageal cancer, 835
- Prognosis, systemic immune-inflammation index, non-small cell lung cancer, surgery, 663
- Prognostic factor, c-Reactive protein-to-albumin ratio, malignant pleural mesothelioma, neutrophil-to-lymphocyte ratio, 445
- Prognostic factor, thyroid cancer, EZH2, epigenetics, 25
- Prognostic factors, high rectal cancer, preoperative chemoradiation, downstaging, 1481
- Prognostic factors, lung cancer, adenocarcinoma, pathology, 1571

- Prognostic tool, cancer of the bladder, cerebral metastases, whole-brain irradiation, estimation of survival, 633
- Prognostication, palliation, radiotherapy, geriatrics, lung cancer, 331
- Progression free survival, mycosis fungoïdes, radiotherapy, overall survival, toxicity, 517
- Proliferation, colon, crypts, stem cells, morphology, 1473
- Proliferation, fatty infiltration, type 2 diabetes mellitus, mouse, pancreatic cancer, 499
- Proliferation, p16, SATB1, ki-67, TMA, tissue microarray, breast cancer, 731
- Prostaglandin analogues, glaucoma, side effects, adverse events, medical therapy, benzalkonium chloride, *in vivo* confocal microscopy, review, 211
- Prostaglandin E2, banana flower extract, benign prostatic hyperplasia, G0/G1 arrest, cyclooxygenase-2, 1373
- Prostate cancer, amino acids, renal cell carcinoma, urinary bladder cancer, 425
- Prostate cancer, androgen-deprivation therapy, bone mineral density, chronic kidney disease, 409
- Prostate cancer, angiogenesis, tumour intravasation, tumour thrombus, melanoma, 461
- Prostate cancer, cost effectiveness, prostatectomy, brachytherapy, radiotherapy, integrated delivery and finance system, 113
- Prostate carcinoma, radiation therapy, salvage treatment, radical prostatectomy, MRI, 125
- Prostatectomy, prostate cancer, cost effectiveness, brachytherapy, radiotherapy, integrated delivery and finance system, 113
- Protection, nerve cell, NGF, differentiation, amyloid β -peptide, hormesis, bamboo leaf extract, 231
- Proteomics, *Opisthorchis viverrini*, cholangiocarcinoma, bile, biomarkers, 871
- Pseudo-cysts, cysts, cytokeratin, oral cavity, diagnosis, classification, review, 999
- Psychometric properties, resilience, validity, CD-RISC, greek version, 1629
- Psychosocial distress, sarcoma, distress screening, cancer, bone tumor, pO-Bado, 1161
- PTEN, triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, AR, EGFR, ALK, PDL-1 and c-MYC, 303
- Pterygium, age, gender, genotype, MMP-8, polymorphism, taiwan, 41
- Pulmonary edema, medium molecular weight heparinyl arginine (MHR), scorpion venom, 537
- Pulmonary metastases, obesity paradox, metastasectomy, disease-free interval, overall survival, 197
- Pulmonary tumor embolism, uterine cervical cancer, autopsy, 337
- PVR gene, polio virus, colorectal cancer, the Cancer Genome Atlas, 1485
- Pyoktanin blue, photodynamic therapy, diode laser, root canal irrigants, 707
- Qualitative analysis, breast cancer, contrast-enhanced ultrasound, prognosis, quantitative analysis, 945
- Quality of life, bladder cancer, ileal conduit, orthotopic neobladder, radical cystectomy, 139
- Quality of life, breast neoplasm, exercise, martial arts, physical activity, kyusho Jitsu, 819
- Quantitative analysis, breast cancer, contrast-enhanced ultrasound, prognosis, qualitative analysis, 945
- R0 resection, neoadjuvant, chemoradiotherapy, pancreatic cancer, gemcitabine, 1183
- Rabbit, decellularized trachea, allotransplantation, platelet-rich plasma, 1443
- Radial forearm flap, head and neck cancer, free-flap transfer, reconstructive surgery, anterolateral thigh flap, 893
- Radial fracture, bone morphogenetic protein-2, cryopolymerization, dog, gelatin methacrylate hydrogel, 575
- Radiation dermatitis, breast cancer, post-operative radiotherapy, dosimetric parameter, 1499
- Radiation exposure, totally implantable central venous port systems, fluoroscopy time, dose area product, training, 179
- Radiation mitigation, ionizing irradiation, JP4-039, 1009
- Radiation therapy, breast cancer, dermatitis, mastectomy, 961
- Radiation therapy, prostate carcinoma, salvage treatment, radical prostatectomy, MRI, 125
- Radical cystectomy, bladder cancer, quality of life, ileal conduit, orthotopic neobladder, 139
- Radical prostatectomy, prostate carcinoma, radiation therapy, salvage treatment, MRI, 125
- Radiosurgery, fractionated stereotactic radiotherapy, brain metastases, survival, scoring-system, validation, 381
- Radiotherapy, lung adenocarcinoma, epidermal growth factor receptor mutation, double EGFR mutation, 203
- Radiotherapy, matrix metalloproteinases, rectal cancer, inflammation, 133
- Radiotherapy, mycosis fungoïdes, progression free survival, overall survival, toxicity, 517
- Radiotherapy, palliation, geriatrics, prognostication, lung cancer, 331
- Radiotherapy, prostate cancer, cost effectiveness, prostatectomy, brachytherapy, integrated delivery and finance system, 113
- Rat calvarial partial defec, vertical bone augmentation, three-dimension, printing, 1111

- Rat, azoxymethane, colorectal cancer, *Capsosiphon fulvescens*, *Hizikia fusiforme*, 101
- Rate responsive function, cardiac pacemaker, pacemaker programming modes, single-chamber pacing, dual-chamber pacing, exercise capacity, 419
- Rats, liver, steatosis, fatty liver disease, ischemia, ischemia-reperfusion injury, 1381
- RAW264.7 cells, cinnamates, (meth)acrylates, cytotoxicity, pro-/anti-inflammatory properties, cox2, nos2 and Ho1 mRNA, 13C-NMR spectra, β-carbon, 1309
- RAW264.7 cells, β-Carotene, lycopene, tri-n-butyl borane, LPS, COX2, NOS2, HMOX1, 255
- Re-administration, drug-induced interstitial lung disease, chemotherapy, EGFR-TKI, corticosteroid, 851
- Real-world experience, renal cell carcinoma, targeted therapy, 1617
- Rebiopsy, EGFR mutation, T790M, non-small cell lung carcinoma, 1199
- Recombinant human soluble thrombomodulin, sinusoidal obstruction syndrome, hematopoietic stem cell transplantation, liver transplantation, oxaliplatin-based chemotherapy, 1409
- Reconstructive surgery, head and neck cancer, free-flap transfer, anterolateral thigh flap, radial forearm flap, 893
- Rectal cancer, matrilysin, matrix metalloproteinases, radiotherapy, inflammation, 133
- Rectal cancer, neoadjuvant chemotherapy, FOLFOX, feasibility, 937
- Rectal cancer, robot-assisted surgery, laparoscopic surgery, meta-analysis, 611
- Rectum, circulating microRNA, colon, biomarker, human, 1333
- Recurrence, green tea, urothelial cancer, human antigen-R, smoking, 721
- Recurrent pericardial effusion, pericardiocentesis, cisplatin, cardio-oncology, 373
- Recurrent, breast cancer, *de novo* stage IV patients, hER2-negative, hR-positive, 353
- Refractory, amrubicin, small cell lung cancer, relapsed, phase II, 1581
- Regeneration, animal, cartilage, treatment, biomaterial, tissue engineering, review, 1289
- Regulation, cell-cycle checkpoints, cancer, cyclins, cyclin-dependent kinases, aneuploidy, review, 1
- Rehabilitation, carbon dioxide treatment, balneotherapy, heart rate variability, 1259
- Relapsed, amrubicin, small cell lung cancer, refractory, phase II, 1581
- Renal cell carcinoma, amino acids, prostate cancer, urinary bladder cancer, 425
- Renal cell carcinoma, real-world experience, targeted therapy, 1617
- Renal, simvastatin, nicotine, antioxidant, HO1, mnSOD, CREB, ERK, p66shc, 1033
- Renin-angiotensin system, *db* Mice, optical coherence tomography, diabetic retinopathy, 265
- Report quality, data mining, structured reporting, objective comparison, text mining, cosine similarity score, 843
- Resection, splenic artery aneurysm, distal splenopancreatectomy, 915
- Resilience, psychometric properties, validity, CD-RISC, greek version, 1629
- Resistance modifying activity, *N. sativa* essential oil, *Listeria monocytogenes*, antimicrobial activity, 737
- Resistive index, amylase, delayed graft function, kidney transplant, 397
- Respiratory rate, heart failure, heart rate, emergency, 921
- Retn*, gene expression, C57BL/6J, iapp, drd5, 813
- Retropertitoneal tumor, paraganglioma, celiac trunk resection, hepatic artery reinsertion, 911
- Review, amyotrophic lateral sclerosis, motor neuron diseases, mouse models, C9ORF72, FUS, SOD1, TARDBP, 983
- Review, animal, cartilage, treatment, regeneration, biomaterial, tissue engineering, 1289
- Review, atherosclerosis, cardiovascular disease, matrix metalloproteinases, vitamin D, vitamin D receptor, 977
- Review, cell-cycle checkpoints, cancer, regulation, cyclins, cyclin-dependent kinases, aneuploidy, 1
- Review, cysts, pseudo-cysts, cytokeratin, oral cavity, diagnosis, classification, 999
- Review, embryo culture media, conditions, trends, epigenetics, 451
- Review, glaucoma, prostaglandin analogues, side effects, adverse events, medical therapy, benzalkonium chloride, *in vivo* confocal microscopy, 211
- Review, sarcoma, mimics, MRI, 221
- Review, sentinel lymph node biopsy, early breast cancer, axillary radiotherapy, axillary dissection, evidence-based medicine, clinical practice update, 1301
- Revision surgery, ankle fusion, osteoarthritis, insurance status, long-term follow-up, 1463
- Rho-associated protein kinase, obstructive sleep apnea syndrome, ROCK, triglycerides, polysomnography, sleep, 319
- Rifampin (RIF), anti-tuberculosis, isoniazid (INH), hyperlipidemia, population-based case-control study, 47
- Risk factor, airway obstruction, interstitial lung disease, lung cancer, nivolumab, 887
- Robot-assisted surgery, rectal cancer, laparoscopic surgery, meta-analysis, 611

- ROCK, obstructive sleep apnea syndrome, rho-associated protein kinase, triglycerides, polysomnography, sleep, 319
- Root canal irrigants, photodynamic therapy, pyoktanin blue, diode laser, 707
- Ruptured HCC, laparoscopic hepatectomy, laparoscopic liver resection, left lobectomy, TAE, 659
- S-1, gastric cancer, complete response, chemotherapy, preoperative therapy, 1211
- Salvage therapy, bevacizumab, non-squamous cell lung cancer, osteonecrosis of the jaw, 1155
- Salvage treatment, prostate carcinoma, radiation therapy, radical prostatectomy, MRI, 125
- Sarcoma, mimics, MRI, review, 221
- Sarcoma, psychosocial distress, distress screening, cancer, bone tumor, pO-Bado, 1161
- Sarcopenia, esophageal cancer, prognosis, nutritional support, 603
- Sarcopenia, myogenesis, statin, geranylgeranylation, C2C12 cells, 1427
- SATB1, p16, ki-67, TMA, tissue microarray, proliferation, breast cancer, 731
- SBRT, lung cancer, pET-computed tomographic, local control, 121
- Scoring-system, radiosurgery, fractionated stereotactic radiotherapy, brain metastases, survival, validation, 381
- Scorpion venom, medium molecular weight heparinyl arginine (MHR), pulmonary edema, 537
- Sentinel lymph node biopsy, early breast cancer, axillary radiotherapy, axillary dissection, evidence-based medicine, clinical practice update, review, 1301
- Sepsis, TLR9, immunosuppression, toll-like receptors, 1653
- Seroma formation, breast cancer therapy, mastectomy, postoperative complications, dead space reduction, surgical adhesive, tissuGlu, 625
- Serum albumins, hypericin, emodin, DNA, interaction, thermal stability, 1063
- Side effects, glaucoma, prostaglandin analogues, adverse events, medical therapy, benzalkonium chloride, *in vivo* confocal microscopy, review, 211
- Silver nanoparticles, cell adhesion, cell proliferation, mesothelial, pleura, 109
- Simvastatin, nicotine, renal, antioxidant, HO1, mnSOD, CREB, ERK, p66shc, 1033
- Single brain metastasis, gynecological malignancies, local therapies, survival score, personalized care, 825
- Single nucleotide polymorphism, asthma, genotype, XRCC3, taiwan, 1039
- Single-chamber pacing, cardiac pacemaker, pacemaker programming modes, dual-chamber pacing, rate responsive function, exercise capacity, 419
- Sinusoidal obstruction syndrome, recombinant human soluble thrombomodulin, hematopoietic stem cell transplantation, liver transplantation, oxaliplatin-based chemotherapy, 1409
- Situs inversus totalis*, superficial spreading gastric cancer, total gastrectomy, 685
- Skin toxicity, surface dose, carbon couch, HM couch, 531
- Sleep, obstructive sleep apnea syndrome, rho-associated protein kinase, ROCK, triglycerides, polysomnography, 319
- Small bowel adenocarcinoma, ileal diverticulosis, crohn's disease, 191
- Small cell lung cancer, amrubicin, refractory, relapsed, phase II, 1581
- Smoking, green tea, urothelial cancer, human antigen-R, recurrence, 721
- Smp30* KO mice, vitamin C, diethylnitrosamine, hepatocellular carcinoma, 93
- SOD1*, amyotrophic lateral sclerosis, motor neuron diseases, mouse models, *C9ORF72*, *FUS*, *TARDBP*, review, 983
- SOX9, oesophageal cancer, prognosis, 835
- Spleen, treatment-related lymphopenia, chemoradiotherapy, bone marrow, dose-volume parameters, 1519
- Splenectomy, esophagogastric junction carcinoma, venous invasion, blood transfusion, 145
- Splenic artery aneurysm, resection, distal splenopancreatectomy, 915
- Splenic artery patch, celiac axis stenosis, median arcuate ligament syndrome, 699
- Squamous cell carcinoma, hypopharyngeal cancer, synchronous cancer, oesophageal cancer, 165
- Stage III, colorectal cancer, high-risk stage II, peritoneal metastasis, 1235
- Stage IV, neutrophil-to-lymphocyte ratio, endocrine therapy, breast cancer, predictive marker, 669
- Staging, lung cancer, interstitial lung disease, FDG/PET-CT, 1457
- Statin, diabetes, adipogenesis, antidiabetic drug, geranylgeranylation, 1339
- Statin, sarcopenia, myogenesis, geranylgeranylation, C2C12 cells, 1427
- Steatosis, liver, fatty liver disease, rats, ischemia, ischemia-reperfusion injury, 1381
- Stem cells, colon, crypts, morphology, proliferation, 1473
- Stereotactic radiotherapy, NSCLC, TKI, 159
- Stomach, diffuse large B cell Lymphoma, plasmablastic lymphoma, ommunohistochemistry, *in situ* hybridization, 413
- Strictures, liver transplantation, biliary complication, cytomegalovirus, hepatic artery stenosis, 1623
- Structured reporting, data mining, report quality, objective comparison, text mining, cosine similarity score, 843

- Subclinical atherosclerosis, chemotherapy, cardiotoxicity, myocardial dysfunction, arterial stiffness, LV function, 1599
- Superficial spreading gastric cancer, *situs inversus totalis*, total gastrectomy, 685
- Surface dose, skin toxicity, carbon couch, HM couch, 531
- Surface topography, plasma electrolytic oxidation (PEO), *in vitro* cytocompatibility, cell adhesion, 241
- Surgery, CD44, early recurrence, pancreatic cancer, 1533
- Surgery, oropharyngeal cancer, human papillomavirus, p16, clinical outcome, 927
- Surgery, ovarian cancer, energy device, caiman®, 359
- Surgery, systemic immune-inflammation index, non-small cell lung cancer, prognosis, 663
- Surgical adhesive, breast cancer therapy, mastectomy, seroma formation, postoperative complications, dead space reduction, tissuGlu, 625
- Surgical margin, pancreatic adenocarcinoma, curative resection, 1591
- Surgical stress, body composition, lean body mass, laparoscopy-assisted total gastrectomy, open total gastrectomy, 1513
- Survival score, gynecological malignancies, single brain metastasis, local therapies, personalized care, 825
- Survival, radiosurgery, fractionated stereotactic radiotherapy, brain metastases, scoring-system, validation, 381
- Susceptibility vessel sign, T2*-weighted images, lacunar infarction, GRE, 973
- SUVpeak, oral squamous cell carcinoma, 18F-FDG-PET/CT, overall survival, uICC8th, 1193
- Swine model, diurnal rhythm, lighting conditions, mealtime, working environments, 55
- Swine, intrathecal catheter, cerebrospinal fluid, melatonin, minipig, 583
- Synchronous cancer, hypopharyngeal cancer, squamous cell carcinoma, oesophageal cancer, 165
- Systemic immune-inflammation index, non-small cell lung cancer, surgery, prognosis, 663
- T-lymphocyte, angiotensin, IL-2, candesartan, ERK, 1353
- T(12;17)(q13;q21), pre-B acute lymphoblastic leukemia, ZNF384/TAF, 1241
- T1 esophageal cancer, local control, concurrent chemoradiotherapy, FDG-PET/CT, 1269
- T2*-weighted images, susceptibility vessel sign, lacunar infarction, GRE, 973
- T790M, EGFR mutation, non-small cell lung carcinoma, rebiopsy, 1199
- TAE, laparoscopic hepatectomy, laparoscopic liver resection, left lobectomy, ruptured HCC, 659
- Taiwan, age, gender, genotype, MMP-8, polymorphism, pterygium, 41
- Taiwan, asthma, genotype, single nucleotide polymorphism, XRCC3, 1039
- Taiwan, bladder cancer, genotype, MMP-7, polymorphism, 1045
- Taiwan, breast cancer, genotype, MMP-1, polymorphism, 487
- Tamoxifen, EGF, epidermal growth factor, perianal tumours, dog, 1175
- TARDBP, amyotrophic lateral sclerosis, motor neuron diseases, mouse models, C9ORF72, FUS, SOD1, review, 983
- Targeted microbubble, ultrasound, intraplaque neovascularization, atherosclerosis, 1025
- Targeted therapy, real-world experience, renal cell carcinoma, 1617
- TAS-102, chemotherapy, unresectable colorectal carcinoma, 1643
- Taurine, neuronal differentiation, PC12 cells, NGF, amino acid concentration, urea, aspartic acid, overlay isolation method, 1403
- Tear osmolarity, acute allergic rhinoconjunctivitis, artificial tears, 403
- Telbivudine, kallikrein-8, estimated glomerular filtration rate, 955
- Text mining, data mining, report quality, structured reporting, objective comparison, cosine similarity score, 843
- Thalidomide, canine, mammary gland, metastasis, metronomic chemotherapy, 1659
- The Cancer Genome Atlas, polio virus, colorectal cancer, PVR gene, 1485
- Theca cell, cyp17a1, luteinizing hormone, granulosa cell, PCOS, androgen synthesis, 1387
- Therapeutic evaluation, biodistribution, pharmacokinetics, GP7TB orthotopic hepatoma model, ¹⁸⁸Re-HSAM, 567
- Therapy, bladder cancer, urothelial carcinoma, peritoneum, computed tomography, 905
- Thermal stability, hypericin, emodin, DNA, serum albumins, interaction, 1063
- Three-dimension, vertical bone augmentation, printing, rat calvarial partial defec, 1111
- Thrombectomy, cerebrovascular stroke, elderly, octogenarian, endovascular procedures, cerebral infarction, 1223
- Thrombosis, TIVAD, venous access system, complication, breast cancer, 1275
- Thyroid cancer, EZH2, prognostic factor, epigenetics, 25
- Thyroid gland, PD-1, CTLA-4, malignant melanoma, ACTH, pituitary gland, irAEs, 345
- Tissue engineering, animal, cartilage, treatment, regeneration, biomaterial, review, 1289

- Tissue microarray, p16, SATB1, ki-67, TMA, proliferation, breast cancer, 731
- TissuGlu, breast cancer therapy, mastectomy, seroma formation, postoperative complications, dead space reduction, surgical adhesive, 625
- TIVAD, venous access system, complication, thrombosis, breast cancer, 1275
- TKI, NSCLC, stereotactic radiotherapy, 159
- TLR9, sepsis, immunosuppression, toll-like receptors, 1653
- TMA, p16, SATB1, ki-67, tissue microarray, proliferation, breast cancer, 731
- Toll-like receptors, sepsis, TLR9, immunosuppression, 1653
- Total gastrectomy, *situs inversus totalis*, superficial spreading gastric cancer, 685
- Totally implantable central venous port systems, radiation exposure, fluoroscopy time, dose area product, training, 179
- Toxicity, mycosis fungoides, radiotherapy, progression free survival, overall survival, 517
- TP53, pancreatic cancer, KRAS, EGFR, BRAF, PIK3CA, CDKN2A, ethnicity, 1527
- Training, totally implantable central venous port systems, radiation exposure, fluoroscopy time, dose area product, 179
- Transdermal, laboratory rats, pain, analgesia, fentanyl, 713
- Trastuzumab, HER2, gastric cancer, 1491
- Trastuzumab, hypofractionated radiotherapy (HRT), breast cancer cardiotoxicity, adjuvant treatment, 879
- Treatment-related lymphopenia, chemoradiotherapy, spleen, bone marrow, dose-volume parameters, 1519
- Treatment, animal, cartilage, regeneration, biomaterial, tissue engineering, review, 1289
- Trends, embryo culture media, conditions, epigenetics, review, 451
- Tri-n-butyl borane, β-carotene, lycopene, LPS, RAW264.7 cells, COX2, NOS2, HMOX1, 255
- Triglycerides, obstructive sleep apnea syndrome, rho-associated protein kinase, ROCK, polysomnography, sleep, 319
- Triple-negative breast cancer, p53, p63, c-kit, ki67, cMet, claudin 7, CK 5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC, 303
- Tumor necrosis factor, polymorphism, high-grade gliomas, 287
- Tumor specificity, alkylaminoguaiazulene, alkylation, morpholine backbone, cytotoxicity, apoptosis, 541
- Tumor specificity, azulene amides, cytotoxicity, hydrophobicity, molecular shape, apoptosis, 479
- Tumor-infiltrating lymphocyte, breast cancer, dendritic cell, cD11c, 1561
- Tumor-infiltrating lymphocytes, colorectal cancer, chemotherapeutic outcome, 151
- Tumour intravasation, angiogenesis, tumour thrombus, prostate cancer, melanoma, 461
- Tumour thrombus, angiogenesis, tumour intravasation, prostate cancer, melanoma, 461
- Type 2 diabetes mellitus, fatty infiltration, mouse, proliferation, pancreatic cancer, 499
- UICC8th, oral squamous cell carcinoma, 18F-FDG-PET/CT, sUVpeak, overall survival, 1193
- Ultrasonic scalpel, liver parenchymal transection, liver resection, hepatectomy, lotus, harmonic, bile leakage, bleeding, 883
- Ultrasound, targeted microbubble, intraplaque neovascularization, atherosclerosis, 1025
- Unresectable colorectal carcinoma, TAS-102, chemotherapy, 1643
- Urea, neuronal differentiation, PC12 cells, NGF, amino acid concentration, taurine, aspartic acid, overlay isolation method, 1403
- Urinary bladder cancer, amino acids, prostate cancer, renal cell carcinoma, 425
- Urinary bladder carcinoma, pressurized aerosol chemotherapy, PAC, penetration, early-stage cancer, intravesical chemotherapy, PIPAC, 1369
- Urothelial cancer, green tea, human antigen-R, smoking, recurrence, 721
- Urothelial carcinoma, bladder cancer, peritoneum, computed tomography, therapy, 905
- Uterine cervical cancer, pulmonary tumor embolism, autopsy, 337
- Uterine malformation, PET/MRI, NMDAR, encephalitis, ovarian teratoma, 1231
- Validation, radiosurgery, fractionated stereotactic radiotherapy, brain metastases, survival, scoring-system, 381
- Validity, resilience, psychometric properties, CD-RISC, greek version, 1629
- Vascular anomaly, virome, head and neck, 1323
- Vascular proliferation, breast cancer, microvessels, immunohistochemistry, angiogenesis, 79
- VEGF, adenohypophysis, neurohypophysis, hIF1α, hIF2α, CD31, 185
- Venous access system, TIVAD, complication, thrombosis, breast cancer, 1275
- Venous invasion, esophagogastric junction carcinoma, splenectomy, blood transfusion, 145
- Vertical bone augmentation, three-dimension, printing, rat calvarial partial defec, 1111
- Virome, vascular anomaly, head and neck, 1323
- Vitamin C, diethylnitrosamine, hepatocellular carcinoma, *smp30* KO mice, 93

- Vitamin D receptor, atherosclerosis, cardiovascular disease, matrix metalloproteinases, vitamin D, review, 977
- Vitamin D, atherosclerosis, cardiovascular disease, matrix metalloproteinases, vitamin D receptor, review, 977
- Weight, height, BMI, age, muscle mass predictors, lower extremity reconstruction, gracilis muscle, free flap, 591
- White blood cell counts, breast cancer patients, neutrophil counts, chemotherapy, new device, preliminary results, 1283
- Whole-brain irradiation, cancer of the bladder, cerebral metastases, prognostic tool, estimation of survival, 633
- Wolbachia pipiensis*, *Otiorhynchus singularis*, DSB-A, pest control, drug design, 1051
- Working environments, diurnal rhythm, lighting conditions, mealtime, swine model, 55
- World Health Organization 2014 criteria, ovarian endometrioid carcinoma, ovarian high-grade serous carcinoma, prognosis, 597
- Wound dressing, β -glucan, paramylon, cytokine, 799
- Xenograft nude mouse model, cholangiocarcinoma, NK cell, 771
- Xenograft, colorectal cancer, anticancer activity, KT2 peptide, apoptosis, 1137
- XRCC3*, asthma, genotype, single nucleotide polymorphism, Taiwan, 1039
- Zanamivir, influenza virus, lung pathology, nitric oxide, 473
- ZNF384/TAF, pre-B acute lymphoblastic leukemia, t(12;17)(q13;q21), 1241

Authors Index

(Figures refer to page numbers)

- | | | | |
|--------------------------------|--|---|------------------------------------|
| Abe M, 55, 171, 265, 583 | Arany I, 1033 | Bastos-Rodrigues L, 1527 | Camporese G, 1231 |
| Abe Takanori, 337 | Ardavanis A, 653 | Batistatou A, 303 | Cao D, 413 |
| Abe Tomoyuki, 231, 745,
765 | Argyra E, 85 | Bau D-T, 41, 47, 487, 753,
829, 1039, 1045, 1373 | Capelli I, 397 |
| Abelson KSP, 713 | Argyroulis I, 291 | Baumann FT, 819 | Cappuccilli M, 397 |
| Acar L, 1653 | Arimura E, 55, 265 | Baying B, 1323 | Cassali GD, 1659 |
| Adam V, 425 | Ariyasu H, 345 | Beneš J, 1063 | Ceauşu RA, 79 |
| Adawi D, 133 | Arsenopoulou ZV, 109 | Beneš V, 1323 | Cecannechia S, 211 |
| Addison WN, 1339, 1427 | Artibani W, 139 | Beppu S, 1193 | Cecchin D, 1231 |
| Afaneh A, 703 | Arvanitakis S, 921 | Béres S, 1145 | Cegielski M, 249 |
| Agiannitopoulos K, 313 | Asano Y, 669 | Beriwal S, 113 | Çelik B, 1105 |
| Agnanti N, 303 | Ataacar A, 1105 | Berri R, 703 | Celik F, 813 |
| Agnifili L, 211, 437 | Atagi S, 887 | Bette M, 1323 | Cernei N, 425 |
| Aibe N, 1499 | Atalan N, 1653 | Beumer J, 1009 | Cerruto MA, 139 |
| Aivalioti F, 921 | Athanasios A, 191 | Binda S, 1255 | Cevik A, 813 |
| Ajimizu H, 1587 | Attar S, 221 | Blanck O, 381 | Champeris Tsaniras S, 859,
1051 |
| Ajtay B, 1555 | Attenberger UI, 125 | Błasiak P, 197 | Chan Y-C, 753, 829 |
| Ajtay Z, 1145, 1259, 1555 | Avenia N, 133 | Böhme J, 973 | Chang C-H, 567 |
| Akamizu T, 345 | Avram A, 1599 | Bolaris S, 451 | Chang H-T, 1635 |
| Akcan U, 319 | Ayabe T, 663 | Bongiorni DR, 113 | Chang JW-C, 905 |
| Akiba J, 1541 | Aydin Ş, 319 | Bonù ML, 159 | Chang P-M, 1635 |
| Akioka K, 55, 583 | Azuma K, 1541 | Bonzano E, 879 | Chang W-S, 41, 487, 1039,
1045 |
| Akiyama H, 603 | Baba H, 1519 | Boonsiri P, 1137 | Chang Y-H, 905 |
| Aksorn N, 871 | Babalis D, 313 | Borghetti P, 159 | Chang Y-J, 567 |
| Alagöl F, 555 | Babjuk M, 425 | Borgia G, 1255 | Chanvorachote P, 71, 871,
1353 |
| Alexiou K, 1381 | Bacalbasa N, 385, 431, 649,
699, 911, 915, 967, 1217,
1247 | Borrelli E, 437 | |
| Alexopoulos A, 303 | Baek SY, 771 | Brand RM, 1009 | |
| Alongi F, 159 | Baiguini A, 159 | Brasoveanu V, 699, 911, 915,
967, 1217, 1247 | |
| Alrafiah AR, 983 | Bakowsky U, 1323 | Bratchikov M, 473 | |
| Al-Samadi A, 1089 | Balabram D, 1659 | Bravaccio C, 1255 | |
| Al-Zghloul M, 973 | Balalau C, 385 | Brezean I, 911, 915, 967,
1217, 1247 | |
| Amano R, 611 | Balalau C, 431 | Briese T, 1323 | |
| Amano S, 637 | Balasubramani GK, 113 | Brodzki A, 1175 | |
| Amaral NS, 1527 | Baldi A, 999 | Brunilda S, 397 | |
| Ambrozaitis A, 473 | Balescu I, 385, 431, 649,
699, 911, 915, 967, 1217,
1247 | Brzecka A, 197 | |
| Ando M, 1581 | Bampali K, 313 | Buergy D, 125 | |
| Andreatos N, 85 | Bang WS, 1561 | Buglione M, 159 | |
| Androudi S, 403 | Banović P, 791 | Bujor IS, 79 | |
| Angeletti A, 397 | Baraldi O, 397 | Buonomo AR, 1255 | |
| Anifandis G, 451 | Barbeck M, 241 | Buss LA, 1071 | |
| Antoniou A, 945 | Baron B, 759 | Büyükören B, 1105 | |
| Antoniou EA, 85 | Bassi P, 139 | Cacciamani G, 139 | |
| Aoyama T, 597, 1513 | | Caloian B, 419 | |
| Araki T, 265 | | | |
| Arano N, 1205 | | | |

- Chiang C-L, 1635
 Chiang C-S, 1119
 Chiang J-H, 677
 Chiang K-C, 1591
 Cho H, 1513
 Choi SH, 1111, 1443
 Chou A-K, 41
 Chou J-S, 523, 1129
 Chou P-Y, 783
 Christodoulou V, 291, 807
 Chuang C-K, 905
 Chuang Y-C, 279, 549
 Chuang Y-Y, 523
 Chung H-Y, 523, 1129
 Chung J-G, 487, 523, 783,
 1119, 1129, 1137
 Chung M-J, 93, 101
 Chung Y-Y, 771
 Ciancaglini M, 211, 437
 Ciciliato S, 139
 Cierpikowski P, 197
 Cîmpean AM, 79, 791, 1599
 Cioca A, 79
 Clemensen J, 713
 Cognetti F, 839
 Collettini F, 179
 Comai G, 397
 Constantinides VC, 1647
 Constantino-Casas F, 7
 Constantinou C, 303
 Conte C, 359
 Contolenco A, 649
 Coran A, 221
 Corradetti V, 397
 Corvò R, 879
 Costantini B, 359
 Crimì F, 221, 1231
 Cuna V, 397
 Currie MJ, 1071
 Cziráki A, 1555
 D'Elia C, 139
 D'Urso G, 1255
 Dachs GU, 1071
 Daduang J, 1137
 Daduang S, 1137
 Dalhaug A, 331
 Damaskos C, 85, 191, 403,
 1265
 Danila E, 1571
- Darocha S, 373
 Darreon J, 121
 De Campos CB, 1659
 De Marchi D, 139
 De Marco L, 1527
 De Marco V, 139
 Deligeoroglou E, 451
 Dellaportas D, 945
 Demirel N, 287
 Di Domenico M, 999
 Di Gregorio A, 211
 Di Maggio A, 221
 Di Staso S, 211, 437
 Di Summa PG, 591
 Diamantopoulos P, 1241
 Dima S, 1247
 Dimitrakopoulou A, 1241
 Dimitroulis D, 191
 Dixit M, 1033
 Dobroitoiu D, 649
 Dobson JM, 7
 Doi H, 531, 1169
 Doi N, 345
 Dos Santos JS, 1527
 Douzenis A, 1629
 Dragoumani K, 859
 Drizou M, 653
 Duong VN, 633
 Duskova K, 425
 Duzkalir AH, 287
 Dziegiel P, 249, 731
 Dziggel L, 381, 633, 825
 Ehrenreich J, 1323
 Eichhorn M, 1457
 Eichinger M, 1457
 Eisenhart-Rothe RV, 1161
 Eivazi B, 1323
 El-Balat A, 1275
 Elfadl AK, 93, 101
 Eliopoulos E, 1051
 Emoto S, 365, 1235
 Endo I, 603
 Endo T, 273
 Epperly MW, 1009
 Ercoli A, 359
 Erdos G, 1009
 Ergen A, 813, 1653
 Erich SA, 7
 Fabi A, 839
- Fagotti A, 359
 Fahr C, 1369
 Falo Jr LD, 1009
 Fanelli G, 1231
 Fang H-Y, 753, 829
 Ferentinos P, 1629
 Ferretti G, 839
 Fialho SL, 1659
 Fisher R, 1009
 Flechsig P, 1457
 Florea R, 1247
 Förster A, 843, 973
 Franicola D, 1009
 Franke N, 1323
 Friedman E, 1527
 Friedrich RE, 241
 Froelich MF, 843
 Fujii S, 851
 Fujii T, 927
 Fujioka H, 643
 Fujisawa K, 685, 1211
 Fujisawa S, 255, 1309
 Fujisawa T, 231
 Fujita J, 353
 Fujita S, 659
 Fujitaka K, 1155
 Fukuchi M, 145
 Fukuda A, 643
 Fukuda S, 273
 Fukuoka T, 151, 611
 Fukuzaki M, 1427
 Fukuzawa K, 659
 Fülop T, 1033
 Funaguchi N, 1169
 Fundowicz M, 517
 Furukawa Y, 345
 Furuya K, 597
 Fushida S, 1409
 Gaballah K, 359
 Gaber A, 133
 Gacci M, 139
 Gaedke IE, 1463
 Galanis P, 945
 Gallotta V, 359
 Garmpi A, 1265
 Garmpis N, 85, 191, 403,
 1265
 Garoufalia Z, 883
 Gasparro S, 839
- Gatzioufas Z, 1265
 Gaudin R, 241
 Gaulke R, 1463
 Gebauer B, 179
 Geisthoff U, 1323
 Gencan IA, 1105
 Gentile I, 1255
 Georgakopoulos N, 1241
 Georganta C, 653
 Gera R, 1301
 Gerasopoulos K, 291, 807
 Ghim S-G, 93, 101
 Giannakeas N, 1433
 Giannakopoulou N, 1241
 Giannelou P, 451
 Giatromanolaki A, 185
 Gieron L, 625
 Giles-Şenyürek Y, 555
 Giriş M, 319
 Gkekə P, 1433
 Gkolfakis P, 191
 Glaser SM, 113
 Glatzel-Plucinska N, 731
 Gokce MO, 813
 Gomi Y, 33
 Gong C-L, 41
 Gong G, 1561
 Goto W, 669
 Goulas P, 807
 Gouliamos A, 945
 Gourgoulianis KI, 109
 Gravenstein S, 473
 Greco D, 159
 Greenberger JS, 113, 1009
 Griniatsos J, 391
 Groden C, 843, 973
 Grubeau D, 241
 Gruslys V, 1571
 Grzegrzółka J, 197, 249, 731
 Gueli Alletti S, 359
 Guenzi M, 879
 Guglielmotti M, 999
 Güл N, 555
 Güngör G, 1105
 Gusetu GN, 419
 Gyöngyi Z, 1333
 Haberkorn U, 1457
 Hallek M, 819
 Hamacher S, 819

Hamada H, 1155	Ho C-L, 567	Iimori N, 669	Jogo T, 1491, 1541
Hamada S, 1265	Ho C-T, 1373	Iki R, 445	Johnson LB, 133
Hamai K, 1155	Hoffman RM, 1025	Ilie V, 1247	Jonczyk M, 179
Hamano S, 871	Hoffmann A, 241	Imai T, 499	Juan Y-H, 905
Hamm B, 179	Hofmann R, 1617	Imamura F, 887	Juan Y-N, 677
Hamza A, 703	Holländer NH, 1283, 1481	Imbimbo C, 139	Jung DE, 771
Hanai N, 1193	Holtrich U, 1275	Inaba H, 345	Jung IH, 771
Hanazaki K, 685, 1211	Hoornstra D, 1089	Inoue T, 887, 1667	Jung O, 241
Hanker LC, 1275	Hori M, 499	Ionescu O, 385, 431, 649	Jurgauskienė L, 473
Hara K, 937, 1513	Horie N, 745, 765	Ionescu P, 649	Kačergius T, 473
Hara Y, 745, 765	Horiike M, 707	Irie D, 961	Kadoglou NPE, 1433
Harisis H, 303	Horimasu Y, 1155	Irie Y, 479	Kadokura H, 707
Hartjen P, 241	Horiuchi M, 55, 231, 265, 583	Isa S-I, 887	Kadono Y, 899
Hasegawa S, 1169	Horiyama S, 493	Isbir S, 561, 1105	Kafadar A, 287
Hasegawa Y, 1193	Horozoglu C, 813	Isbir T, 287, 561, 1653	Kafantaris I, 291, 807
Hashimoto M, 479, 541	Horváth IG, 1555	Iseki Y, 151	Kagaya H, 479
Hashimoto T, 171	Hoshino T, 1541	Ishibashi H, 597	Kagota S, 493
Hata K, 365, 1235	Hou H-T, 1129	Ishibashi K, 145	Kaino S, 637
Hata M, 1269, 1609	Hsia N-Y, 41	Ishida H, 145	Kairi E, 85
Hatai M, 493	Hsia T-C, 1039, 1045	Ishida N, 1211	Kakisis J, 1433
Hatano T, 669	Hsiao C-L, 487	Ishigami S, 835	Kaku S, 445
Hattori N, 1155	Hsiao J-H, 1635	Ishigamori R, 499	Kakuta H, 19, 1387
Hatzoglou C, 109	Hsiao W-Y, 1039	Ishiguro T, 145	Kalash R, 113
Havlova K, 425	Hsieh C-L, 279	Ishikawa N, 1155	Kalbermatten DF, 591, 893
Hayashi T, 1513	Hsu C-P, 1533	Ito K, 25, 409	Kalogeropoulos CD, 403
Haycock JW, 461	Hsu F-T, 279, 549, 1097, 1361	Iurciuc M, 1599	Kamachi H, 1183
Heers H, 1617	Hsu J-T, 1533, 1591	Iwabu J, 685, 1211	Kamigaki S, 353
Hegele A, 1617	Hsu S-L, 1119	Iwahashi H, 597	Kamiyama T, 1183
Heger Z, 425	Hsu S-W, 487, 1045	Iwai T, 937	Kämpe TA, 327
Heiland M, 241	Hsu Y-P, 1533	Iwaki K, 659	Kaneko M, 365, 1235
Hejjel L, 1145, 1259	Hsueh S-C, 523, 783, 1129	Iwakura H, 345	Kaneko Tadayoshi, 745, 765
Henklewska M, 1081	Hu H, 1025	Iwama S, 231, 765	Kaneko Takahiro, 745, 765
Henningsen A, 241	Hu M, 413	Iwamoto H, 899, 1155	Kaneiji T, 1339
Henzler T, 843	Hu P-S, 41, 1045	Iwasaki H, 25	Kang B-J, 575
Heo S-H, 1561	Huang C-S, 279	Iwasaku M, 1581	Kang K-K, 93, 101
Heron DE, 113	Huang C-Y, 41	Iwase M, 33	Kang SS, 63, 1419
Herschbach P, 1161	Huang H-Y, 753, 829	Izumi H, 265, 583, 1205	Kano K, 1513
Heussel CP, 1457	Hung C-M, 1373	Izumi K, 899	Kanou S, 1409
Heussel G, 1457	Hung NQ, 381	Jacobs BL, 113	Kapiris M, 653
Higo N, 835	Hung Y-W, 41	Jair H-W, 523	Kapran Y, 555
Himi T, 165	Hural O, 1457	Jäkälä P, 1223	Karandreas N, 1647
Hirabayashi M, 445	Hwang NS, 575	Jang K, 63, 1419	Karatzas T, 1381
Hirai F, 1541	Hwang T-L, 1533, 1591	Jang SJ, 1443	Karhi S, 1223
Hirai T, 33, 1587	Iafrate M, 139	Janssen S, 633, 1481	Karlíkova M, 1551
Hiraishi H, 171	Igarashi G, 273	Jarosz Ł, 1175, 1289	Karn T, 1275
Hirakawa K, 151, 611, 669	Iguchi T, 19, 1387	Jeong K-S, 93, 101	Karyda E, 303
Hirasawa K, 1269	Iimori M, 1491	Jeong SH, 771	Kasem A, 1301
Hirashima T, 887		Jinescu G, 649	Kashiwabara K, 851
Hiroshige S, 659		Jirström K, 133	Kashiwagi S, 151, 669

- Kataoka Y, 445
 Kato K, 597
 Kato S, 337
 Katoh H, 961
 Katoh N, 1183
 Katsimpoulas M, 1433
 Kauczor H-U, 1457
 Kawaguchi H, 55, 265, 583
 Kawaguchi T, 691, 1505
 Kawahara A, 1541
 Kawai K, 365, 1235
 Kawai N, 691, 1505
 Kawano M, 637
 Kawasaki T, 659
 Kawata A, 255, 1309
 Kaya M, 287
 Kazama S, 365
 Kępski J, 373
 Khiem VH, 633
 Khoa MT, 381, 633
 Khosrawipour T, 1369
 Khosrawipour V, 1369
 Kida K, 927
 Kijima T, 1169
 Kim DH, 771
 Kim H, 19
 Kim J-H, 1111
 Kim J-M, 1111
 Kim SE, 63, 1419
 Kim YD, 93, 101
 Kim YH, 1587
 Kimura M, 273
 Kinoshita E, 493
 Kinoshita J, 1409
 Kirchhoff C, 1161
 Kiskó G, 737
 Kiss I, 1145, 1259, 1333,
 1555
 Kita Y, 835
 Kitagawa C, 1581
 Kitagawa H, 685, 1211
 Kitagawa M, 1609
 Kitagawa T, 759
 Kitajima T, 643
 Kittisenachai S, 871
 Kiuchi Y, 33, 231
 Kiyohara H, 961
 Klaynongsruang S, 1137
 Klokkevold PR, 707
- Kluwe L, 241
 Knebel C, 1161
 Knipfer C, 241
 Kobayashi K, 337
 Kobayashi M, 685, 1211
 Kobierzycki C, 249, 731
 Koç U, 1105
 Kogure Y, 1199, 1581
 Kohlmann T, 625
 Koide Y, 1193
 Koike H, 409
 Koizumi M, 937
 Kokabu S, 1339, 1427
 Kokkali S, 653
 Kokotis P, 1647
 Komiotis D, 291
 Komoike Y, 353
 Komura M, 1205
 Kondo A, 165
 Kondo T, 25
 Kopp A, 241
 Korkolopoulou P, 191
 Kosaka T, 603
 Kostakis ID, 883, 1381
 Kostaropoulos T, 1051
 Kostomitsopoulos N, 1433
 Kotsampasi B, 291, 807
 Kott O, 1551
 Koukourakis MI, 185
 Kouraklis G, 85
 Koureas A, 945
 Kouretas D, 291, 807
 Kouroupi M, 185
 Koutsilieris M, 451, 977
 Kreska Z, 1259, 1555
 Krettek C, 1463
 Kreuter M, 1457
 Kuan L-Y, 1361
 Kubo N, 1667
 Kucera R, 1551
 Küçükali Cİ, 319
 Kudsioglu T, 1653
 Kudsk KR, 1623
 Kumagai Y, 145
 Kunisaki C, 603, 1269
 Kunt AT, 561
 Kuo Y-C, 549
 Kuramitsu Y, 759
 Kurata N, 33
- Kurabayashi K, 1169
 Kurose M, 165
 Kurz C, 1323
 Kurzyna M, 373
 Kushiyama S, 1667
 Kuwahara M, 597
 Kwon S, 575
 La Manna G, 397
 Lacognata C, 1231
 Lai C-C, 1591
 Lai J, 413
 Lai Y-L, 487
 Laino L, 999
 Laios K, 403, 1265
 Lake D, 1265
 Lalošević D, 791
 Lalošević V, 791
 Lambropoulou M, 451
 Lamnissou K, 313
 Lattanzi B, 1623
 Lavalle GE, 1659
 Lavaris A, 403, 1265
 Lee B-H, 1111
 Lee E, 1419
 Lee E-J, 93, 101
 Lee H, 1561
 Lee HJ, 1561
 Lee K-C, 549, 1097
 Lee L-Y, 1533
 Lee M-H, 783, 1129
 Lee M-Z, 1129
 Lee T-K, 1443
 Lee W-C, 567
 Lee Y-R, 47
 Leelawat K, 871
 Lehrer S, 1485
 Lek-Uthai U, 871
 Lenze F, 1161
 Lenze U, 1161
 Levra NG, 159
 Li C, 1025
 Li M-H, 203
 Li P-C, 753, 829
 Li R, 1081
 Li S, 1009
 Liao C-H, 41, 1045, 1591
 Liao N-C, 783
 Liao T-Y, 905
 Liapis CD, 1433
- Liappas I, 1629
 Liaw C-C, 905
 Lighezan D, 1599
 Lim Y-P, 47
 Lima LF, 1527
 Limberi S, 921
 Lin C-L, 47, 955
 Lin C-W, 41
 Lin J-C, 203
 Lin P-C, 677
 Lin S-S, 279, 549, 1097
 Lin W-W, 1119
 Lin Y-C, 1373
 Lin Y-H, 1373
 Lindhardt CL, 1283
 Ling B, 893
 Lipkin WI, 1323
 Liu C-C, 1119
 Liu J-Y, 523
 Liu K-L, 523
 Liu L-C, 487, 1373
 Liu T-T, 279, 1361
 Liu X, 413
 Liu Y-C, 203, 1097, 1361
 Lodoli C, 359
 Lohman AC, 1283
 Lohr F, 125
 Lonardi C, 139
 Losuwannarak N, 71
 Lu C-C, 677
 Lu H-F, 523, 783, 1129
 Lu M-C, 753, 829
 Machairas N, 883, 977
 Mack E, 1323
 Macneil S, 461
 Maddalo M, 159
 Madduri S, 591
 Madroszyk A, 121
 Maeda H, 685, 1211
 Maeda K, 151, 611, 1667
 Maeda R, 663
 Maehara Y, 659, 1491, 1541
 Maekawa K, 643
 Maezawa Y, 1513
 Magou E, 653
 Magrini SM, 159
 Maijaroen S, 1137
 Makino I, 1409
 Makino T, 899

- Mäkipaakkanen E, 1223
 Makri S, 291, 807
 Malicka I, 249
 Mańczak R, 373
 Manda P, 1647
 Mandani A, 1071
 Mandic R, 1323
 Mangir N, 461
 Manig L, 633
 Manninen H, 1223
 Mannsåker B, 331
 Mantaiou M, 859
 Mantas D, 191
 Mantziaras G, 1433
 Maraming P, 1137
 Marcu M, 649
 Margonis GA, 85
 Mariolais A, 977
 Maros M, 973
 Maros ME, 843
 Marquardt A, 1323
 Marten-Mittag B, 1161
 Maruyama R, 479
 Mastropasqua L, 437
 Masuda M, 25, 1513
 Masuda R, 1427
 Masuda T, 1155
 Masuda Y, 231, 707
 Masudo K, 25
 Masui K, 1499
 Matsubara T, 1339, 1427
 Matsui H, 409
 Matsumoto K, 531
 Matsuo K, 1339
 Matsuo T, 721
 Matsushita K, 1499
 Matsutani S, 151
 Matsuyama T, 1519
 Matsuzu K, 25
 Matusz P, 1599
 Matuura H, 597
 Mavrova-Risteska L, 1275
 Mederle OA, 791
 Megalooikonomou V, 859
 Melekoglu A, 813
 Menditti D, 999
 Merli M, 1623
 Mertzanos G, 313
 Mezzogiorno A, 999
 Micci F, 1241
 Michail O, 391
 Michopoulos I, 1629
 Miettinen T, 1223
 Mikami K, 273, 1169
 Mikolajczyk A, 1369
 Militaru A, 1599
 Militaru M, 1599
 Minami T, 1169
 Minemura H, 541
 Mirone V, 139
 Misumi T, 1269
 Miura N, 583
 Miwata K, 1155
 Miyagi Y, 25
 Miyamoto H, 603
 Miyamoto M, 597
 Miyamoto S, 1155
 Miyashita T, 1409
 Miyata Y, 721, 1155
 Miyawaki M, 171
 Miyazawa Y, 409
 Mizokami A, 899
 Mizuyama Y, 611
 Mochiki E, 145
 Mohácsi-Farkas C, 737
 Mokbel K, 1301, 1477
 Molyvdas P-A, 109
 Monteiro LN, 1659
 Monzen H, 531
 Moraes DC, 1527
 Morikawa K, 1427
 Moris D, 191, 391
 Moschos MM, 403, 1265
 Mościbrodzka M, 197
 Motohiro A, 659
 Motomura H, 669
 Mountzalia L, 1381
 Mouwakeh A, 737
 Mukoyama N, 1193
 Munekage E, 1211
 Munekage M, 1211
 Munesue S, 1409
 Murakami Y, 255, 1309
 Muraki K, 1205
 Muramatsu Y, 1339
 Murano G, 437
 Murata H, 961
 Murono K, 365, 1235
 Mutoh M, 499
 Nagahara H, 151, 611
 Nagashima O, 1205
 Nagata H, 365
 Nagatsu A, 1183
 Nagayoshi S, 643
 Naitoh H, 145
 Nakagawa H, 611
 Nakagawa M, 231, 765
 Nakahama K, 887
 Nakai T, 1505
 Nakajima T, 1427
 Nakakuma M, 265
 Nakamichi A, 1339, 1427
 Nakamura K, 493, 537, 663,
 1205, 1409
 Nakamura Y, 25, 721
 Nakanishi R, 1491
 Nakanishi Y, 1541
 Nakano T, 961
 Nakano Y, 799
 Nakanuma S, 1409
 Nakashima A, 799, 1499
 Nakashima T, 1155
 Nakatomi C, 1339, 1427
 Nakayama H, 25
 Nakos I, 1433
 Namba H, 33
 Namikawa T, 685, 1211
 Nanimoto Y, 759
 Narihiro S, 1643
 Nasi D, 653
 Nasioulas G, 313
 Natori T, 231
 Natsagdorj A, 899
 Natsugoe S, 835
 Neff A, 1323
 Negi Y, 1169
 Németh Á, 1145
 Németh B, 1145, 1259, 1555
 Nerg O, 1223
 Nica C, 79
 Nieder C, 327, 331
 Niero M, 139
 Ninomiya I, 1409
 Ninomura S, 1519
 Nishii T, 1667
 Nishikawa D, 1193
 Nishikawa H, 927
 Nishikawa T, 365, 1235
 Nishimura T, 1499
 Nishimura Y, 33, 531
 Nishio M, 1193
 Nitoda E, 403
 Nitsa A, 977
 Niwa T, 1581
 Noda M, 835
 Nodin B, 133
 Noguchi M, 55
 Nohara T, 899
 Nomizo T, 1587
 Nomura M, 409
 Nomura S, 611
 Nonaka T, 643
 Nowak K, 1369
 Nozawa H, 365, 1235
 Ntanou P, 291
 O'Loughlin PF, 1463
 Obata K, 165
 Obmińska-Mrukowicz B,
 1081
 Oda Y, 1541
 Ogata T, 1499, 1513
 Ogino I, 1269, 1609
 Oguchi K, 231
 Ogushi M, 799
 Ohba K, 721
 Ohbatake Y, 1409
 Ohbayashi C, 1505
 Ohira M, 151, 611, 669
 Ohlinger R, 625
 Ohno T, 541
 Ohta K, 937
 Ohta T, 1409
 Ohtani H, 611
 Ohtsu M, 1643
 Oi S, 583
 Oizumi H, 231
 Oizumi T, 231
 Okada M, 1155
 Okamoto I, 1541
 Okamoto K, 1409
 Okamoto M, 659, 961
 Okamoto T, 171, 1643
 Okamoto Y, 1155
 Okano N, 961
 Okatani H, 265
 Okazaki S, 337

- Oki E, 1491
 Oki M, 1199
 Okita S, 55
 Okudaira N, 479, 541
 Okumura H, 835
 Okumura M, 531
 Omori Y, 927
 Omoto I, 835
 Oranges CM, 591, 893
 Orimo T, 1183
 Ornati M, 197
 Orosz E, 1333
 Orsatti G, 221
 Osato H, 353
 Oshima T, 25, 1513
 Osoegawa A, 171
 Ota T, 345
 Otani K, 365, 1235
 Otoshi T, 445
 Ott P, 1623
 Ottociani B, 133
 Owaki T, 835
 Oya N, 1519
 Ozasa H, 1587
 Özbek U, 555
 Özdemir C, 319
 Ozdogan S, 287
 Pacelli F, 359
 Pan S-Y, 487
 Pan T-L, 955
 Panourgias E, 945
 Panta S, 921
 Pantos K, 451
 Pantou A, 451
 Papadimas GK, 1647
 Papadopoulos S, 303
 Papageorgiou L, 859, 1051
 Papahatzaki MM, 1647
 Papalois A, 1381
 Papazoglou D, 185
 Pappas A, 451
 Park IA, 1561
 Park J, 575
 Park M-H, 1443
 Park SW, 771
 Pärnänen P, 1089
 Paslawska U, 249
 Pautov M, 915, 1217
 Pavlopoulou P, 313
 Pawlaczek M, 517
 Pawlak A, 1081
 Pawlik TM, 85
 Pecen L, 1551
 Pedretti S, 159
 Pêgas GRA, 1659
 Pellegrinelli L, 1255
 Pellegrini D, 839
 Pestova M, 1551
 Péter I, 1259, 1555
 Petpiroon N, 1353
 Petrotos K, 291, 807
 Philippou A, 977
 Phillips E, 1071
 Pinchera B, 1255
 Piotrowska A, 249, 731
 Piotrowski T, 517
 Plociennik M, 1369
 Pniewski G, 197
 Podhorska-Okolow M, 249
 Pohlig F, 1161
 Polistena A, 133
 Polkowska I, 507, 1449
 Polymeneas G, 85
 Ponzoni A, 221
 Pop D, 419, 649
 Popescu I, 1247
 Porcaro A, 139
 Precht C, 241
 Pregliasco F, 1255
 Prodromidou A, 883
 Quatela O, 241
 Racioppi M, 139
 Rades D, 381, 633, 825,
 1283, 1481
 Radzki RP, 1449
 Raftopoulou S, 859
 Raica M, 79, 791
 Rapani A, 451
 Rasmussen A, 1623
 Rasmussen LV, 713
 Rastrelli M, 221
 Raza A, 461
 Rechl H, 1161
 Resende V, 1527
 Rheinstein PH, 1485
 Rino Y, 1513
 Rino Y, 25, 1513
 Roberts MS, 113
 Roca E, 159
 Rodepeter FR, 1323
 Rody A, 1275
 Romano M, 359
 Romanowicz H, 731
 Rotzinger R, 179
 Roytrakul S, 871
 Rubio CA, 1473
 Russillo M, 839
 Rutkowski R, 625
 Ryosuke D, 835
 Ryu S, 1643
 Rzechonek A, 197
 Sachpekidis C, 1457
 Saeki H, 1491
 Saeki K, 1427
 Sagara Y, 721
 Saito K, 145
 Saito T, 1519
 Saka H, 1199, 1581
 Sakagami H, 231, 479, 541,
 707, 745, 765, 1403
 Sakagami M, 927
 Sakai A, 659
 Sakai F, 337
 Sakai H, 721
 Sakai S, 1409
 Sakaida I, 637
 Sakamori Y, 1587
 Sakamoto S, 1155
 Sakamoto T, 597
 Sakuraba H, 273
 Sakurai K, 1667
 Salah E, 159
 Saleh O, 139
 Salem N, 121
 Salo T, 1089
 Samaha M, 85
 Samara P, 313
 Sano A, 1403
 Sasaki K, 85, 365, 835, 1235
 Sasaki S, 1205
 Sasaki Y, 1519
 Sato K, 603
 Sato S, 603
 Sato T, 19, 1387, 1513
 Sava S, 999
 Savva S, 291
 Sawabata N, 691, 1505
 Sawada N, 273
 Scambia G, 359
 Schaefer DJ, 591, 893
 Schervish E, 703
 Schild SE, 381, 633, 825, 1481
 Schmeil I, 1275
 Schnapauff D, 179
 Schoenberg SO, 125, 843
 Schubert J, 1369
 Schwab M, 1617
 Scott NJA, 1071
 Sekine Y, 409
 Semba H, 851
 Sen-Yo M, 637
 Serni S, 139
 Sertdemir M, 125
 Sfakianoudis K, 451
 Shang H-S, 783
 Shelan M, 125
 Shen H-Y, 47
 Shen T-C, 487, 1039, 1045
 Shi H, 745, 765, 1403
 Shi M, 1025
 Shiba S, 961
 Shibata Y, 409
 Shibutani M, 151
 Shibutani M, 611
 Shigehara K, 899
 Shigematsu F, 1199
 Shigeyama-Tada Y, 1339
 Shih T-C, 487
 Shih Y-L, 523, 783, 1129
 Shim J-H, 63
 Shim KM, 63, 1419
 Shimada S, 1183
 Shimada T, 759
 Shimizu D, 1499
 Shimoyama Y, 1643
 Shinji S, 937
 Shinoda S, 637
 Shinozuka K, 493
 Shinto O, 611
 Shirataki Y, 1403
 Shiratsuchi H, 745, 765
 Shiroyama T, 887
 Shono T, 1519
 Shu S, 1491
 Siewierska K, 249
 Sifakis E, 945

- Sikalias N, 1381
 Silmanowicz P, 1289
 Silva JDC, 425
 Simonato A, 139
 Simopoulou M, 451
 Singh ATK, 1
 Siniorakis E, 921
 Siracusano S, 139
 Sirma-Ekmekçi S, 555
 Sitar-Taut AV, 419
 Sivridis E, 185
 Slouka D, 1551
 Smeets R, 241
 Smolarz B, 731
 Sobczyńska-Rak A, 507, 1175, 1289, 1345, 1449
 Söküçü SN, 319
 Solim LA, 1105
 Sommer WH, 843
 Son Y-S, 93, 101
 Song IH, 1561
 Sorop A, 1247
 Sotiropoulos GC, 883
 Soyama H, 597
 Spartalis E, 191
 Spartalis M, 191
 Spengler G, 737
 Sritularak B, 71
 Stagos D, 291, 807
 Staničová J, 1063
 Steck J, 819
 Stefanou D, 653
 Stene C, 133
 Stoica C, 385, 431, 649
 Stramare R, 221
 Strunk MA, 819
 Stuck BA, 1323
 Su C-H, 487
 Suematsu H, 603
 Suenaga S, 637
 Suganuma N, 25
 Sugino K, 25
 Sugio K, 171
 Sun J, 1025
 Sun Y, 1025
 Suwa K, 1643
 Suzuki G, 1499
 Suzuki H, 231, 765, 887, 1193
- Suzuki K, 409, 799
 Suzuki R, 1403
 Suzuki S, 255, 1309
 Svobodova S, 1551
 Sysak A, 1081
 Syuto T, 409
 Szmit S, 373
 Szponder T, 507, 1289, 1345, 1449
 Tachimori A, 1667
 Tagawa T, 1541
 Taina M, 1223
 Taitzoglou IA, 109
 Tajima H, 1409
 Takada K, 669, 1541
 Takada S, 1409
 Takahashi G, 937
 Takahashi K, 669, 1205
 Takahashi M, 499
 Takahashi Y, 1427
 Takakura N, 1339
 Takamori S, 1541
 Takamura H, 1409
 Takano K, 165
 Takano M, 597
 Takashima T, 669
 Takatsuki M, 643
 Takayanagi N, 337
 Takeda K, 937
 Takeda S, 537
 Takei HH, 707
 Takeishi K, 55
 Takenaka T, 1499
 Takeshige T, 1205
 Takeshima H, 231, 745, 765
 Taketomi A, 1183
 Takeuchi H, 171
 Takiyama A, 365
 Takiyama H, 365
 Takumi Y, 171
 Takuwa T, 1169
 Talamini R, 139
 Tallet A, 121
 Tamagawa H, 1513
 Tamaki T, 1193
 Tamamori Y, 1667
 Tamiya A, 887
 Tamiya M, 887
 Tamura M, 531
- Tamura N, 231, 745, 765
 Tanaka H, 151
 Tanaka K, 231, 603, 765
 Tanaka T, 365, 1235
 Tanaka Y, 603
 Tanase A, 911, 915
 Taniguchi K, 643
 Taniguchi S, 691, 1505
 Taniguchi Y, 887
 Tanimoto A, 55
 Tatara M, 1175
 Tawinwung S, 1353
 Telbisz Á, 737
 Temel B, 555
 Terada T, 927
 Teske E, 7
 Teymoortash A, 1323
 Thabit A, 1265
 Thai PV, 381
 Theocharis S, 391
 Tien N, 47
 Timirci-Kahraman O, 813
 Ting L-L, 203
 Toda T, 537
 Toffoli L, 139
 Tokuda K, 759
 Tokunaga T, 643
 Tomita M, 663
 Tomita S, 669, 1205
 Tomita Y, 927
 Tomomura A, 231
 Tomomura M, 231
 Topanurak S, 871
 Topolcan O, 1551
 Torbicki A, 373
 Toutouza M, 977
 Toya R, 1519
 Toyokawa G, 1541
 Treder M, 1481
 Tremp M, 591, 893
 Treska V, 1551
 Trevino J, 413
 Triggiani L, 159
 Tripodaki E-S, 653
 Triposkiadis F, 921
 Troiano G, 999
 Tsai C-W, 41, 487, 1039, 1045
 Tsai J-J, 549
- Tsai J-T, 203
 Tsai Y-F, 677
 Tsalikakis DG, 1433
 Tsamis K, 313
 Tsarouhas K, 921
 Tsatsos M, 403
 Tseng C-W, 549
 Tseng Y-D, 1635
 Tsigkaropoulou E, 1629
 Tsitas N, 1629
 Tsitsimpikou C, 921
 Tsuboi M, 1339
 Tsuchiya H, 33
 Tsuda H, 597
 Tsuda S, 685, 1211
 Tsuji M, 231
 Tsuji T, 1587
 Tsujii S, 685, 1211
 Tsumura S, 851
 Tsuruga Y, 1183
 Tsuzuki K, 927
 Tunca F, 555
 Tüzün E, 319
 Tyan Y-S, 677
 Tyran M, 121
 Tzallas AT, 1433
 Tzevelekos P, 921
 Uchida E, 937
 Uchikado Y, 835
 Uehara M, 541
 Uemura S, 685, 1211
 Uesawa Y, 479
 Ullah HMA, 93, 101
 Unger J, 625
 Urata M, 1339, 1427
 Ushigome T, 1643
 Ushikai M, 55, 265, 583
 Ustek D, 555
 Uwa N, 927
 Van Rijn I, 1283
 Vanninen R, 1223
 Varjas T, 1333
 Veaceslav F, 79
 Verebová V, 1063
 Vered M, 1089
 Verze P, 139
 Vesely S, 425
 Vesterlin J, 1089
 Vidiri A, 839

Vilcu M, 911, 915, 967, 1217, 1247	Wenz F, 125	Yang L, 413	Yoshimoto Y, 961, 1427
Villadsen G E, 1623	Wenz H, 843, 973	Yang M, 703	Yoshioka H, 1581
Viniou N-A, 1241	Wenz R, 843	Yang M-D, 753, 829	Yoshiya S, 659
Visalli F, 139	Wenzel ES, 1	Yang Z, 1025	Yoshizumi F, 659
Vizzielli G, 359	Wessely-Szponder J, 1345, 1449	Yapici N, 1653	Youssef A, 1275
Vlachakis C, 859	Wettstein R, 591, 893	Yasuda K, 799, 1339	Yu H, 1025
Vlachakis D, 859, 1051	Wiebking U, 1463	Yasuda M, 337	Yuan H, 1025
Vogelsang RP, 1481	Wilk M, 373	Yasuda T, 721	Yueh T-C, 1045
Vonthein R, 1283	Wipf P, 1009	Yasuda Y, 1587	Yukawa A, 583
Voros D, 85	Wojnar A, 731	Yasui T, 231	Yukawa N, 603, 1513
Vraka I, 945	Wozniewski M, 249	Yasukawa M, 691, 1505	Zablockienè B, 473
Wada T, 479	Wu C-C, 1119	Yeh C-N, 1533, 1591	Zablockis R, 473, 1571
Wakabayashi H, 479, 541	Wu C-W, 41	Yeh C-T, 955	Zambelis T, 1647
Wakayama K, 1183	Wu H-C, 1045	Yeh T-S, 1591	Zampelis C, 921
Walaszkowska-Czyż A, 373	Wu M-F, 41	Yen T-H, 279	Zappulo E, 1255
Wang B-W, 1635	Wu Y-T, 1533	Yi J-E, 1081	Zarogiannis SG, 109
Wang C-Y, 1119	Yagishita S, 1205	Yilmaz N, 813	Zdrenghaea DT, 419
Wang H-C, 487	Yaltirik CK, 287	Yilmaz SG, 287, 561, 1653	Zervakis K, 1241
Wang H-E, 955	Yamada K, 1499	Yilmaz U, 813	Zeybek U, 813
Wang K, 1361	Yamada T, 937, 1513	Yobuta R, 331	Zhang M, 1339, 1427
Wang S, 1039	Yamaguchi K, 1155	Yokoi T, 1169	Zhao J, 1081
Wang S-Y, 1533, 1591	Yamakawa T, 33	Yokoo H, 1183	Zitka O, 425
Wang W, 591	Yamamoto K, 165	Yokose S, 231, 707	Zlotogorski-Hurvitz A, 1089
Wang W-S, 1361	Yamamoto T, 1587	Yokoyama Y, 937	Zoccarato M, 1231
Watakabe T, 1519	Yamamoto Y, 345, 1409	Yoo DK, 771	Zopf EM, 819
Watanabe S, 1269, 1609	Yamamura J, 353	Yoshida H, 937, 1587, 1609	Žurauskas E, 473, 1571
Way T-D, 487, 1373	Yamaoka H, 345	Yoshida K, 1499	Zygmunt M, 625
Wazir U, 1477	Yamasaki T, 707	Yoshida N, 1519	Żylińska B, 507, 1175, 1289, 1449
Weidner A, 125	Yamazaki H, 1499	Yoshihara M, 25	Zylis D, 653
Weiss MJ, 85	Yanaga K, 1643	Yoshikawa N, 493	
Wen L, 1081	Yang J-S, 677	Yoshikawa T, 583, 597, 1513	

Instructions for Authors 2018

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

Open Access Policy. IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 600.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear **at the end** of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

Tables. All tables should appear **at the end** of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC -IUB", "Berger's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.

4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for IN VIVO:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to IN VIVO may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to IV.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 59%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iilar-anticancer.org.
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).

Copyright© 2018 – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

General Policy: IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of human physiology, pathology and disease management. The special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models for biomedical research. The principle aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports (a) the aims and research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Publication Data: IN VIVO is published bimonthly online-only and open access by the International Institute of Anticancer Research. Each annual volume comprises six issues. Annual Author and Subject Indexes are included in the sixth issue of each volume. IN VIVO Vol. 18 (2004) and onwards appears online with Stanford University HighWire Press. All published articles are deposited in PubMed Central.

Copyright: Once a manuscript has been published in IN VIVO, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Open Access Policy: Open Access Policy: IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to contribute an online publication fee of US\$ 600 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged US\$ 60,00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume, issue, and page numbering.

Articles in IN VIVO are regularly indexed in bibliographic services, including PubMed, Index Medicus, MEDLINE, Biological Abstracts, BIOSIS, Chemical Abstracts, Excerpta Medica, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, CANCER-LIT Database, University of Sheffield Biomedical Information Service (SUBIS), Current Clinical Cancer, AIDS Abstracts, Progress in Palliative Care, Update-Research Information Systems Inc., Inpharma-Reactions Datastar, BRS, Reference Update (I.S.I.), Research Alert (I.S.I.), Google Scholar, BioBase, MedBase, Investigational Drugs Database, VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Databases.

The Editors and Publisher of the journal IN VIVO accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

All correspondence (status of submitted manuscripts, change of address, general editorial matters, advertising rate requests) should be addressed to the Editorial Office, e-mail: journals@iilar-anticancer.org. Articles should be submitted only through our online submission system (www.iiar-submissions.com).

Editorial Office: International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel & Fax: +30-22950-53389.

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ, 07732, USA. e-mail: journals@iilar-anticancer.org.

E-mails:

Editorial Office: journals@iilar-anticancer.org

Managing Editor: editor@iilar-anticancer.org

For more information about IN VIVO and the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, please visit the IIAR website: www.iilar-anticancer.org; www.iv.iiarjournals.org

Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved